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ABSTRACT
Soybeans are a rich source of isoflavones, which are classified as phytoestrogens. Despite numer-
ous proposed benefits, isoflavones are often classified as endocrine disruptors, based primarily on
animal studies. However, there are ample human data regarding the health effects of isoflavones.
We conducted a technical review, systematically searching Medline, EMBASE, and the Cochrane
Library (from inception through January 2021). We included clinical studies, observational studies,
and systematic reviews and meta-analyses (SRMA) that examined the relationship between soy
and/or isoflavone intake and endocrine-related endpoints. 417 reports (229 observational studies,
157 clinical studies and 32 SRMAs) met our eligibility criteria. The available evidence indicates that
isoflavone intake does not adversely affect thyroid function. Adverse effects are also not seen on
breast or endometrial tissue or estrogen levels in women, or testosterone or estrogen levels, or
sperm or semen parameters in men. Although menstrual cycle length may be slightly increased,
ovulation is not prevented. Limited insight could be gained about possible impacts of in utero iso-
flavone exposure, but the existing data are reassuring. Adverse effects of isoflavone intake were
not identified in children, but limited research has been conducted. After extensive review, the







Over the past 30 years, the health effects of soyfoods and
soybean isoflavones have been rigorously investigated.
Modern interest in isoflavones began with the US National
Cancer Institute funding research aimed at understanding
the role of these soybean constituents in cancer prevention
and treatment (Messina and Barnes 1991) Within a decade
the number of purported health benefits of isoflavones being
investigated greatly expanded to include areas such as bone
health (Blair et al. 1996; Potter et al. 1998), hot flash allevi-
ation (Murkies et al. 1995) and cognitive function (Pan,
Anthony, and Clarkson 1999a, 1999b).
Research interest in soyfoods coincided with the interest in
isoflavones because, although they are only one of >100
potentially biologically active components in soybeans and
soyfoods (Kang et al. 2010; Fang, Yu, and Badger 2004),
among commonly consumed foods the soybean is a uniquely
rich source of these diphenolic molecules (Thompson et al.
2006; Franke et al. 1998). To this point, mean isoflavone
intake in Japan among older adults ranges from approxi-
mately 30 to 50mg/d (Messina, Nagata, and Wu 2006;
Konishi et al. 2019) whereas per capita intake in the United
States (Bai, Wang, and Ren 2014; Sebastian et al. 2015; Chun,
Chung, and Song 2007; Chun et al. 2007) and Europe
(Zamora-Ros et al. 2013; Ziauddeen et al. 2019) is only a few
mg. Thus, soyfoods are often equated with isoflavones.
Genistein (molecular weight, 270 g/mol), daidzein
(molecular weight, 254.2 g/mol) and glycitein (molecular
weight, 284.3 g/mol), and their respective glycosides (the
predominate form in soybeans and unfermented soyfoods)
account for approximately 50, 40 and 10%, respectively, of
the total isoflavone content of soybeans (Murphy, Barua,
and Hauck 2002). In fermented soyfoods, the percentage of
isoflavones in aglycone form increases but is quite variable
depending upon the food and duration of fermentation
(Murphy, Barua, and Hauck 2002; Jang et al. 2008; Chan
et al. 2009; Fukutake et al. 1996; Wei, Chen, and Chen
2008). Commonly consumed fermented foods include tem-
peh, miso and natto whereas unfermented soyfoods include
tofu, soymilk and edamame. In this manuscript, isoflavone
amounts refer to the aglycone equivalent weight. When con-
verting the glycoside to the aglycone amount, a conversion
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factor of 0.6 is used since the sugar component of the glyco-
side accounts for approximately 40% of the total mass.
Of the three soybean isoflavones, genistein is generally
considered the most potent based on in vitro assays measur-
ing estrogenic potential (Gramec Skledar et al. 2020;
Matsumura et al. 2005). In addition to the isoflavones in
soybeans, upon ingestion, endogenous metabolites with
varying biological activity are produced. Especially notable
in this regard is that approximately 25% of Westerners and
50% of Asians host the gut microbiome composition that
convert daidzein into equol, a conversion that some specu-
late will benefit the health of those consuming isoflavones
(Setchell, Brown, and Lydeking-Olsen 2002).
Although in observational studies involving Asian cohorts
isoflavone exposure occurs via traditional soyfoods, which
are made from whole soybeans, clinical studies typically util-
ize isoflavone supplements or soy ingredients, commonly
referred to as soy protein products, because they are easily
standardized and incorporated into the diet. These products
include soy flour, soy protein concentrate (SPC) and soy
protein isolate (SPI), which range in protein content from
50% (flour) to 90% (SPI). Soy protein products are widely
used by the food industry for their functional properties.
For example, they are added to foods to increase shelf life
and moisture retention and to modify texture (Thrane et al.
2017). Because only small amounts of soy protein products
are added to foods for functional purposes, when used in
this way (as ingredients) they make a negligible contribution
to nutrient intake. However, soy protein products are also
used as a base for making meat alternatives and nondairy
beverages and are often added to foods in larger amounts,
such as breakfast cereals and energy bars, to boost protein
content. When used in this way, they can greatly contribute
to protein intake.
Despite interest in the proposed benefits of isoflavones,
for almost the entire time their benefits have been investi-
gated, they have been embroiled in controversy. In some
sense this controversy is not surprising when recognizing
that isoflavones first came to the attention of the scientific
community in the 1940s as a result of breeding problems
experienced by female sheep in Western Australia (Bennetts,
Underwood, and Shier 1946; Adams 1995) grazing on a type
of clover rich in isoflavones (Bradbury and White 1954;
Lundh, Pettersson, and Martinsson 1990). Even those
researchers who recognized the potential health benefits of
isoflavones acknowledged the possibility that they could
impair female fertility (Setchell et al. 1984). This particular
concern gained support when in 1987, it was determined
that the addition of soy meal to the diet of the captive chee-
tah contributed to its inability to reproduce (Setchell et al.
1987). Despite the large populations of soyfood-consuming
countries, concerns that isoflavones impair fertility continue
to be discussed and debated (West et al. 2005; Cooper 2019;
Cederroth, Zimmermann, and Nef 2012). Patisaul and
Jefferson (2010) reviewed the animal data related to this topic.
The estrogen-like effects of isoflavones underlie both the
proposed benefits as well as concerns about adverse effects.
By the 1950s, investigators had already demonstrated the
estrogen-like properties of isoflavones in experimental
animals, which led them to be viewed as possible growth
promoters for use by the animal feed industry (Carter,
Matrone, and Smart 1955; Carter, Smart, and Matrone 1953;
Cheng et al. 1953). In the 1960s, Folman and Pope
(Cederroth, Zimmermann, and Nef 2012; Patisaul and
Jefferson 2010) established the relative binding affinities of
soybean isoflavones for the only estrogen receptor (estrogen
receptor alpha, ERa) known at that time (Folman and Pope
1966; Folman and Pope 1969). Somewhat prophetically, their
work led them to conclude that the importance of genistein
“… might lie as much in its ability to antagonize the nat-
ural steroid estrogens as in its own estrogenic activity”
(Folman and Pope 1966).
Although an antiestrogenic effect of isoflavones has only
infrequently been observed in clinical studies, early on it
served as a partial theoretical basis for enthusiasm about a
protective effect of isoflavones against hormone-dependent
cancers, especially breast cancer (Messina and Barnes 1991;
Stewart, Westley, and May 1992). It also formed a theoret-
ical basis for classifying isoflavones as selective estrogen
receptor modulators (SERMs) (Brzezinski and Debi 1999).
This classification gained support with the discovery in 1996
of a second estrogen receptor – ERb (Kuiper et al. 1996) –
and the recognition that in contrast to estrogen, which binds
with equal affinity to ERa and ERb, isoflavones preferen-
tially bind to the latter (Kuiper et al. 1998; Jiang et al. 2013).
In general, activation of ERa and ERb are seen as exerting
proliferative and anti-proliferative effects, respectively
(Paruthiyil et al. 2004).
The isoflavone controversy began in earnest in the late
1990s as a result of research showing that in ovariectomized
athymic mice implanted with MCF-7 cells (an estrogen-
dependent human breast cancer cell line), genistein stimu-
lated the growth of existing mammary tumors (Hsieh et al.
1998). Published at nearly the same time were the results of
two human studies that intervened with isoflavone-rich soy
protein that appeared to support these findings, one, a pilot
study examining nipple aspirate fluid (Petrakis et al. 1996) and
the other, a preliminary analysis of research examining in vivo
breast cell proliferation (McMichael-Phillips et al. 1998).
However, prior to the breast cancer controversy, ques-
tions about the safety of soy infant formula (SIF) had
already been raised (Irvine et al. 1995; Irvine, Fitzpatrick,
and Alexander 1998; Setchell et al. 1997), despite it having
been widely used for many decades (Merritt and Jenks
2004) and the conclusion by the Committee on Nutrition of
the American Academy of Pediatrics in 1983, that SIF pro-
duces normal growth and development in full-term infants
(Committee on Nutrition 1983). In subsequent years, much
in the same way interest in the benefits of isoflavones
expanded, concern about isoflavones expanded to include
areas such as thyroid function (Divi, Chang, and Doerge
1997; Divi and Doerge 1996) and cognitive function (White
et al. 2000). In fact, both isoflavones (and other phytoestro-
gens) and soy are routinely referred to as endocrine disrup-
tors (Lee et al. 2019; Bar-El and Reifen 2010; Chung et al.
2019; Fernandez-Lopez et al. 2016; Beszterda and Franski
2018; Patisaul 2017; Salsano et al. 2019; Kwack et al. 2009;
Xiao et al. 2018; Rietjens, Louisse, and Beekmann 2017;
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Min, Wang, and Liang 2020), a designation first made
>20 years ago (Ginsburg 1996), although there has also been
pushback against this classification, especially in the case of
soyfoods (Messina 2011).
Endocrine disruptors were defined at a US
Environmental Protection Agency workshop in 1996 as
“exogenous agents that interfere with the production,
release, transport, metabolism, binding action or elimination
of natural hormones in the body responsible for the main-
tenance of homoeostasis and the regulation of developmen-
tal processes” (Kavlock et al. 1996). The World Health
Organization defines an endocrine disruptor as “an exogen-
ous substance or mixture that alters the function(s) of the
endocrine system and consequently causes adverse effects in
an intact organism, or its progeny, or (sub) populations”
(Solecki et al. 2017). An adverse effect is defined as a “…
change in morphology, physiology, growth, reproduction,
development or lifespan of an organism which results in
impairment of functional capacity or impairment of capacity
to compensate for additional stress or increased susceptibil-
ity to the harmful effects of other environmental influences.”
Endocrine disruptors have been linked with increased risks
for obesity, diabetes mellitus and cardiovascular diseases,
impaired male and female reproduction, hormone sensitive
cancers, thyroid disruption and neurodevelopmental and
neuroendocrine abnormalities (Gore et al. 2015).
While there is general recognition that isoflavones are
endocrine-active substances, as discussed by the European
Food Safety Authority (EFSA), endocrine active substances
are not necessarily endocrine disrupting chemicals
(European Food Safety Authority 2010). According to EFSA,
an endocrine active substance is any chemical that can inter-
act directly or indirectly with the endocrine system, and
subsequently result in an effect on the endocrine system, tar-
get organs and tissues. Whether the effect is adverse
(“disruptive”) or not will depend on the type of effect, the
dose and the background physiological situation (European
Food Safety Authority 2010).
Over the past 20 years, several scientific and regulatory
bodies and organizations have evaluated the safety of isofla-
vones and soyfoods. For example, in 1999, in the process of
reviewing evidence in support of a proposed health claim
for soyfoods and coronary heart diseases based on the hypo-
cholesterolemic effect of soy protein, the US Food and Drug
Administration (FDA) concluded that when consumed at a
level of 25 g/d, soy protein was safe and the claim was lawful
(Food Labeling: Health Claims; Soy Protein and Coronary
Heart Disease 1999). Although the claim was based on soy
protein and not isoflavones, health concerns examined by
the FDA were those primarily related to the latter. Nearly
20 years later, in the process of reevaluating evidence in sup-
port of the existing health claim, the FDA reached the same
conclusion (Department of Health and Human Services
2017). Other organizations that evaluated isoflavones (as
supplements and/or in foods) include the UK Committee on
Toxicity of Chemicals in Foods, Consumer Products and the
Environment (COT) (2003, 2013), the French Agency for
Food, Environmental and Occupational Health & Safety
(ANSES) (2005), the Japanese Food Safety Commission,
Novel Foods Expert Committee (2006), the US National
Toxicology Program (2006, 2009), the EFSA (2015) and the
Permanent Senate Commission on Food Safety of the
German Research Foundation (SKLM) (2018). Recently,
both the ANSES and the COT have announced their
intention to consider reevaluating isoflavone safety in young
children. From a public health perspective, as interest in
plant-based diets increases, it is reasonable to expect that the
consumption of soyfoods will also, so it is critical to have a
clear understanding of the health effects of isoflavones.
Therefore, this technical review will examine claims that
isoflavones are endocrine disruptors as well as concerns
raised about soy/isoflavones that may not be limited to those
typically associated with endocrine disruption. This examin-
ation will focus primarily on the clinical data; and secondar-
ily, on observational data. With respect to the latter, because
with rare exceptions (e.g., Adventist Health Studies 1
(Beeson et al. 1989) and 2 (Butler et al. 2008) and the
Oxford Arm of the European Prospective Investigation into
Cancer (Davey et al. 2003)), soy consumption is extremely
low among Western cohorts, the focus will be on studies
involving Asian cohorts. This perspective on the epidemio-
logical data was articulated nearly two decades ago (Messina
2004). Cohorts involving low-intake populations will be
cited, but with the appropriate caveat. For the most part,
in vitro and animal studies will be highlighted only as part
of the background information needed to understand the
origins of the claims of harmful effects.
This approach to the literature has been adopted not
because of the failure of supporters of using animals to
study endocrine disruptors (Gore et al. 2015; Patisaul,
Fenton, and Aylor 2018) to recognize limitations of such
models (Jocsak et al. 2019), in particular the differences in
isoflavone metabolism between rodents and humans that
make extrapolating from the latter to the former especially
problematic (Gu et al. 2006; Setchell et al. 2011). Rather, it
is because there are ample human data upon which to reach
conclusions about the possible endocrine-disrupting effects
of soy and isoflavones in nearly all areas for which concerns
have been raised. Unlike other compounds classified as
endocrine disruptors, human intervention studies have rou-
tinely examined the health impact, and in many cases, the
long-term health impact, of isoflavone exposure via supple-
ments and foods. Areas for which there may be some ques-
tion about whether enough data exist to reach conclusions
will be highlighted
Finally, soy infant formula (SIF) will be occasionally cited
but for the following reasons it will not be a focus of
this review:
1. SIF has been extensively reviewed by previous authors
(Vandenplas et al. 2014; Testa et al. 2018; Jefferson,
Patisaul, and Williams 2012; Badger et al. 2009; Stevens
2017) and committees (McCarver et al. 2011; Bhatia
and Greer 2008).
2. On a body weight (bw) basis, isoflavone exposure is
much higher in infants fed SIF than in children or
adults consuming soyfoods in amounts compatible with
Asian consumption, as are blood isoflavone levels
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(Table 1) (Setchell et al. 1997; Badger et al. 2002).
Isoflavone intake of older Asian children is approxi-
mately 1mg/kg bw whereas in infants it is 1.8 to 9.5-
fold higher. For comparison, the UK COT estimated
that mean isoflavone intake among British infants aged
6 to 18 months and children aged 18 months to 5 years
would be 2.88 and 2.29mg/kg bw respectively, if current
dairy product intake was replaced by soy-based dairy
alternatives. Intake was primarily due to the replace-
ment of cow’s milk with soymilk; the isoflavone content
of the latter was estimated to contain 100mg/l.
Isoflavone intakes at the 97.5 percentile for the younger
and older age groups were 8.97 and 7.21mg/kg body
weight, respectively.
3. During the first few weeks and months of life (prior to
the introduction of foods or non-formula beverages),
infants are likely more sensitive to hormonal influences
than are children or adults (Patisaul 2017; Jefferson,
Patisaul, and Williams 2012; Yilmaz et al. 2020; WHO
& UNEP 2013). This point has been highlighted by the
US National Institute of Environmental Health Sciences
(Soy Infant Formula 2019) and the Endocrine Society’s
Second Scientific Statement on Endocrine-Disrupting
Chemicals (Gore et al. 2015).
4. Recommendations to increase soy consumption based
on nutritional and health attributes, especially related to
the prevention of chronic disease, do not apply to SIF,
although one very preliminary report found that SIF
use was associated with a reduced breast cancer risk
(Boucher et al. 2008).
Background
Isoflavone intake
The isoflavone content (aglycone equivalent weight) of soy-
foods derived from whole soybeans varies but expressed on
a per gram protein basis, is approximately 3.5mg/g
(Messina, Nagata, and Wu 2006). For such soyfoods, one
serving (e.g. 200 or 250ml soymilk, 100 g tofu, 1 ounce
[28 g] soynuts) provides approximately 25mg isoflavones. In
contrast, the isoflavone content of SPI and SPC processed in
the usual manner which involves the use of alcohol, is gen-
erally only 1mg/g protein, because during processing as
much as 90% of the isoflavone content is eliminated
(Murphy, Barua, and Hauck 2002; Murphy et al. 1998).
Extensive isoflavone intake data are available for adults
because of the many large cohort and case-control studies
that have been published from several high-soy-consuming
Asian countries. As noted previously, mean isoflavone intake
in Japan among older adults ranges from approximately 30
to 50mg/d (Messina, Nagata, and Wu 2006; Konishi et al.
2019) whereas per capita intake in the United States is
<3mg/d (Bai, Wang, and Ren 2014; Sebastian et al. 2015;
Chun, Chung, and Song 2007; Chun et al. 2007; Vieux,
Maillot, and Rehm 2020). Isoflavone intake in Shanghai,
China (Yang et al. 2005; Lee et al. 2007; Shu et al. 2015), is
comparable to Japan, but is much higher than other regions
within China (Liu et al. 2004). Examples of the range of iso-
flavone intake in China and Japan are shown in Table 2.
Isoflavone intake in Korea (Lee and Kim 2007; Kim et al.
Table 2. Isoflavone intake reported in large prospective epidemiologic studies from China and Japan.
Sex/Ref. Assumed bw (kg) N Age (y) range Country
Isoflavone intake, mg/kg bw
Intake quartile
1 2 3 4
Men (Gu et al. 2006; Yu et al. 2014) 61 (Gu et al. 2006) 55,474 40-74 China 0.22 0.42 0.62 0.96
Men (Hara et al. 2012; Matsushita et al. 2008) 62.5 (Matsushita et al. 2008) 39,569 40-69 Japan 0.23 0.45 0.68 1.26
Women (Hara et al. 2012; Matsushita et al. 2008) 54 (Matsushita et al. 2008) 45,312 40-69 Japan 0.27 0.52 0.79 1.43
Intake percentile
Mean 8.8 51 28.1 10 2.2
Women (Yang et al. 2005; Ma et al. 2013) 61.4 (Ma et al. 2013) 45,694 40-70 China 0.664 0.12 0.43 0.87 1.39 2.37
Table 1. Isoflavone intake in infants using soy infant formula and free-living Asian children and adolescents.
Group/Reference N Age (y) Mean ± SD or range Country
Isoflavone exposure
Intake (mg/d) mg/kg/bw
Infants (Setchell et al. 1997, 1998) 4months US 28–47 6–9
Infants UK COTa 0–4months UK 2.4–9.5
Infants UK COTa >4–6months UK 1.– 7.2
Boys (Wada et al. 2011) 230 5.12 ± 0.89 Japan 12.2 0.70
Girls (Wada et al. 2011) 198 5.14 ± 0.90 Japan 11.4 0.66
Boys/Girls (Surh et al. 2006) NI 1–2 Korea 14.5 NCb
Boys/Girls (Surh et al. 2006) NI 3–6 Korea 8.9 NC
Boys/Girls (Surh et al. 2006) NI 7–12 Korea 12.4 NC
Boys/Girls (Surh et al. 2006) NI 13–19 Korea 10.1 NC
Boys/Girls (Hsiao and Lyons-Wall 2000) 66 8–9 Taiwan 36.6 1.13
Children/Adolescents (Hu et al. 2014) 174 0–14 China 0.53
Children (Messina, Nagata, and Wu 2006; Kato et al. 2014) NI 1–6 Japan 14 1.0 c
Adolescents (Messina, Nagata, and Wu 2006; Hatena Blog) NI 7–14 Japan 20 0.54d
aEstimates based on an isoflavone concentration of SIF of 18.0 to 46.7mg/l and an intake of 800 or 1200ml/d.
bNC, not calculated.
c14 kg as bw.
d37 kg used as bw.
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2015) is lower than in Japan but higher than in Singapore
(Talaei et al. 2014; Mueller et al. 2012) and Hong Kong (Ho
et al. 2003; Koh et al. 2005). Most soy consumed throughout
the world is in unfermented form, as ethnic Chinese con-
sume relatively little fermented soy whereas in Japan, about
half of all soy consumed is fermented (Messina, Nagata, and
Wu 2006). Table 3 shows the isoflavone intake among par-
ticipants in several long-term intervention trials. As can be
seen, intake was quite a bit higher than typical Asian isofla-
vone intake. The trial identified with the highest exposure
was a Taiwanese study involving postmenopausal women
that intervened with 300mg/d isoflavones (Tai et al. 2012).
Isoflavone occurrence and function in plants
Isoflavones are distinct from the much more common flavo-
noids in the position of the phenyl B ring – in isoflavonoids,
it is a substituent at the 3-position of the heterocyclic ring
(flavonoids have the B-ring at the 2-position). Isoflavonoids
are formed from flavonoids by the enzyme isoflavone
isomerase. The main source of isoflavones are legumes from
the family Fabaceae (Dixon and Sumner 2003), namely
soybeans (Glycine max) which contain daidzein (7,40-
dihydroxyisoflavone), genistein (5,7,40-trihydroxyisoflavone)
and glycitein (7,40-dihydroxy-6-methoxyisoflavone), and red
clover (Trifolium pratense), which contains the methylated
isoflavones formononetin (7-hydroxy-40-methoxyisoflavone)
and biochanin A (5,7-dihydroxy-40-methoxyisoflavone). Less
common sources of isoflavones in plants used as foods are
the tubers of the American groundnut, Apios americana,
where they are as glycosyl-glycosides and in the root of
Pueraria lobata (Kudzu) as C-glucosides (Barnes et al. 2002;
Ichige et al. 2013).
Gut bacterial metabolism of isoflavones in mammals
results in reduction of the heterocyclic ring to form the iso-
flavanones, dihydrodaidzein and dihydroxygenistein, and the
ring cleaved O-desmethylangolensin. Further bacterial
reduction of isoflavonones leads to the isoflavan equol (40,7-
dihydroxyisoflavan) (Setchell, Brown, and Lydeking-Olsen
2002). None of these metabolites are normally found in
foods although they are a consequence of consuming isofla-
vone-containing foods. Small amounts, however, are present
in dairy products from cows, goats and sheep consuming
soybeans or isoflavone-containing clover.
In plants, isoflavones function as phytoalexins, low-
molecular compounds synthesized and accumulated in
plants during stress and microbe attacks. These active
defense compounds have fungistatic, antibacterial, antiviral,
and antioxidant properties (Dakora and Phillips 1996).
Isoflavone concentration rises during stress (e.g., lowered
humidity, pathogen attack, or plant diseases) and is, to a
large extent, influenced by environmental and climatic con-
ditions such as temperature, precipitation, harvest period and
soil fertility (Scilewski da Costa Zanatta et al. 2017; Bobby
et al. 2014; Hasanah et al. 2015). However, an even greater
determinant of isoflavone concentration is soybean variety as
isoflavone content has been shown to vary as much as 10-fold
among varieties (Eldridge and Kwolek 1983; Kim et al. 2014;
ILSI range is from ILSI Crop Composition Database 2019),
although the genetic modification of soybeans does not appear
to appreciably alter isoflavone concentration (Padgette et al.
1996; Taylor et al. 2017; Lepping, Herman, and Potts 2013;
Harrigan et al. 2007; McCann et al. 2005; Novak and
Haslberger 2000; Lappe et al. 1998).
In addition to functioning as phytoalexins, isoflavones
play many roles in plant-microbe interactions, including rhi-
zobia-legume symbiosis (Rıpodas et al. 2013). Isoflavones
are essential for nodulation because of their ability to induce
the nodulation genes (Subramanian, Stacey, and Yu 2006).
They are therefore responsible for natural enrichment of
fixed nitrogen in soils, a role well known to farmers who
unknowingly used plants producing isoflavones in a crop
rotation strategy.
As noted previously, genistein, daidzein and glycitein
account for approximately 50, 40 and 10%, respectively, of
the total isoflavone content of soybeans, although this can
vary from strain to strain (Murphy, Barua, and Hauck
2002). The hypocotyls of soybeans contain much higher iso-
flavone concentrations than cotyledons with a much higher
proportion of glycitein (up to 45%). Isoflavones in soybeans
prior to food processing are b-glycosides esterified with mal-
onic acid (Kudou et al. 1991). In fermented soyfoods, much
of the isoflavones present are in aglycone form but the per-
centage varies markedly (Murphy, Barua, and Hauck 2002;
Jang et al. 2008; Chan et al. 2009; Fukutake et al. 1996; Wei,
Chen, and Chen 2008; Kuo et al. 2006; Chun, Chung, and
Song 2007; Chun et al. 2007). If the fermentation is a
lengthy process (for miso or some forms of soy sauce this
can be up to nine months), additional oxidative metabolism
can occur introducing hydroxyl groups into the 6- and 8-
positions on the A-ring (Esaki et al. 1999).
Hexane extraction to recover the oil fraction of soybeans
does not alter the isoflavone content of soybean protein.
However, the boiling water extraction of soybeans to make
Table 3. Selected examples of isoflavone exposure in intervention trials of at least approximately 2 years duration.
Sex N Age (y) Mean ± SD or 95% CI Country Duration
Isoflavone exposure
mg/d mg/kg/bw
Women (Hodis et al. 2011) 76 60.8 ± 7.2 US 3 years 91 1.31
Women (Alekel et al. 2010) 73 54.7 (52.0, 56.9) US 3 years 120 1.80
Women (Tai et al. 2012) 200 55.8 ± 3.6 Taiwan 96weeks 300 5.46
Women (Unfer et al. 2004) 154 49 ± 4.3 Italy 5 years 150 2.24
1.34
Men (Bosland et al. 2013) 53 61.3 ± 7.2 US 2 years 41 0.47
Men (Fleshner et al. 2011) 153 62.5 Canada 3 years 100 1.20
Assumed dose refers to aglycone equivalent weight (unclear from text).Assumed dose refers to glycoside weight (unclear from text).
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soymilk (and then tofu) causes the hydrolysis of the malonyl
group, yielding simple b-glucosides (Barnes, Kirk, and
Coward 1994). This also occurs during the hot aqueous
alcohol extraction of soy flour and accordingly, the remain-
ing protein fraction is largely depleted of isoflavones. When
the alcohol is evaporated from the extract, the residue is soy
molasses, a rich source of isoflavone b-glucosides. When
heating soy in a dry format (extrusion of soy protein
concentrate or toasting of soybeans, soy flour or the hypoco-
tyls), the malonyl group is decarboxylated to form the 60’-O-
acetyl-7-O-b-glucoside (Barnes, Kirk, and Coward 1994).
Isoflavone absorption and metabolism
According to EFSA, no estimate of bioavailability of isofla-
vones in humans can be given although it concluded bio-
availability was low (EFSA ANS Panel (EFSA Panel on Food
Additives and Nutrient Sources added to Food) 2015). In
rats, absolute bioavailability of genistein was 7% and 15% in
males and females, respectively. Setchell et al. (2001, 2003)
showed that the bioavailability of genistein is greater than
that of daidzein as determined by the area under the curve
for the serum isoflavones. In cheetahs and domestic cats, the
UDP-glucuronyltransferase gene specific for b-glucuronida-
tion of genistein (UGT1A6) contains a stop codon (Court
and Greenblatt 2000). In these animals, the predominant
form of isoflavones in their blood is their sulfonates
(Whitehouse-Tedd et al. 2011).
Unlike the aglycones, b-glycosides cannot be absorbed
due to their higher hydrophilicity and higher molecular
mass (Hur et al. 2000). They become bioavailable and can
be absorbed only when hydrolyzed (Setchell, Brown, and
Lydeking-Olsen 2002), which can occur along the entire
length of the gastrointestinal tract, including colonic bacteria
(Hur et al. 2000), but mostly, they are hydrolyzed in the
jejunum (Zubik and Meydani 2003) by brush border mem-
brane and b-glucosidases (Nemeth et al. 2003), such as lac-
tase-phlorizin hydrolase, which are active from relatively
early life (Day et al. 2000). Lactase-phlorizin hydrolase is
also responsible for lactose hydrolysis (Rivera-Sagredo et al.
1992). Once the glycosides are hydrolyzed, the resulting
aglycone can be absorbed via passive diffusion (Decroos
et al. 2005); typically this occurs within 1–2 h (King,
Broadbent, and Head 1996; Sfakianos et al. 1997). The iso-
flavones in the root of kudzu vine (Pueraria lobata) are C-
glycosides. Because of this, puerarin, the C-glycoside of
daidzein, is absorbed without deconjugation with a peak
concentration in the blood within the hour (Prasain et al.
2007). It is inferred that intestinal absorption occurs via the
Naþ-dependent glucose transporter since puerarin depresses
glucose absorption whereas daidzin does not (Meezan
et al. 2005).
In rats, intraduodenally administered genistein is almost
completely absorbed; however, it is converted in enterocytes
to its 7-O-b-glucuronide, the principal form of genistein and
other isoflavones found systemically (Cheng et al. 1953).
Genistein-7-O-b-glucuronide is excreted into bile. Only
about 20% of intraduodenally administered genistein-7-O-
b-glucuronide is recovered in bile over a 4-h period; how-
ever, when it is distally administered, biliary recovery is
60–70% (Cheng et al. 1953). This suggests that genistein-7-
O-b-glucuronide undergoes bacterially-induced hydrolysis
and hence undergoes enterohepatic circulation. In addition,
genistein is converted to p-ethylphenol and its sulfonate and
b-glucuronide metabolites. Genistein can also be converted
to double conjugates (di-b-glucuronide and b-glucuronide/
sulfonates) (Soukup et al. 2016; Paul et al. 2017). In mice,
absolute bioavailability amounted to 9–14% for genistein and
29–34% for daidzein (Andrade et al. 2010). Urinary or plasma
isoflavones have been shown to be reliable biomarkers of soy
consumption (Atkinson et al. 2002; Grace et al. 2004; Wu
et al. 2003) and, when the timing of specimen collection is
considered, the urinary appearance of isoflavones has been
shown to accurately reflect circulating levels (Franke, Custer,
and Hundahl 2004; Franke et al. 2006).
There is a biphasic isoflavone appearance pattern in
plasma and urine of humans after the consumption of soy
or purified isoflavone preparations with peak isoflavone lev-
els occurring 1–2 h and again 4–8 h after intake (Setchell
et al. 2003; Zubik and Meydani 2003; Fanti et al. 1999;
Franke et al. 1999; King and Bursill 1998). The time of the
first peak represents small intestinal absorption via passive
absorption (Setchell et al. 2003) of aglycones and glycosides
that were hydrolyzed (Day et al. 2000), whereas the second
peak represents absorption of isoflavone glycosides by the
large intestine after hydrolysis by gut bacteria (Franke,
Custer, and Hundahl 2004; Franke, Lai, and Halm 2014).
After absorption, genistein and daidzein are metabolized
by UDP-glucuronyl transferase to glucuronides, and to a
lesser extent by sulfotransferases to sulfate esters in the
intestinal mucosa cells and liver (Ronis et al. 2006).
Conjugation can occur in one or two (40 or 70) locations of
the isoflavone ring. These metabolites (mono- and diglucur-
onides, mono- and disulfates, and sulfoglucuronides of daid-
zein and genistein), which can be found in the plasma
(Hosoda et al. 2010), are excreted in the bile and deconju-
gated in the distal part of the intestine. Deconjugation
allows them to be absorbed again and be part of the entero-
hepatic circulation (Barnes 2010).
The isoflavone daidzein is metabolized to S-equol and O-
desmethylangolensin (ODMA) by gut bacteria and excreted
predominantly through the urine (Axelson et al. 1984). Most
people are able to make ODMA, but the ability to produce
S-equol is limited to 25–50% of the population; whether this
metabolic feature results in more beneficial health effects
from soy consumption remains uncertain (Setchell, Brown,
and Lydeking-Olsen 2002; Atkinson, Frankenfeld, and
Lampe 2005).
The extent of isoflavone metabolism varies among indi-
viduals and may be influenced by dietary factors (Lampe
et al. 1999; Rowland et al. 2000). There is a wide inter-indi-
vidual variability in serum levels among individuals in
response to isoflavone ingestion (Wiseman et al. 2004;
Mathey et al. 2006). For example, in two studies involving
postmenopausal women who consumed 100mg/d isofla-
vones, in one the mean (SD) genistein level after 10weeks
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(N¼ 25) was 806 nmol/l (1238) (Wiseman et al. 2004),
whereas in the other (N¼ 12), after 60 days it was
2.42 mmol/l (0.84–4.15) (Mathey et al. 2006).
Setchell et al. (2011) extensively examined phase II isofla-
vone conjugation and found major differences between
humans and rodents. Namely, the proportion of unconju-
gated genistein in plasma from adults and infants who con-
sumed different soyfoods, pure genistein, or an isoflavone
supplement was <1% in steady state and <2% at peak con-
centrations. By contrast, the plasma percentages of unconju-
gated genistein concentrations in Sprague-Dawley rats and
C57BL/6, nude, and transgenic AngptL4B6 mice were
4.0 ± 0.6%, 4.6 ± 0.6%, 11.6 ± 0%, and 30.1 ± 4.3%, respect-
ively, which represent 20, 23, 58, and 150 times that in
humans. Similar results were reported by Gu et al. (2006);
for example, they found <1% of the isoflavones in human
plasma were present as aglycones whereas in monkey serum,
6% was. Soukup et al. (2016) concluded that “… there are
marked differences between humans, rats and mice in the
profile of major metabolites following IF [isoflavone] phase
II metabolism.”
That much less unconjugated isoflavone is present in
human compared to rodent serum is an important observa-
tion because the conjugate has relatively little biological
activity (Yuan et al. 2012; Islam et al. 2015). It is the isofla-
vone aglycones that show an affinity for ERs and have other
non-hormonal effects (Setchell 2000).
Pharmacokinetic studies show that peak plasma level
(Cmax) is achieved faster when aglycones as opposed to glu-
cosides are consumed (Setchell et al. 2001; Izumi et al. 2000;
Kano et al. 2006; Cassidy et al. 2006). Cmax may also be
higher, but whether total isoflavone absorption is greater in
response to the ingestion of aglycones vs glycosides is
unclear as the data are quite conflicting with some studies
showing no difference in urinary isoflavone excretion
between fermented and unfermented foods or glycosides
and aglycones (Zubik and Meydani 2003; Beeson et al. 1989;
Butler et al. 2008; Davey et al. 2003; Messina 2004; Patisaul,
Fenton, and Aylor 2018; Jocsak et al. 2019; Gu et al. 2006;
Setchell et al. 2011; Vandenplas et al. 2014; Testa et al. 2018;
Jefferson, Patisaul, and Williams 2012; Badger et al. 2009;
Stevens 2017; McCarver et al. 2011; Bhatia and Greer 2008;
Badger et al. 2002; Yilmaz et al. 2020; WHO & UNEP 2013;
Soy Infant Formula 2019; Boucher et al. 2008; Murphy et al.
1999; Vieux, Maillot, and Rehm 2020; Yang et al. 2005; Lee
et al. 2007; Shu et al. 2015; Liu et al. 2004; Lee and Kim
2007; Kim et al. 2015; Talaei et al. 2014; Mueller et al. 2012;
Ho et al. 2003; Koh et al. 2005; Tai et al. 2012; Dixon and
Sumner 2003; Barnes et al. 2002; Ichige et al. 2013; Dakora
and Phillips 1996; Scilewski da Costa Zanatta et al. 2017;
Bobby et al. 2014; Hasanah et al. 2015; Eldridge and Kwolek
1983; Kim et al. 2014; ILSI range is from ILSI Crop
Composition Database 2019; Padgette et al. 1996; Taylor
et al. 2017; Lepping, Herman, and Potts 2013; Harrigan
et al. 2007; McCann et al. 2005; Novak and Haslberger 2000;
Lappe et al. 1998; Rıpodas et al. 2013; Subramanian, Stacey,
and Yu 2006; Kudou et al. 1991; Kuo et al. 2006; Chun,
Chung, and Song 2007; Chun et al. 2007; Esaki et al. 1999;
Barnes, Kirk, and Coward 1994; EFSA ANS Panel (EFSA
Panel on Food Additives and Nutrient Sources added to
Food) 2015; Setchell et al. 2003; Setchell et al. 2001; Court
and Greenblatt 2000; Whitehouse-Tedd et al. 2011; Hur
et al. 2000; Setchell, Brown, and Lydeking-Olsen 2002;
Zubik and Meydani 2003; Nemeth et al. 2003; Day et al.
2000; Rivera-Sagredo et al. 1992; Decroos et al. 2005; King,
Broadbent, and Head 1996; Sfakianos et al. 1997; Prasain
et al. 2007; Meezan et al. 2005; Soukup et al. 2016;
Paul et al. 2017; Andrade et al. 2010; Atkinson et al. 2002;
Grace et al. 2004; Wu et al. 2003; Franke, Custer, and
Hundahl 2004; Franke et al. 2006; Fanti et al. 1999; Franke
et al. 1999; King and Bursill 1998; Franke, Lai, and Halm
2014; Ronis et al. 2006; Hosoda et al. 2010; Barnes 2010;
Axelson et al. 1984; Atkinson, Frankenfeld, and Lampe
2005; Lampe et al. 1999; Rowland et al. 2000; Wiseman
et al. 2004; Mathey et al. 2006; Yuan et al. 2012; Islam et al.
2015; Setchell 2000; Izumi et al. 2000; Kano et al. 2006;
Cassidy et al. 2006; Tsangalis et al. 2005; Richelle et al. 2002;
Xu et al. 2000; Tsunoda, Pomeroy, and Nestel 2002;
Maskarinec et al. 2008) whereas other studies show greater
absorption with fermented foods/aglycone isoflavones
(Setchell et al. 2001; Izumi et al. 2000; Kano et al. 2006;
Cassidy et al. 2006; Hutchins et al. 1995; Silva et al. 2020;
Jang et al. 2020).
Finally, although estimates vary somewhat, the elimin-
ation half-life for isoflavones is approximately 8 h (Setchell
et al. 2003; Setchell et al. 2001; King and Bursill 1998;
Watanabe et al. 1998; Shelnutt et al. 2002; Busby et al. 2002;
Burnett et al. 2011; Takimoto et al. 2003). Therefore, as con-
cluded by Setchell et al. (2003), steady state plasma concen-
trations would be more readily maintained by repeated
ingestion of isoflavones throughout the day than by inges-
tion just once a day. Also, the bioavailability of isoflavones
is nonlinear at higher intakes, suggesting that uptake is rate-
limiting and saturable (Setchell et al. 2003). Work in post-
menopausal women showed that doubling isoflavone intake
increased plasma concentrations by 55–62% for daidzein,
genistein and equol (only for producers) (van der Velpen
et al. 2014).
Serum and tissue isoflavone levels
Adlercreutz, Markkanen, and Watanabe (1993) were the first
to report serum isoflavone levels in free living native
Japanese (Table 4). They found that among 14 middle-aged
men the geometric means (95% CI (Confidence Interval))
for serum total genistein and daidzein were 276 (116, 652)
and 107 (47, 237) nmol/l, respectively. Samples were col-
lected in the morning but no information about the dietary
intake of the study participants was provided. These levels
dwarfed the mean genistein and daidzein levels of 6.3 and
6.2 nmol/l, respectively, in Finnish men (Adlercreutz,
Markkanen, and Watanabe 1993). For comparison, plasma
genistein and daidzein levels in 7 infants fed SIF were 2.5
and 1.2 mmol/l, respectively (Setchell et al. 1997). Also for
comparison, serum genistein and daidzein concentrations
among vegetarian and vegan participants of the Oxford cen-
ter (UK) of the European Prospective Investigation into
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Cancer and Nutrition were 148 and 79 nmol/l, respectively,
which were 5–50 times higher than those in the other study
center regions which involved almost exclusively non-vegeta-
rians (Peeters et al. 2007). The values reported by Adlercreutz,
Markkanen, and Watanabe (1993) are generally in line with
those of several other investigators as shown in Table 4.
Two studies nicely illustrate the circulating levels of iso-
flavones that can be reached in response to an isoflavone
intake that greatly exceeds typical Asian intake. In a study
by Busby et al. (Busby et al. 2002), 30 healthy men ingested
a single dose of one of two soy-derived isoflavone prepara-
tions. The delivered doses of genistein were 1, 2, 4, 8, or
16mg/kg bw. Formulation A was composed of approxi-
mately 90% genistein, 10% daidzein, and 1% glycitein
whereas formulation B was composed of 43% genistein, 21%
daidzein, and 2% glycitein. As shown in Table 5, in response
to a single dose (formulation B) that provided 4, 8 or 16mg
genistein per kg bw, serum total genistein concentrations
were approximately 9, 18 and 27mmol/l, respectively. The
data included in Table 5 also show the extremely low per-
centage of isoflavones in serum in the unconjugated form.
In the other study, Tai et al. (2012) found that among
postmenopausal women, genistein levels reached approxi-
mately 7 mmol/l in response to the consumption of 300mg/d
isoflavones (172.5mg genistein þ 127.5mg daidzein) at
4 weeks, although levels decreased as the 2-year study
progressed, which may reflect a decrease in compliance
(Table 6).
Finally, research in humans confirms that isoflavones end
up in tissues (Pumford et al. 2002; Hong et al. 2002;
Br€ossner et al. 2006). For example, in women who con-
sumed approximately 60mg/d isoflavones for five days in
the form of either soymilk or as a supplement, total genis-
tein and daidzein concentrations (aglycone equivalents)
ranged from 135.1 to 2831 nmol/L and 105.1 to 1397 nmol/
L, respectively, in hydrolyzed serum and from 92.33 to
Table 5. Serum isoflavone levels in men in response to varying isoflavone doses (Busby et al. 2002).
Formulation
Dose (mg/kg bw) Genistein (mM) Daidzein (mM)
Genistein Daidzein Unconjugated Total Unconjugated Total
A 1.0 0.11 0.929 ± 0.088
A 2.0 0.22 2.095 ± 0.451
A 4.0 0.44 4.418 ± 2.502 0.583 ± 0.279
A 8.0 0.89 0.131 ± 0.021 8.037 ± 2.203 0.906 ± 0.228
A 16.0 1.8 0.066 ± 0.031 7.594 ± 1.384 1.315 ± 0.057
B 1.0 0.49 0.074 2.729 ± 1.710 0.060 1.429 ± 0.767
B 2.0 0.98 0.069 ± 0.033 5.492 ± 1.516 0.040 ± 0.010 2.221 ± 0.640
B 4.0 2.0 0.084 ± 0.014 9.479 ± 2.053 0.070 ± 0.012 4.857 ± 0.384
B 8.0 3.9 0.258 ± 0.134 17.87 ± 2.426 0.139 ± 0.027 7.678 ± 1.961
B 16.0 7.8 0.363 ± 0.213 27.46 ± 15.38 0.315 ± 0.261 16.94 ± 8.711
Table 4. Serum isoflavone levels in native Japanese adults.
Author/Year/Reference
Genistein (nmol/l) Daidzein (nmol/l)
Sex/N Mean SD Median IQR Mean SD Median IQR
Nagata 2016 (Nagata et al. 2016) M/56 317 146, 685 112 177, 268
Otokozawa 2015 (Otokozawa et al. 2015)
Minatoya 2015 (Minatoya et al. 2015) 185 75, 530 87 28, 266
Premenopausal F/31 411 729 197 431
Postmenopausal F/45 428 508 328 540
Michikawa 2015 (Michikawa et al. 2015) M/121c 239 116, 601 108 39, 263
F/54c 165 63, 608 85 21, 256
Sugiyama 2014 (Sugiyama et al. 2014) M/28 219 118, 418 76 34, 124
Hara 2013 (Hara et al. 2013) M/71, 81 826a 111a
F/34, 39 710a 102a
Hozawa 2013 (Hozawa et al. 2013) M/73, F/104 538, 996d 302, 502d
Shimazu 2011 (Shimazu et al. 2011) F/252 268 110, 470 125 46, 242
Kurahashi 2008 (Kurahashi et al. 2008) M/402 319 145, 722 140 55, 320
Fujimoto 2008 (Fujimoto et al. 2008)
Japanese M/18b 408 372 274 27, 1324 229 207 124 8, 593
Korean M/20b 429 423 229 28, 1512 379 780 142 15, 3676
Iwasaki 2008 (Iwasaki et al. 2008) F/288 535 292, 946 70 22, 160
Nagata 2006 (Nagata et al. 2006) F/194e 117 50
Zhao 2006 (Zhao et al. 2006) F/129 617 808 376 545 166 199 109 177
Takashima 2004 (Takashima et al. 2004)
Equol producers
Non-producers
M/41 290 40, 2110 50 28, 1522
M/47 262 27, 1432 78 11, 502
Ozasa 2004 (Ozasa et al. 2004) M/151 368 185, 850 139 64, 320
Akaza 2004 (Akaza et al. 2004) M/162 313 96
Morton 2002 (Morton et al. 2002) M/102 493 601 288 283 375 149
F/125 502 718 234 247 370 110
Nagata 2002 (Nagata et al. 2002) F/87 414 644 162 204
Yamamoto 2001 (Yamamoto et al. 2001) M,F/202 475 510 120 136
Adlercreutz 1993 (Adlercreutz, Markkanen, and Watanabe 1993) M/14 276 116, 652 107 47, 237
Interquartile range aMedian for third tertile bAged 50–59 years cSubjects with hepatitis virus infection dRange for third tertile eConcentration at delivery. For
studies reporting values for cases and controls, only the latter were used.
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493.8 pmol/g and 22.15 to 770.8 pmol/g, respectively, in
hydrolyzed breast tissue (Bolca et al. 2010). Pumford et al.
(2002) reported that in four women who consumed 45mg/d
isoflavones for two weeks prior to surgery, mean tissue gen-
istein and daidzein concentration was 0.665 nmol/g and
0.145 nmol/g wet breast tissue, respectively.
Interestingly, Gardner et al. (2009) concluded that pros-
tate tissue may have the ability to concentrate dietary soy
isoflavones. In their study, men received 82mg/d isoflavones
for two weeks prior to radical prostatectomy. The median
total isoflavone concentration in the isoflavone supple-
mented group was 2.3mmol/L in the prostate tissue and
0.7mmol/L in the serum. Total isoflavone concentrations in
this group were an average of 6-fold greater in prostate tis-
sue compared to serum; the tissue versus serum ratio was
significantly lower for genistein than daidzein, 4-fold versus
10-fold. The conclusion that the prostate concentrates isofla-
vones relative to the serum was also reached by Rannikko
et al. (2006) and Hedlund et al. (2005) (daidzein only).
Receptor binding
In general, phytoestrogens act through nuclear estrogen
receptors, ERa and ERb, influencing transcription of their
target genes. They exert effects on cellular processes that
include proliferation, apoptosis and migration. The ERs can
also be associated with the plasma membrane and cause rapid
cytosolic signaling. Phytoestrogens also serve as ligands for
the nonclassical membrane G-protein coupled estrogen recep-
tor (GPR30) and induce estrogenic responses in
cardiovascular and metabolic regulation through mitogen-
activated protein kinases, phosphoinositide 3-kinase, adenylyl
cyclase and phospholipase C signaling pathway (Govind and
Thampan 2003; Prossnitz, Arterburn, and Sklar 2007).
The identification of ERb in 1996 (Kuiper et al. 1996)
and the subsequent demonstration that in comparison to
ERa, soybean isoflavones preferentially bind to this newly
discovered ER (Kuiper et al. 1998; Kuiper et al. 1997)
changed the way in which isoflavones, as well as many other
ER ligands are viewed. This is because in general, activation
of ERa and ERb are seen as exerting proliferative and anti-
proliferative effects, respectively (Paruthiyil et al. 2004). As
noted previously, the selectivity of isoflavones with respect
to receptor binding, provided a molecular explanation for
classifying isoflavones as SERMs (Oseni et al. 2008).
Typically, the relative potency of isoflavones in discussed
in terms of relative binding affinity (RBA) and compared to
17b-estradiol, with the latter arbitrarily set at 100. Early
results from Kuiper et al. (1998) show isoflavones are less
potent than 17b-estradiol, that they bind with greater affin-
ity to ERb vs ERa and that genistein is more potent than
daidzein (Table 7). Several years later, Hwang et al. (2006)
reported similar values for the isoflavones as did Jiang et al.
(Table 8) (Jiang et al. 2013).
Hwang et al. (2006) also examined the ability of the iso-
flavones to regulate gene expression using a transiently
transfected estrogen sensitive reporter gene in embryonic
kidney cells and found genistein was nearly as potent as
17b-estradiol at stimulating gene expression (Hwang et al.
2006). In addition, they reported that in kidney cells isofla-
vones acted as estrogen agonists when cultured in media
Table 7. Relative binding affinity of isoflavones in comparison to estrogen (Kuiper et al. 1998).
Compound
RBAa RBAb
ERa ERb ERa ERb
17b-estradiol 100 100 100 100
Genistein 4 87 0.7 13
Daidzein 0.1 0.5 0.2 1.0
aDetermined from solid-phase (Scintistrip) competition experiments.
bDetermined from solubilized receptor competition experiments Affinities are expressed as RBA values where the affinity of E2 for ERa or ERb was set at 100%.
Table 8. RBA of isoflavones for ERa and ERb and comparison with E2 (Jiang et al. 2013).
Compound RBA (ERa) RBA (ERb) b/a
17b-estradiol 100 100 1.0
Genistein 0.021 6.80 324
Daidzein 0.003 0.051 17
S-Equol 0.144 3.50 24
Binding affinities for human full-length ERa and ERb were determined by
aRadiometric competitive binding assay using tritiated 17b-E2 as tracer and E2 as standard.
Table 6. Mean (SD) of serum genistein and daidzein concentrations at each visit among postmenopausal women from three medical centers in Taiwan partici-
pating in a 2-year clinical trial in which participants received either 300mg/d isoflavones or a placebo (Tai et al. 2012).
mmol/l/(n)
Week 0 Week 4 Week 48 Week 96
Genistein
Isoflavone 0.34 ± 1.26/212) 6.85 ± 5.05/(210) 4.10 ± 4.34/(204) 3.30 ± 3.18/(200)
Placebo 0.23 ± 0.74/(211) 0.19 ± 0.71/(210) 0.20 ± 0.67/(203) 0.24 ± 0.80/(198)
Daidzein
Isoflavone 0.09 ± 0.36/(212) 1.44 ± 1.35/(212) 1.12 ± 1.16/(204) 0.73 ± 0.92/200
Placebo 0.05 ± 0.20/(211) 0.07 ± 0.35/(211) 0.10 ± 0.48/(203) 0.04 ± 0.23/(199)
Blood samples taken after an overnight fast.
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Table 9. Search strategy.













7. exp Soybean Proteins/
8. exp Soy Foods/
9. exp Soy Milk/
10. (soy adj3 milk).mp.
11. soybeans.mp.
12. (soy adj3 bean$).mp.
13. soy food$.mp.
14. (soy adj3 beverage$).mp.
15. or/1-14
16. Endocrine.mp.
17. exp Reproductive Health/
18. exp Fertility/








27. exp Menstrual Cycle/
28. menstrual cycle.mp.
29. exp Leiomyoma/
30. (uterine adj3 fibroid$).mp.
31. exp Endometriosis/
32. endometriosis.mp.
33. exp Endometrial Neoplasms/
34. endometrial cancer.mp.
35. exp Lactation/
36. exp Lactation Disorders/
37. lactation.mp.
38. exp Breast Feeding/
39. (breast adj3 feeding).mp.
40. exp Breast Neoplasms/
41. (breast adj3 cancer).mp.
42. exp Sexual Maturation/
43. exp Puberty/
44. (puberty adj3 onset).mp.
45. exp Growth Disorders/
46. exp Adrenal Insufficiency/
47. exp Pituitary-Adrenal System/
48. (adrenal adj3 function).mp.
49. exp Thyroid Gland/
50. thyroid.mp.
51. exp Mucocutaneous Lymph Node Syndrome/
52. (kawasaki adj3 disease).mp.
53. or/16-52
54. 15 and 53
55. limit 54 to animals
56. 54 not 55
57. "randomized controlled trial".pt.
58. (random$ or placebo$ or single blind$
or double blind$ or triple blind$).ti,ab.
59. (retraction of publication or retracted publication).pt.
60. or/57-59
61. (animals not humans).sh.
62. ((comment or editorial or meta-analysis or practice-guideline
or review or letter or journal correspondence) not "randomized
controlled trial").pt.
63. (random sampl$ or random digit$ or random effect$ or
random survey or random regression).ti,ab.
not "randomized controlled trial".pt.
64. or/61-63
65. 60 not 64
66. exp cohort studies/
67. cohort$.tw.
68. controlled clinical trial.pt.
69. epidemiologic methods/
70. limit 69 to yr ¼ 1966-1989
71. exp case-control studies/
72. (case$ and control$).tw.
73. (case$ and series).tw.
74. case reports.pt.
75. (case$ adj2 report$).tw.




80. (meta-analys$ or meta analys$ or metaanalys$).tw,sh.
81. (systematic$ adj5 review$).tw,sh.
82. (systematic$ adj5 overview$).tw,sh.
83. (quantitativ$ adj5 review$).tw,sh.
84. (quantitativ$ adj5 overview$).tw,sh.
85. (quantitativ$ adj5 synthesis$).tw,sh.
86. (methodologic$ adj5 review$).tw,sh.
87. (methodologic$ adj5 overview$).tw,sh.
88. (integrative research review$ or research integration).tw.
89. or/78-88
90. 65 or 77 or 89
91. 56 and 90






6. (soy adj3 beans).mp.
7. soy protein.mp.
8. exp soybean protein/
9. exp soy food/
10. exp tofu/
11. miso.mp.
12. exp soybean milk/




17. exp reproductive health/
18. exp fertility/








27. exp menstrual cycle/
28. menstrual cycle.mp.
29. exp leiomyoma/
30. (uterine adj3 fibroid$).mp.
31. exp endometriosis/
32. endometriosis.mp.
33. exp endometrium cancer/
34. endometri$ cancer.mp.
35. exp lactation/
36. exp lactation disorder/
37. lactation.mp.
38. exp breast feeding/
39. (breast adj3 feeding).mp.
40. exp breast cancer/
41. (breast adj3 cancer).mp.
42. exp puberty disorders/
43. (puberty adj3 onset).mp.
44. exp growth disorder/
45. exp adrenal insufficiency/
46. exp adrenal function/
47. (adrenal adj3 function).mp.
48. exp thyroid gland/
49. thyroid.mp.
50. exp mucocutaneous lymph node syndrome/
51. (kawasaki adj3 disease).mp.
52. or/16-51
53. 15 and 52
54. limit 53 to human





58. (animal$ not human$).sh,hw.
59. (book or conference paper or editorial
or letter or review).pt.
not exp randomized
controlled trial/
60. (random sampl$ or random digit$
or random effect$ or random survey
or random regression).ti,ab.
not exp randomized controlled trial/
61. or/58-60
62. 57 not 61
63. exp cohort analysis/
64. exp longitudinal study/
65. exp prospective study/
66. exp follow up/
67. cohort$.tw.
68. exp case control study/
69. (case$ and control$).tw.
70. exp case study/
71. (case$ and series).tw.
72. case report/
73. (case$ adj2 report$).tw.
74. (case$ adj2 stud$).tw.
75. or/63-74
76. exp review/
77. (literature adj3 review$).ti,ab.
78. exp meta analysis/
79. exp "Systematic Review"/
80. or/76-79
81. (medline or medlars
or embase or pubmed or cinahl
or amed or psychlit
or psyclit or psychinfo
or psycinfo or scisearch
or cochrane).ti,ab.
82. RETRACTED ARTICLE/
83. 81 or 82
84. 80 and 83
85. (systematic$ adj2 (review$ or overview)).ti,ab.
86. (meta?anal$
or meta anal$ or meta-anal$
or metaanal$
or metanal$).ti,ab.
87. 84 or 85 or 86
62 or 75 or 87






6. (soy adj3 bean$).mp.
7. exp Soybean Proteins/
8. soy protein.mp.
9. exp Soy Foods/
10. exp Soy Milk/
11. (soy adj3 milk).mp.
12. soy food$.mp.
13. (soy adj3 beverage$).mp.
14. or/1-13
15. Endocrine.mp.


















32. exp Endometrial Neoplasms/
33. endometrial cancer.mp.
34. exp Lactation/
35. exp Lactation Disorders/
36. lactation.mp.
37. exp Breast Feeding/
38. (breast adj3 feeding).mp.
39. exp Breast Neoplasms/
40. (breast adj3 cancer).mp.
41. exp Puberty/
42. Sexual Maturation/
43. (puberty adj3 onset).mp.
44. exp Growth Disorders/
45. exp Adrenal Insufficiency/
46. (adrenal adj3
function).mp.




50. (kawasaki adj3 disease).mp.
51. or/15-50
52. 15 and 51
53. limit 52 to embase records
54. 52 not 53
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containing a low concentration of estrogen (1 1011 M),
but as estrogen antagonists in the presence of a high estro-
gen concentration (1 109 M)).
Earlier work had already demonstrated a biphasic effect
of genistein on the growth of MCF-7 cells (an estrogen-
dependent human breast cancer cell line) (Hsieh et al.
1998). At relatively low concentrations genistein stimulated
growth, an effect dependent upon interaction with the ERs,
whereas at higher concentrations (>105 M), growth was
inhibited (Wang et al. 1996). The latter effect was independ-
ent of ERs, likely a result of the ability of genistein to
inhibit the activity of enzymes overexpressed in cancer cells
such as protein-tyrosine kinases or DNA topoisomerases
(Constantinou and Huberman 1995; Constantinou et al.
1995). However, there is considerable doubt as to the bio-
logical relevance of these higher in vitro levels.
Methods
Search strategy
To identify relevant literature, a systematic search in
Medline, EMBASE, and the Cochrane Library (from incep-
tion through January 2021), using the search strategy shown
in Table 9 was conducted. Manual searches of reference lists
of review articles and included studies supplemented the
electronic database searches. The electronic and manual
searches were performed by one author (SBM). Articles
found by experts in the field contributed to manual searches.
Eligible for inclusion were clinical studies, observational
studies and systematic reviews and meta-analyses (SRMAs)
that investigated the effects or associations of soyfoods or
soy/isoflavone supplements on outcomes of the endocrine
human system. The search was restricted to humans. British
Medical Journal (BMJ) study design search filters were used
for clinical trials, observational studies and SRMAs
(Anderson, Smith, and Washnock 1999). Duplicate articles,
abstracts, reviews, in vitro and animal studies, as well as
studies including soy as part of a dietary pattern were
excluded. An assessment of study quality and certainty of
evidence was not formally undertaken as doing so was
beyond the scope of this technical review.
Results
Figure 1 shows the flow of the literature search and study
selection. Of the 2038 reports identified, 1621 were excluded
whereas 417 reports were included (229 observational stud-
ies, 157 clinical studies and 32 SRMAs).
Individual observational and clinical studies with relevant
endpoints are generally not specifically discussed if they
were included in systematic reviews and meta-analyses that
were cited. Further, individual studies published prior to the
publication of a systematic review and/or meta-analysis that
were not included in the review or meta-analysis were in
general not discussed even if the endpoints were relevant,
because it was assumed these studies were eliminated for
failure to meet the established inclusion/exclusion criteria.
Thyroid function
The impact of soy on thyroid function has been investigated
for nearly a century (McCarrison 1933) and for at least
30 years, soy has been labeled as a goitrogenic food in the
peer-reviewed literature (Gaitan 1990). In the early 1960s,
several cases of goiter were attributed to the use of SIF,
although this issue was eliminated soon thereafter once the
formula began to be fortified with iodine (van Wyk et al.
1959; Shepard et al. 1960; Pinchera et al. 1965). However,
concern arose again several decades later based primarily on
in vitro and animal studies involving isolated isoflavones
(Divi, Chang, and Doerge 1997; Divi and Doerge 1996;
Doerge and Chang 2002). Drawing attention to the thyroid
issue were remarks about the goitrogenic effects of isofla-
vones submitted to the US FDA in 1999 during the open
comment period in connection with the FDA’s evaluation of
the evidence in support of the heart health claim for soy-
foods (Food Labeling: Health Claims; Soy Protein and
Coronary Heart Disease 1999).
Several mechanisms have been offered for the untoward
effects of isoflavones on thyroid function (de Souza Dos
Santos et al. 2011). For example, in vitro isoflavones inhibit
the activity of thyroid peroxidase (TPO) and serve as an
alternate substrate to tyrosine for iodination (Doerge and
Chang 2002). TPO liberates iodine for addition onto tyro-
sine residues on thyroglobulin for the production of thyrox-
ine (T4) and triiodothyronine (T3) (Divi and Doerge 1996).
A variety of flavonoids inhibit TPO activity in vitro (Divi
and Doerge 1996), although isoflavones are more potent
than most (Divi, Chang, and Doerge 1997). High flavonoid
intake reportedly contributed to the high prevalence of iod-
ine deficiency disease among Indian children living in an
iodine-deficient area (Brahmbhatt, Brahmbhatt, and Boyages
2000). Isoflavones were also shown in vitro to interfere with
thyroxine binding to the transport protein transthyretin
(K€ohrle 2004; Radovic, Mentrup, and Kohrle 2006).
In 2004, a retrospective analysis of infants with congenital
hypothyroidism that included eight fed SIF and 70 not fed
SIF, led Conrad, Chiu, and Silverman (2004) to conclude
that SIF-fed infants had prolonged increases in levels of thy-
roid stimulating hormone (TSH). This increase was not
attributed to a direct effect on the thyroid, but rather to an
inhibitory effect of soy on the absorption of levothyroxine, a
medication used for the treatment of hypothyroidism.
Earlier work in rats showed a soy-containing diet caused
greater T4 excretion than the control diet (Van
Middlesworth 1957), an effect also reported in an infant
who was refractory to thyroid hormone while on SIF
(Pinchera et al. 1965). Thus, in the case of infants with con-
genital hypothyroidism, it may be prudent to avoid using
SIF (Conrad, Chiu, and Silverman 2004; Fruzza, Demeterco-
Berggren, and Jones 2012).
In hypothyroid adults, it is not clear as to whether soy
warrants special consideration as food in general and many
herbs, drugs and fiber and calcium supplements also inhibit
levothyroxine absorption (Liel, Harman-Boehm, and Shany
1996; Chiu and Sherman 1998; Shakir et al. 1997; Liel,
Sperber, and Shany 1994; Sperber and Liel 1992; Sherman,
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Tielens, and Ladenson 1994; Siraj, Gupta, and Reddy 2003;
Rosenberg 1994; Harmon and Seifert 1991; Liwanpo and
Hershman 2009; Garber et al. 2012). Recommendations do
not call for soyfoods to be avoided by hypothyroid patients
as one can opt to temporally separate ingestion of levothyr-
oxine from soyfood ingestion. General recommendations are
to consume levothyroxine 30–60minutes before breakfast or
4 hours after the last meal (Garber et al. 2012). An alternate
approach to temporal separation is to be consistent in medi-
cation administration and food (soy) consumption so that, if
necessary, the levothyroxine dose can be appropriately
titrated (Zeitler and Solberg 2010).
In 2006, a narrative review of 14 clinical trials concluded
that there is “… little evidence that in euthyroid, iodine-
replete individuals, soy foods, or isoflavones adversely affect
thyroid function” (Messina and Redmond 2006). This con-
clusion is consistent with considerable subsequently
published data. Notable in this regard is a 3-year random-
ized, double blind, placebo-controlled trial involving 138
postmenopausal women that intervened with 54mg/d genis-
tein (provided as aglycone). No effects were seen on T3, T4,
and TSH, autoantibodies against TPO, thyroglobulin and
thyroid microsomal antigen and thyroid hormone receptor
and retinoid receptor expression from peripheral blood
monocytes (Bitto et al. 2010). Other long-term trials (2–3 y)
have also shown isoflavone exposure does not affect thyroid
function (Alekel et al. 2015; Levis et al. 2011; Steinberg
et al. 2011).
In 2019, the first meta-analysis to examine the effect of
soy and isoflavones on thyroid hormones, which included
18 studies, found that soy had no effect on free T3 or free
T4 (Otun et al. 2019). Studies mainly intervened with food
supplements containing soy isoflavones, soy extracts, soy
protein, daidzein-rich isoflavones and isolated genistein. The
149 Reports discussed














502 Reports reviewed in full
417 Total reports*
157 Clinical studies 
229 Observational studies
32 SRMAs 








12 Clinical trial registration
1 Animal studies
1476 Reports reviewed for title and abstract






495 No endocrine disruption endpoint
136 Dietary patterns or non soy
173 Reviews
3 Methods paper, non-clinical or non-observational studies
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295 Cochrane Library (through January 2021)
149 Manual Searches
562 Duplicate reports 
269 Reports not discussed (Included in other 
SRMAs discussed, negligible isoflavone/soy 
intake, breast cancer incidence, case reports, or 
articles in other language than English)
Figure 1. Flow of the literature search and study selection. 1 report included both an SRMA and an observational study (Wei, Y.L., J. Guo, Y. Bian, Z. Gao, M. Du,
H. Yang, L. Chen, Y. Zhang, X. Wang, T. Chen, J. Chen, Z. Yu, C. Huo, D. Li, L. China Kadoorie Biobank Collaborative, Group, Soy intake and breast cancer risk: a pro-
spective study of 300,000 Chinese women and a dose-response meta-analysis. European Journal of Epidemiology, 2019. 21: p. 21.). Abbreviation: SRMA-systematic
review and meta-analysis.
12 M. MESSINA ET AL.
isoflavone dose ranged from 40 to 200mg/d. Of the 18 stud-
ies, two included both men and women, three included only
men, and 13 included only women. Two studies involved
subclinical hypothyroid patients.
The 2006 review previously referenced noted that “…
there remains a theoretical concern based on in vitro and
animal data that in individuals with compromised thyroid
function and/or whose iodine intake is marginal soy foods
may increase risk of developing clinical hypothyroidism”
(Messina and Redmond 2006). Both conditions have since
been addressed. Regarding the latter, as noted previously,
there is the potential for isoflavones to compete with the
amino acid tyrosine for iodination (Doerge and Chang
2002). However, Sosvorova et al. (Sosvorova et al. 2012)
found that daily supplementation with 80mg isoflavones
derived from red clover or soy for three months led to only
negligible amounts (0.01%) of iodinated isoflavones in
urine samples from study participants. Mean urinary genis-
tein levels increased from 20 nmol/l at baseline to 121 nmol/l
after 3months of supplementation. These results suggest,
although do not prove, that even in those whose iodine
intake is marginal, isoflavones will not adversely affect thy-
roid function.
Data on the effect of soy in individuals whose thyroid
function is suboptimal was published in 2011 (Sathyapalan
et al. 2011) and 2018 (Sathyapalan et al. 2018). Sathyapalan
et al. (2011) found in a cross-over study that exposure to
30 g/d SPI for eight weeks that provided 16mg isoflavones
increased the likelihood of progressing from subclinical to
overt hypothyroidism in comparison to the consumption of
30 g/d SPI that provided only 2mg isoflavones. However, in
2018, a similarly-designed study conducted by the same
research group found isoflavone exposure had no effect on
the progression of subclinical hypothyroidism, even though
a much larger dose of isoflavones (30 g/d SPI; 66mg isofla-
vones vs 0 isoflavones) was used (Sathyapalan et al. 2018).
These follow up results call into question the initial findings.
Two points about these two studies involving subclinical
hypothyroidism warrant comment. Both studies used as a
control a SPI from which the content of naturally occurring
isoflavone had been almost totally eliminated. Eliminating
isoflavones by alcohol extraction to such an extent can
potentially disrupt the tertiary nature of the protein, thereby
calling into question the suitability of the control protein
(Nikolaidis, Andreadis, and Moschakis 2017). Also, in the
2011 study, the decrease in blood pressure, insulin resist-
ance and inflammation was much greater than had previ-
ously been reported (Sathyapalan et al. 2011), which
suggests that the study findings may not be generalizable.
In 2015, EFSA concluded that “… the administration of
food supplements containing isoflavones is not associated
with clinically relevant changes in thyroid function (hypo or
hyperthyroidism) in the population of interest” that is, peri-
and postmenopausal women (EFSA ANS Panel (EFSA Panel
on Food Additives and Nutrient Sources added to Food)
2015). Three years later, after extensively reviewing the lit-
erature, the SKLM concluded that isoflavone exposure does
not adversely affect thyroid function in healthy women
(men were not evaluated) (H€user et al. 2018).
However, the SKLM also noted that special attention
should be given to susceptible risk groups; for example, peo-
ple who are iodine deficient and subclinical hypothyroid
patients. In regard to the former, the study by Sosvorova
et al. (2012) was cited by the SKLM, but only as evidence
that isoflavones are iodinated, not as evidence that they are
iodinated to a negligible extent and therefore, unlikely to
exacerbate marginal iodine status. In regard to subclinical
hypothyroid patients, the report by the SKLM was published
prior to the follow up study by Sathyapalan et al. (2018),
which as noted, found that in contrast to their initial study
(Sathyapalan et al. 2011), isoflavone exposure did not affect
the progression of subclinical hypothyroidism.
As noted previously, the meta-analysis of soy and thyroid
hormones by Otun et al. (2019) found no effects on free T4
or T3. However, there was a small, but statistically signifi-
cant rise in TSH levels (weighted mean difference: 0.248
mIU/L, 95% CI: 0.001, 0.494; p¼ 0.049) (Otun et al. 2019).
The authors concluded that the clinical significance of this
finding, if any, is unclear. There is disagreement about that
which constitutes the normal TSH reference range; however,
the upper limit is thought to be <5mIU, although treatment
is typically not recommended until levels reach 10 mIU
(Biondi 2013). Thus, the increase noted by Otun et al.
(2019) would appear to be relatively modest. Nevertheless, it
is consistent with a finding from a subset of participants of
the Adventist Health Study-2, in which high soy/isoflavone
intake was associated with elevated TSH (>5 mIU/l) among
women (n¼ 548), although not among men (n¼ 295)
(Tonstad et al. 2016). When comparing the 5th with the 1st
isoflavone intake quintile, the odds ratios (OR, 95% confi-
dence interval [CI]) for women and men were 4.17 (1.73,
10.06; p¼ 0.001) and 1.05 (0.27, 4.07; p¼ 0.9). However, in
contrast to this observational study, no relationship between
urinary isoflavone levels and serum TSH was noted among
participants in the in the National Health and Nutrition
Examination Survey (2007–2010) (Janulewicz et al. 2019),
but given the low isoflavone intake of the general US popu-
lation (Bai, Wang, and Ren 2014), this finding is of ques-
tionable value.
The increased TSH level reported by Otun et al. (2019)
was of marginal statistical significance; furthermore, the for-
est plot of the results shows that the increase was driven
almost entirely by four of the 26 comparisons, all four of
which were conducted by the same research group; two of
these are the studies involving subclinical hypothyroid
patients already discussed (Sathyapalan et al. 2011, 2018),
another involved early menopausal women (Sathyapalan
et al. 2017), and one men with type 2 diabetes mellitus and
subclinical hypogonadism (Sathyapalan et al. 2016). In add-
ition, in a two-year study not included in the meta-analysis
involving postmenopausal women who were given either a
placebo (n¼ 126) or 200mg/d isoflavones (n¼ 122), neither
TSH levels nor the number of women with positive thyroid
peroxidase autoantibodies differed between groups (Levis
et al. 2011).
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Recently, the effects of isoflavone intake on reverse T3
(rT3) were published although they are derived from a post
hoc analysis of two studies in which men or women con-
sumed 15 g/d SPI lacking in isoflavones or that provided
66mg isoflavones (Sathyapalan et al. 2018). In the study
involving men, there was an increase rT3 in the isoflavone
group compared to the control (0.45 vs 0.40 nmol/L;
p< 0.001) over the 3-month study period (Sathyapalan et al.
2016) whereas in the study involving women there was an
increase in the isoflavone group (0.33–0.37 nmol/L;
p< 0.001) at the 3month but not at the 6month time point
(0.33–0.31 nmol/l) (Sathyapalan et al. 2017). Although rT3 is
a major endogenous T4 metabolite, it is probably devoid of
major biological action in adults and its clinical significance
has not been established (Schmidt et al. 2018; Gomes-Lima
and Burman 2018).
One study was identified that examined the impact of
isoflavone intake on thyroid function in patients with
Hashimoto thyroiditis (Zhang et al. 2017), which is consid-
ered to be the most common autoimmune disease
(Caturegli, De Remigis, and Rose 2014). The women in this
study were randomized to either the placebo (n¼ 143) or
genistein (n¼ 135) group. Women in the latter group con-
sumed 600mg/d as the purified soy extract. After one
month of genistein treatment, T4 concentration increased
from 9.53 ± 2.51 mg/dl to 12.69 ± 2.71 mg/dL; fT4 concentra-
tion increased from 0.92 ± 0.22 mg/dL .34 ± 0.31 mg/dl and
serum TSH concentration decreased from 12.8 ± 3.1 nmU/L
to 8.8 ± 2.3mU/L. Genistein also decreased thyroperoxidase
antibody (TPOAb) and thyroglobulin antibody (TgAb) lev-
els. The authors of this study concluded that since levothyr-
oxine dosage was unchanged, the results suggest genistein
improved thyroid function. However, the genistein dose
used for this study should be considered a pharmacological,
not a physiological, dose.
Finally, there are the results of three observational studies
that examined isoflavone intake in relation to thyroid func-
tion. One found no relationship between soyfood intake
(n¼ 505) and urinary isoflavone levels (n¼ 95) and meas-
ures of thyroid function (serum free T4, TSH, and TPOAb
levels and TPOAb-positive percentages) among pregnant
women from Shenyang, China (Li et al. 2011). Another,
which involved 139 girls and 129 boys aged 8–15 y from the
Czech Republic, found positive associations between circu-
lating isoflavone levels and several measures of thyroid func-
tion, but not between soyfood intake (soyfood consumed
within the past 24 h, yes or no) and TSH and free T3 levels,
although free T4 levels were higher in the soyfood consum-
ers (16.48 vs 15.42 pmol/l, p¼ 0.0032) (Milerova et al. 2006).
A third case-control study involving nearly 600 Iranian chil-
dren ages 6 to 12 y found that the occurrence of goiter did
not differ according to soy intake (Mousavi, Tavakoli, and
Mardan 2006). Since the latter two studies involved low-soy-
consuming populations, their relevance is of questionable
value (Messina 2004). In the study from the Czech Republic,
blood genistein and daidzein levels were below 1 nmol/l
(Milerova et al. 2006). Even among those children who con-
sumed soyfoods within the past 24 h, mean genistein and
daidzein blood levels were only 1.4 and 1.1 nmol/l, respect-
ively. And in the Iranian study, soy intake was expressed as
the percentage of cases (goiter) and controls who had con-
sumed soy within the past month, which illustrates soy
intake is not common in Iran (Mousavi, Tavakoli, and
Mardan 2006).
Conclusions
Concerns about goitrogenic effects of isoflavones are based
primarily on the results of in vitro and animal studies. In
contrast to this research, extensive clinical data show that
isoflavones, even when intake greatly exceeds typical
Japanese intake, do not adversely affect T4 or T3 in euthyr-
oid individuals. Less research has focused on the effects of
isoflavones in those with a compromised thyroid function
such as subclinical hypothyroid patients and/or whose iod-
ine intake is marginal, but the studies that have involved
such individuals do not raise concerns. Still, more research
involving subclinical hypothyroid patients is warranted.
Research involving men only
Feminization/hormone levels
The idea that soy isoflavones may affect hormone levels in
men has been prompted by some studies but not corrobo-
rated by most others. Weber et al. (2001) found that an iso-
flavone-rich diet lowered testosterone levels in adult male
Sprague-Dawley rats. Three years earlier, Strauss et al.
(1998) found that genistein reduced serum and testicular
testosterone concentrations and prostate weight in mice.
Results from these rodent studies and others raised concern
that isoflavones feminize men, a concern which coincided
with rising apprehension that environmental estrogens play
a role in the declining sperm count occurring among men
worldwide (Sharpe and Skakkebaek 1993; Toppari et al.
1996; Skakkebaek, Rajpert-De Meyts, and Main 2001).
A few clinical studies have also reported decreases in tes-
tosterone levels in response to soy consumption (Goodin
et al. 2007; Gardner-Thorpe et al. 2003). For example,
Gardner-Thorpe et al. (2003) found that in young men con-
suming 3 scones daily providing a total of 120mg isofla-
vones, serum testosterone levels decreased over a 6 week
period in a pre-post comparison from 19.30 to 18.20 nmol/l
(p¼ 0.03). There was no decrease in the control group
although data were not presented. Four years later, Goodin
et al. (2007) found that in response to 56 g/d SPI, serum tes-
tosterone decreased 19% in healthy males during the 4-week
supplementation period and increased within 2weeks after
discontinuation of soy protein. This study did not involve a
control group and the isoflavone content of the SPI was not
reported. The amount of soy protein taken by the study par-
ticipants was approximately 5–6 times typical Japanese
intake (Konishi et al. 2019).
Two additional publications can be credited with raising
early concerns about male feminization. One was a US pilot
case-control study by Chavarro et al. (2008), which found
that soy intake was associated with lower sperm
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concentration among 99 males in subfertile couples treated
at a fertility center. Testosterone was not measured in this
study (Chavarro et al. 2008). The other was a case-report by
Martinez and Lewi (Martinez and Lewi 2008), which
described a 60-y-old male who developed gynecomastia
allegedly as a result of consuming 3 liters of soymilk per day
that was estimated to provided 360mg isoflavones (9 times
Japanese intake). In this case, testosterone levels were nor-
mal but estrogen and estradiol levels were elevated
(Martinez and Lewi 2008).
In contrast to this single case-report of gynecomastia, two
clinical trials reported no such effects. In one, men con-
sumed for 3months either 15 g/d SPI that provided 66mg
isoflavones or 15 g SPI that was devoid of isoflavones
(Sathyapalan et al. 2016). Breast ultrasounds were performed
on each study participant at enrollment and study termin-
ation. No changes in breast tissue volume were noted in
either group. In the other study, >300 men consumed a pla-
cebo or 40 g/d SPI that provided approximately 100mg iso-
flavones for nearly 3 years (Fleshner et al. 2011). There were
no differences in breast tenderness or swelling/enlargement
between groups.
In contrast to the few reports of lowered testosterone, the
first meta-analysis of clinical studies to examine the effects
of soy on reproductive hormone levels in men, which was
published in 2010, found no statistically significant effects of
isoflavone exposure via supplements or foods on circulating
levels of total testosterone, free testosterone, sex hormone
binding globulin (SHBG) or the free androgen index,
regardless of statistical model employed (Hamilton-Reeves
et al. 2010). This analysis included 15 placebo-controlled
treatment groups with baseline and ending measures and 32
reports involving 36 treatment groups. Study participants
ranged in age from 21 to 74 y; study length ranged from
1week to 4 y (although 1-y data were used in the analysis
for 4-y study (Li et al. 2008)) and daily isoflavone and soy
protein intake ranged from 20 to 900mg and from 0 to 71 g,
respectively.
Reports showing soy lowered testosterone have been pub-
lished subsequent to the meta-analysis (Hamilton-Reeves
et al. 2010). For example, a case-report by Siepmann et al.
(2011) described a 19-y-old vegan who developed hypo-
gonadism and erectile dysfunction allegedly as a result of his
soy consumption. Coincidentally, his isoflavone intake was
estimated to be 360mg/d, the same as in the previously cited
case-report (Martinez and Lewi 2008). Also, in resistance-
trained young men, supplementation with soy protein
resulted in lower testosterone levels in comparison to whey
protein and carbohydrate supplementation within
30minutes after exercise performance (Kraemer et al. 2013),
although evidence indicates that this acute decrease in tes-
tosterone level does not affect muscle protein synthesis
(Morton et al. 2018). In support of this contention are the
results of a recent meta-analysis showing that soy protein
supplementation in men undergoing resistance exercise
training led to gains in muscle mass and strength similar to
those observed in men supplemented with whey protein or
other animal proteins (Messina et al. 2018). In addition, a
subsequently published study found no differences in
increases in lean mass and strength in untrained participants
engaged in a resistance exercise program who supplemented
their diet with whey protein (19 g/d) or soy protein (26 g/d)
matched for leucine content (Lynch et al. 2020).
In 2021, an update to the 2010 meta-analysis (Hamilton-
Reeves et al. 2010) that included 41 clinical studies that
measured circulating total testosterone (n¼ 1753) and/or
free testosterone (n¼ 752) levels in men reached the same
conclusion as the 2010 analysis, that is, isoflavone intake,
even when exceeding 75mg/d, did not affect hormone levels
(Hamilton-Reeves et al. 2010; Reed et al. 2020). In addition
to the lack of effect on testosterone, there were also no
effects on circulating estradiol (n¼ 1000) or estrone levels
(n¼ 239). These latter findings concur with a previously
published narrative review that found soy/isoflavones have
no effect on estrogen levels in men or other endpoints
related to feminization (Messina 2010). Furthermore, subse-
quent to the updated meta-analysis an 18-month study was
published in which older men were randomized to receive
daily either approximately 19 g casein or 19 g soy protein
containing approximately 41mg isoflavones (Bosland et al.
2021). No differences between groups were found for circu-
lating levels of free testosterone or estradiol. Finally, as
somewhat of an aside because this research did not involve
an intervention, a Taiwanese cross-sectional study found
that a diet rich in preserved vegetables or processed meat or
fish, deep-fried foods, innards organs, rice or flour products
cooked in oil, and dipping sauce, but low in milk, dairy
products, legumes, or beans (soy), and dark or leafy vegeta-
bles) was associated with poor testicular function (lower tes-
tosterone levels, lower sperm concentration and subpar
sperm morphology) (Kurniawan et al. 2021).
Conclusions
The overwhelming amount of clinical evidence indicates nei-
ther soyfood nor isoflavone intake affect levels of total or
free testosterone or estrogen or estradiol levels in men.
Fertility
Male fertility, like female fertility, has also become a soy-
related topic of interest in part because estrogen is vital for
the development, maintenance and function of the male
reproductive system (Schulster, Bernie, and Ramasamy
2016). In addition, several animal studies raised concern
about the adverse impact of isoflavone exposure on sperm-
atogenesis. For example, Glover and Assinder (2006) found
that a high-isoflavone diet (465 lg/g) fed to rats for
3–25 days reduced fecundity, likely as a result of lipid perox-
idation of epididymal sperm. A year later, these researchers
showed that a high-isoflavone diet disrupted spermatogen-
esis and increased germ cell apoptosis in Wistar rats, an
effect attributed to an estrogenic effect in the testis
(Assinder et al. 2007). On the other hand, the authors of a
case report suggested that isoflavones could be a treatment
for low sperm concentration (Casini, Gerli, and Unfer
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2006). The observational (Toshima et al. 2012; Xia et al.
2013; Yuan et al. 2019; Mınguez-Alarcon et al. 2015) and
clinical (Mitchell et al. 2001; Beaton et al. 2010; Messina,
Watanabe, and Setchell 2009) studies providing insight into
the effects of isoflavones on spermatogenesis and fertility are
discussed below.
Observational studies
A study involving 42 Japanese males (age, 36.8 ± 5.4) of cou-
ples who had an infertility consultation at a gynecology
clinic in Tokyo found urinary daidzein was inversely related
to sperm concentration (p  0.001) and equol (p  0.05)
was inversely related to sperm motility (Toshima et al.
2012). As noted previously, urinary isoflavones are consid-
ered to be a good representative for exposure assessment
(Chavez-Suarez et al. 2017; Franke et al. 2010; Franke et al.
2006). In contrast, there was no statistically significant rela-
tionship between soyfood intake and semen parameters
based on data collected from a self-administered question-
naire. The questionnaire was used to collect information on
smoking status and consumption frequency of some food
items (vegetable, fruit, soy products, alcohol, coffee, and
tea), but it is not clear whether the statistical analysis con-
trolled for confounding variables.
In agreement with the Japanese study is a Chinese study
involving 608 idiopathic infertile men (age, 28.89 ± 4.39) and
469 fertile controls (age, 29.86 ± 3.58), that found urinary
daidzein and genistein levels were significantly associated
with idiopathic male infertility, and with idiopathic male
infertility with low sperm concentration and reduced motil-
ity (Xia et al. 2013). A questionnaire was used to collect
information including personal background, lifestyle factors,
occupational and environmental exposures, genetic risk fac-
tors, sexual and reproduction status, medical history and
physical activity. However, soy intake was not reported in
this study and other than age and abstinence time, it does
not appear that the results were adjusted for possible
confounders.
More recently, in a cross-sectional study involving 1319
reproductive-aged men (age, 32.2 ± 5.8 years) from
Shenzhen, China, there were inverse associations between
semen genistein and sperm counts (p¼ 0.02) and concentra-
tions (p¼ 0.02) (Yuan et al. 2019). However, these relation-
ships did not exist for daidzein. The results were adjusted
for age, body mass index (BMI), abstinence time, and diet
preference (meat lovers, vegetable lovers or vegetarians and
balanced diets with meat and vegetables). This study also
found statistically significant associations between semen
concentrations of the lignan secoisolariciresinol and lower
sperm concentrations, sperm counts and total motility.
Finally, a Chinese study found no associations between the
urinary daidzein metabolic rate and infertile risk (Qin et al.
2014). In this study, which involved 401 infertile Chinese
men aged 30 (range, 20–44) and 600 cases aged 29 (19–51)
that were recruited from the affiliated Hospitals of Nanjing
Medical University, daidzein metabolic rate represented the
urinary equol concentration divided by the concentration of
daidzein plus equol.
The results of the three Asian studies described above are
consistent with the previously mentioned US pilot case-con-
trol study, which found that soy intake was associated with
lower sperm concentration (33%) among 99 male partners
in subfertile couples who presented for semen analyses to a
fertility center (Chavarro et al. 2008). However, it is notable
that in this study about half of the decreased sperm concen-
tration resulted from the higher ejaculate volume in the
fourth (4.1ml) compared to the first (3.5ml) soyfood intake
quartile. Total sperm count was only reduced by 10%
when comparing extremes of soy intake, a decrease which
was not statistically significant; nor was there an effect of
soyfood intake on sperm motility or morphology. Since
there is no biological basis for soy increasing ejaculate vol-
ume, the observed association between soy and sperm con-
centration lacks credibility. A closer look at the data
supports this contention.
In multivariate analyses, men in the highest soyfood
intake category (0.30 servings/d, median isoflavone intake,
13.5mg/d) had on average, 41 million fewer sperm/ml than
men who did not eat soyfoods (p¼ 0.02). Men in the second
soyfoods intake category had 24 million fewer sperm/ml
than men who did not eat soyfoods even though the intake
category amount of 0.01–0.07 servings/d (median isoflavone
intake, 0.85mg/d) is highly unlikely to exert a biological
effect. In any event, a follow up study by this research group
involving 184 men from couples undergoing infertility treat-
ment with in vitro fertilization, found that male partners’
intakes of soyfoods and soy isoflavones were unrelated to
fertilization rates, proportions of poor quality embryos,
accelerated or slow embryo cleavage rate, and implantation,
clinical pregnancy and live birth (Mınguez-Alarcon
et al. 2015).
Four additional observational studies examined the rela-
tionship between sperm and semen parameters and isofla-
vone exposure; however, all four involved low-soy-intake
Western populations. In one, which involved 501 male part-
ners of couples desiring pregnancy and discontinuing
contraception, Mumford et al. (2015) found that urinary
genistein and daidzein were associated with a lower percent-
age of normal sperm and increased abnormalities in semen
morphology after adjustment for age, research site, serum
lipids, and cotinine. Isoflavone exposure was not associated
with couple fecundity and the association between genistein
and daidzein and sperm concentration and semen morph-
ology was reduced as BMI increased. The BMI finding con-
trasts with a finding by Chavarro et al. (2008), in that in
their study, there was a suggestion that the association
between soyfood intake and sperm concentration was more
pronounced among overweight and obese men than among
lean men (p for interaction, 0.10).
Chung et al. (2019) examined the relationships between
urine and serum concentrations of 128 chemicals classified
as endocrine disruptors, including isoflavones, and 7 semen
quality endpoints in a prospective cohort study comprising
473 men. None of the chemicals were associated with semen
quality endpoints after adjusting for multiple tests. The ref-
erent study population were couples participating in the
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LIFE Study (Longitudinal Investigation of Fertility and the
Environment), all of whom were discontinuing contracep-
tion for purposes of becoming pregnant. Participants were
recruited between 2009 and 2012 from 16 counties in
Michigan and Texas, USA. From this cohort 473 male part-
ners provided semen samples representing the study cohort
for analysis.
Song et al. (2006) recruited 48 men from New York State
with abnormal semen parameters who had been trying to
conceive with their partners for at least one year. Controls
were 10 men with normal semen analyses who had fathered
a pregnancy within the previous year. Block food frequency
questionnaires were used to estimate the dietary intake of
isoflavones (genistein and daidzein) of each patient. Higher
mean intake of genistein and daidzein were observed in fer-
tile control men compared to infertile men (p< 0.05).
Daidzein and genistein were also higher in men with good
sperm DNA integrity compared to men with poor sperm
DNA integrity. Regression analysis showed significant cor-
relation between dietary intake of genistein and daidzein
and semen parameters including sperm count, motility, pro-
gressive motility, and sperm DNA fragmentation index.
However, this study exists only as an abstract. Furthermore,
as expected isoflavone intake was extremely low (genistein,
527 ± 183mg/d in infertile men vs. 1722 ± 714 ug/d in
fertile controls; daidzein, 241 ± 84mg/d vs. 788 ± 327mg/d,
p< 0.05).
Finally, there is a case-referent study involving the male
partners of couples attempting conception with unprotected
intercourse for 12months or more without success, recruited
from 14 UK assisted reproduction clinics (Povey et al.
2020). Food intake was estimated by a 65-item food fre-
quency questionnaire (FFQ) covering the 12months prior to
recruitment. After adjustment for clustering and potential
confounding, among the 1907 participants low motile sperm
concentration was inversely related to daidzein intake (OR,
0.58; 95% CI: 0.42, 0.82)0.58 (0.42–0.82) but was unrelated
to poor sperm morphology.
Clinical studies
Clinical data show isoflavone exposure is unrelated to sperm
or semen parameters. Three such studies, two published in
full manuscript form and one described in the proceedings
from a scientific meeting, have been conducted. None of the
studies reported any adverse effects. In one, healthy British
volunteers aged 18–35, took a placebo or a daily supplement
containing 40mg isoflavones for two months (Mitchell et al.
2001). Mean plasma concentrations of genistein and daid-
zein increased to approximately 1 mM and 0.5 mM respect-
ively, during supplementation. In addition to the lack of
effect on sperm concentration, there was no effect on ejacu-
late or testicular volumes. In another study, which utilized a
cross-over design, 32 healthy Canadian men (age,
27.5 ± 5.67 y) consumed diets in random order for 57 d
which were supplemented with milk protein isolate or SPI
that provided isoflavones at either 0.02 or 0.75mg/kg bw
per day (Beaton et al. 2010). Urinary isoflavones were sig-
nificantly higher after consumption of the high isoflavone vs
low isoflavone SPI and milk protein isolate. Semen parame-
ters, including semen volume, sperm concentration, sperm
count, sperm percent motility, total motile sperm count, and
sperm morphology, were not significantly affected by con-
sumption of either the low or high SPI compared to the
milk protein isolate. In the third study, 20 Italian men were
randomized to three different groups in which they were
provided 60, 320 or 480mg/d isoflavones for three months
(Messina, Watanabe, and Setchell 2009). There were no stat-
istically significant effects on any of the outcomes measured
(ejaculate volume, sperm concentration, sperm count, and
motility of spermatozoa).
Conclusions
Observational studies have found inconsistent associations
between sperm/semen parameters and isoflavone intake.
Three clinical studies that varied in duration from 2-
3months and in which men consumed from 40 to 480mg/d
isoflavones did not report any adverse effects, although one
of these studies was not published as a com-
plete manuscript.
Research involving women only
Reproductive hormones
In theory, isoflavones may influence estrogen action by vir-
tue of effects on enzymes involved in steroid metabolism,
such as aromatase (Rice, Mason, and Whitehead 2006), 17b-
hydroxysteroid dehydrogenases, steroid sulfatases and sulfo-
transferases (Lacey et al. 2005), among others (Mesiano
et al. 1999; Ohno et al. 2002). Isoflavones could also affect
biologically active levels of hormones by affecting SHBG
concentrations (Loukovaara et al. 1995).
Hooper et al. (2009) published a systematic review and
meta-analysis of clinical studies that evaluated the impact of
isoflavone exposure via foods, soy protein and supplements
on reproductive hormones in pre- and postmenopausal
women. The meta-analysis included 11 studies involving 579
premenopausal women, 35 studies involving 1,165 postme-
nopausal women and 1 study involving 69 perimenopausal
women. The number of women analyzed in these studies
ranged in size from 10 to 304 (mean, 59). Thirty-two studies
were parallel in design and 15 were crossover. Nineteen
studies assessed the effect of an isoflavone supplement (vs
control), nine compared an isoflavone-containing SPI with
an isoflavone-depleted SPI, 13 compared SPI with a non-soy
control, and nine compared whole soy or soyfoods with a
control (some studies included more than one comparison).
Studies ranged in length from 4 to 104weeks: 29 were
4–12weeks in duration; nine were 13–26weeks; seven
27–52weeks; and two were >1 year.
Soy and isoflavone consumption had no effect on circu-
lating total estradiol, estrone or SHBG concentrations in
premenopausal women (based on 6–11 studies per compari-
son). In postmenopausal women, there was a small increase
(14%) in circulating total estradiol concentrations follow-
ing soy isoflavone consumption (based on 21 studies
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involving 580 women), but this change was not statistically
significant (p¼ 0.07). Soy isoflavones had no effect on circu-
lating total estrone (7 studies, 152 in control) or SHBG (17
studies, 459 women in control groups) concentrations.
In premenopausal women, soy isoflavones significantly
reduced circulating levels of follicle stimulating hormone
(FSH) by 22% (p¼ 0.01) and luteinizing hormone (LH) by
24% (p¼ 0.05), based on 7 studies involving 73 partici-
pants using standardized mean differences, but not mean
differences. However, in sensitivity analysis when only stud-
ies at low risk of bias were retained, the results were no lon-
ger statistically significant. Soy isoflavones had no
statistically significant effects on progesterone or circulating
free estradiol concentrations.
Hooper et al. (2009) were unable to conclude whether
the observed but tentative premenopausal changes in FSH
and LH reflect an estrogenic or anti-estrogenic effect
because these hormones were assessed in different studies at
different points in the menstrual cycle. During the midcycle
gonadotrophin surge, a decrease in LH is best construed as
an anti-estrogenic effect, whereas during the luteal phase a
decrease in LH may be an estrogenic effect. A surge in LH
is required for ovulation, although there is a diversity of LH
surges in terms of configuration, amplitude, and duration in
cycles of normally fertile women (Direito et al. 2013).
In postmenopausal women, soy isoflavone intake had no
effect on circulating FSH, LH, circulating estrone sulfate or
free estradiol (where there were at least three studies and at
least 50 women in combined control groups). In the one
study involving perimenopausal women, there were no
effects on circulating FSH, estrone or estradiol.
Subsequent to the meta-analysis by Hooper et al. (2009),
10 studies were identified that examined the impact of iso-
flavone exposure on reproductive hormone levels in women.
Seven of these involved postmenopausal women (Levis et al.
2011; Delmanto et al. 2013; Ye et al. 2012; Evans et al. 2011;
Carmignani et al. 2015; Husain et al. 2015; Villa et al. 2009),
one premenopausal women (Maskarinec et al. 2011) and
two included pre- and postmenopausal women (Chung et al.
2019; Khan et al. 2012). Studies ranged in duration from
8weeks (Husain et al. 2015) to 2 years (Levis et al. 2011),
sample size in the isoflavone group from 20 (Carmignani
et al. 2015) to 97 (Levis et al. 2011) and isoflavone dose
from 30mg/d (genistein only) (Evans et al. 2011) to 235mg/
d (Khan et al. 2012).
In the premenopausal study, no significant effects of
50mg/d isoflavones from soyfoods were observed on estra-
diol, estrone or estradiol sulfate (Maskarinec et al. 2011). In
the two studies that included pre- and postmenopausal
women, there were no statistically significant effects on
estradiol (Chung et al. 2019; Khan et al. 2012), and no
effects on FSH and SHBG in the study that assessed these
endpoints (Khan et al. 2012). In the other seven studies, all
of which involved postmenopausal women, only one
reported a statistically significant effect on estradiol or FSH
or LH. In this one study, Ye et al. (2012) found the percent
decrease in estradiol in the high dose isoflavone group
(126mg/d) was less than the decrease in the placebo group
whereas there was no difference between the placebo and
the group consuming 84mg/d isoflavones.
The following text consists of brief comments about the
several of the studies published after the 2009 Hooper et al.
meta-analysis (Hooper et al. 2009). The study by Ye et al.
(2012), was the only one that intervened with isoflavones
derived from soy germ; consequently, genistein exposure
was quite low (15% of total isoflavone intake). The study
by Villa et al. (2009) intervened with 54mg/d genistein pro-
vided in aglycone form. The six-month study by Khan et al.
(Khan et al. 2012), which involved pre and postmenopausal
women, is notable for several reasons. One, all the partici-
pants were at an increased risk for breast cancer or had a
history of unilateral minimal risk breast cancer. Two, of the
total daily isoflavone dose of 235mg taken by the partici-
pants, 150mg was genistein. Three, the lack of effect of iso-
flavones on FSH (baseline mean 5.73, interquartile range
[IQR]: 2.46–8.30; final mean, 6.01: IQR: 0.01–9.64 mIU/ml)
in the 53 premenopausal women in this study, contrasts
with the 22% decrease in FSH noted by Hooper et al.,
(2009) in a total of 73 women from seven studies. In the
study by Husain et al. (2015), which involved postmeno-
pausal women, although the difference was not statistically
significant, in the control group estradiol increased approxi-
mately 10% whereas in the soy/isoflavone group it increased
by about 50%. Finally, in the study by Carmignani et al.
(2015), final estradiol values increased 10 times more in the
group given hormone therapy (1mg estradiol þ 0.5mg nor-
ethisterone) than in women taking isoflavones (53mg/d).
One 12-week intervention study involving perimenopausal
women that did not assess hormone levels found that vagi-
nal bleeding occurred in three participants (12.5%) ingesting
100mg/d isoflavones and in one participant (4.3%) ingesting
50mg/d isoflavones (4.3%) whereas no bleeding occurred in
the placebo group (Schneider et al. 2019). However, these
findings were not statistically significant.
Finally, there are suggestive clinical data that isoflavones
favorably affect conditions common among women with
polycystic ovary syndrome (PCOS), which may affect as
many as 25% of reproductive age women (Setji and Brown
2014). For example, among women with PCOS, Karamali
et al. (2018) found that a soy-containing diet lowered testos-
terone and insulin levels, findings which agree with those of
Khani et al. (2011), who reported that genistein (36mg/d)
decreased testosterone levels and Jamilian and Asemi (2016),
who reported that soy isoflavones (50mg/d) significantly
reduced the free androgen index among women with PCOS.
In contrast, Romualdi et al. (2008) reported that in a small
pilot study (n¼ 12), genistein (36mg/d) had no effect on
androstenedione levels
Conclusions
Despite the in vitro identification of mechanisms whereby
isoflavones can potentially impact hormone levels and some
reports of isoflavone-induced hormonal disturbances noted
in animal studies, a critical review of the clinical literature
shows neither soy intake nor isoflavone exposure signifi-
cantly affects reproductive hormone levels in women.
18 M. MESSINA ET AL.
Menstrual cycle
Observational data
Four observational studies that have related soy intake or
urinary isoflavone excretion to menstrual cycle length
(MCL) have been conducted across different geographical
regions including Japan (Nagata, Oba, and Shimizu 2006),
Singapore (Jakes et al. 2001), England (Verkasalo et al.
2001) and the US (Levine et al. 2020). In the Japanese study,
Nagata, Oba, and Shimizu (2006) found that among 341
women aged 18–29 y, a higher habitual soy intake (median
1st and 5th soy intake (g/d) was 14.9 and 100.9, respectively)
was unrelated to MCL. In contrast, a higher habitual intake
of polyunsaturated fat and fiber was associated with shorter
and longer MCL, respectively. Mean isoflavone intake is dif-
ficult to accurately estimate from the data reported, but
from the information about soyfood consumption, a conser-
vative estimate would be approximately 25mg/d isoflavones
(Messina, Nagata, and Wu 2006).
In contrast to the Japanese study, Jakes et al. (2001)
found that among Singaporean women, a higher habitual
intake of soy protein tended to be associated with increased
MCL based on self-report when assessed cross-sectionally
and prospectively by recording three consecutive cycles, but
the results did not reach statistical significance. More specif-
ically, comparing the highest versus lowest quartile of self-
reported soy protein (Q1, <3.3 g/d versus Q4 8.7 g/d),
MCL was 30.8 days in Q4 compared to 28.2 days in Q1 (p
for trend, 0.052), while based on food diary data, MCL was
30.9 days in Q4 compared to 29.7 d in Q1 (p for
trend, 0.16).
In another cross-sectional study involving predominantly
premenopausal British vegetarian and vegan participants
(n¼ 636), Verkasalo et al. (2001) found a non-statistically
significant trend toward a higher soymilk intake being asso-
ciated with a shorter MCL (0.7 d; p¼ 0.086 for trend).
Isoflavone intake in this study was estimated by Verkasalo
et al. (2001) to be 12.4 and 36.8mg/d in the intermediate
and high soymilk-consuming groups, respectively. Although
this research involved a Western population, because it was
comprised mostly of vegetarians (65%), it avoids the major
limitation of Western populations cited previously (Messina
2004). On the other hand, of the various soy products con-
sumed by British women, only the intake of soymilk was
considered (Verkasalo et al. 2001).
Finally, there are the results of two US studies. In a
population-based prospective cohort of 326 women aged
18–40 (followed until pregnancy or for 12months of
attempting) urinary isoflavone levels were not associated
with MCL (Levine et al. 2020). However, it is evident that
the women in this study consumed little soy given that
mean urinary genistein levels in women whose cycles were
<26 d, 26–35 d and >35 d were only 167, 104, and
152 nmol/l, respectively. There was no association with
MCL; however, each 1 nmol/L increase in genistein was
associated with menstrual cycle irregularity (OR 1.19, 95%
CI 1.02, 1.38), although the authors concluded that the
results were reassuring for women attempting pregnancy.
In the other study, which involved women with regular
menstrual cycles (246 participants in final analysis), who
were followed-up for two menstrual cycles, luteal phase defi-
ciency (LPD) (which may be associated with an increased
risk of infertility/early miscarriage) occurred in 8.9% of the
menstrual cycles (Andrews et al. 2015). In multivariate anal-
yses, LPD was associated with a higher Mediterranean diet
score, higher intake of dietary fiber and isoflavones, and
lower intake of selenium. Given the limited number of LPD
cycles included in this exploratory study and the associations
observed with quite low isoflavone intakes (7mg/d), add-
itional data are required to further interpret these findings.
Also, given that the Mediterranean diet score and fiber were
associated with LPD, it may be that the association with iso-
flavone intake simply reflects the consumption of a more
plant-based diet.
Clinical data
The impact of soy on MCL was first reported in studies
published by Cassidy, Bingham, and Setchell (1994) and
Cassidy, Bingham, and Setchell (1995) both of which
involved participants following carefully controlled diets
while living in a metabolic ward (Franke, Custer, and
Hundahl 2004; Franke et al. 2006). In 2009, with the inclu-
sion of 10 intervention studies, Hooper et al. (2009) pub-
lished a systematic review and meta-analysis of the effects of
soy/isoflavone exposure on MCL; they found that MCL was
increased by 1.05 d (95% CI: 0.13, 1.97; 10 studies, n¼ 148
soy intervention; n¼ 153, control). In sensitivity analysis,
removing studies not at low risk of bias, resulted in statis-
tical significance being lost but this result was based on only
two studies. Menstrual cycle function is suggested to be a
sentinel of fecundity, irrespective of pregnancy intentions
(Mumford et al. 2012; Vassena et al. 2014). However, short,
but not long, menstrual cycles have been linked to 11–36%
longer time to pregnancy (Crawford et al. 2017; Wesselink
et al. 2016; Wise et al. 2011). Since the publication of this
analysis (Hooper et al. 2009), no subsequently published tri-
als evaluating MCL were identified.
Conclusions
The available data from the limited population-based studies
provide little evidence for an association between habitual
soy intake and MCL although levels of intake of soy and
isoflavones were low in three of the four studies. Based on
the most recent meta-analysis of clinical trials, soy/isoflavone




Several population-based studies have examined the associa-
tions between soy intake or urinary isoflavone levels and
fertility. Although there are limited data in high soy-con-
sumers, in studies with low habitual intakes, no relationship
was found between isoflavone intake and fecundability
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among two web-based preconception cohorts, one involving
4880 women participating in the Pregnancy Study Online
(PRESTO, North America) and the other involving 2898
women participating in the Snart Foraeldre (SF, Denmark)
(Wesselink et al. 2020). In the PRESTO and SF, the cutoff
for the 90th percentile isoflavone intake was only 3 and
2mg/d, respectively. Study participants had been attempting
conception for 6 cycles at study entry. There was some
evidence of improved fecundability with increasing isofla-
vone intake among women age 30 y in the PRESTO
(fecundability ratios: 1.12; 95% CI: 0.94, 1.34, for compari-
son of  90th with < 25th percentile intake) and SF
(fecundability ratios: 1.19; 95% CI: 0.92, 1.55).
In a US study involving 18,555 women without a history
of infertility who were followed as they attempted a preg-
nancy or became pregnant, replacing animal protein with
vegetable protein was associated with a decreased risk of
ovulatory infertility; however, tofu intake was unrelated to
ovulatory infertility (Chavarro et al. 2008). And in another
US study, which involved 315 women undergoing assisted
reproductive technology, a higher soy isoflavone intake was
positively related to live birth rates and in multivariable-
adjusted models, the ORs of live birth (95% CI) for women
in increasing categories of isoflavone intake were 1.32
(0.76–2.27) for women consuming 0.54–2.63mg/d, 1.87
(1.12–3.14) for women consuming 2.64–7.55mg/d, and 1.77
(1.03–3.03) for women consuming 7.56–27.89mg/d
(Vanegas et al. 2015).
To date, only two studies have examined the associations
between urinary isoflavone concentrations and pregnancy
related outcomes. In a study of 501 couples who were fol-
lowed for 12months or until pregnancy, urinary isoflavone
concentrations in men and women were not associated with
time to pregnancy (Mumford et al. 2014). Likewise, in a pre-
viously cited US population-based prospective cohort of 326
women ages 18–40 with self-reported cycles 21–42 days who
were followed until pregnancy or for 12months of attempt-
ing pregnancy, urinary isoflavone levels were not associated
with MCL (Levine et al. 2020).
Only one study involving women with a high habitual
soy intake suggests that isoflavones may be associated with a
reduction in pregnancy rate. This cross-sectional study,
which involved 11,688US women aged 30–50 years, found
that a higher habitual intake of isoflavones was associated
with an increased risk of nulliparity and nulligravidity
(Jacobsen et al. 2014). The mean isoflavone intake (17.9mg/
d) of this population (North American Seventh-day
Adventists) is much higher than typical North American
intake (<3mg/d) (Bai, Wang, and Ren 2014). Only 6% of
the women indicated no isoflavone intake.
After adjustment for age, marital status, and educational
level, a higher isoflavone intake was associated with a lower
likelihood of ever having become a mother. In women with
high (40mg/d) isoflavone intake (12% of the cohort), the
adjusted lifetime probability of giving birth to a live child
was reduced by approximately 3% compared to women with
low (<10mg/d) intake. No relationships were found
between the isoflavone intake and parity or age at first
delivery in parous women. A similar inverse relationship
(p¼ 0.03) was found between isoflavone intake and the risk
of nulligravidity with a 13% higher risk of never have been
pregnant in women with high (40mg/d) isoflavone intake.
These relationships were found mainly in women who
reported problems becoming pregnant. Although of more
limited informative value, in the Shanghai Women’s Health
Study, among 33,054 postmenopausal women, no relation-
ship between soy intake and reproductive span (years
between menses and menopause) or menopause onset was
noted (Dorjgochoo et al. 2011).
Finally, Chavarro et al. (2016) examined the interactions
between environmental estrogens such as bisphenol A
(BPA) and soy intake on pregnancy-related outcomes in a
prospective study of women undergoing in vitro fertilization
treatment. A higher habitual soyfood intake modified the
association of urinary BPA concentration with live birth
rates (P for interaction ¼ 0.01). Among women who did
not consume soyfoods, the adjusted live birth rates per initi-
ated cycle in increasing quartiles of cycle-specific urinary
BPA concentrations were 54%, 35%, 31%, and 17% (p for
trend ¼ 0.03). The corresponding live birth rates among
women reporting pretreatment consumption of soyfoods
were 38%, 42%, 47%, and 49% (p for trend ¼ 0.35). A simi-
lar pattern was found for implantation (P for interaction ¼
0.02) and clinical pregnancy rates (p for interaction ¼ 0.03)
per initiated cycle, where urinary BPA was inversely related
to these outcomes among women not consuming soyfoods,
but unrelated to them among soy consumers. These data
suggest significant interactions between soy and environ-
mental estrogens, an area which warrants further research.
Clinical studies
The topic of isoflavones and female fertility has only periph-
erally been identified in two supplementation studies. In
one, patients with unexplained infertility and recurrent
clomiphene citrate (CC) induction failure, were randomized
to group I (n¼ 60) or group II (n¼ 59). Both groups
received CC (150mg/d; days 3–7) (Shahin et al. 2008).
Group I also received 120mg/d phytoestrogens derived from
Cimicifuga racemosa (C. racemosa) on days 1 to 12. Human
chorionic gonadotrophin injection (10,000 IU i.m.) was
given and timed intercourse was recommended when a lead-
ing follicle reached >17mm and serum estradiol exceeded
200 (pg/ml). Although there was a trend toward a shorten-
ing of induction cycles in group I, it did not reach statistical
significance. Estradiol and LH concentrations were higher in
group I as was endometrial thickness, serum progesterone
and clinical pregnancy rate (8.9 ± 1.4mm versus
7.5 ± 1.3mm, p< 0.001; 13.3 ± 3.1 ng/ml versus 9.3 ± 2.0 ng/
ml, p< 0.01; 36.7% versus 13.6%, p< 0.01, respectively).
These data suggest that the addition of C. racemosa extract
to CC induction can improve the pregnancy rate and cycle
outcomes. However, C. racemose does not contain
isoflavones.
In the other study, infertile women (n¼ 134, aged
25–35 years with duration of infertility > 2 years) who had
oligomenorrhea or amenorrhea were randomly assigned to
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CC (100mg daily for 5 days) or CC (100mg daily for 5 days)
in combination with isoflavones (1500mg daily for 10 days)
(Unfer et al. 2004). Both treatments resulted in an increase
in FSH, LH and 17b-estradiol plasma concentrations, but
there were no differences between groups. In contrast, endo-
metrial thickness was significantly increased in the isofla-
vone group, although no significant differences in the
pulsatility index values or in the number of preovulatory fol-
licles were noted. These data suggest that a high isoflavone
dose can reverse the deleterious effects of CC on endomet-
rial thickness and could contribute to higher pregnancy
rates. However, because a pharmacological dose was used,
the findings do not have bearing upon dietary exposure to
isoflavones.
Conclusions
To date no clinical studies have directly examined the effect
of soy on fertility, however,a small study that included the
addition of a phytoestrogen supplement to standard fertility
treatment supports its potential to improve endometrial
thickness and pregnancy rate, but further robust trials are
required. Furthermore, a pharmacological dose of isofla-
vones was used in this study (Unfer et al. 2004). In relation
to population-based studies, specifically examining the
impact of a dietary constituent on pregnancy is difficult, but
the available data provide limited evidence to suggest soy
intake has any impact on pregnancy related outcomes.
Future studies should focus on high-soy-consuming
populations.
Breast cancer
As noted at the onset, beginning in the late 1990s, concerns
based on rodent research were raised that isoflavone intake,
and more specifically, genistein intake, may increase the risk
of high-risk women developing breast cancer and worsen
the prognosis of breast cancer survivors (Hsieh et al. 1998).
The research group responsible for much of this work con-
tinued to publish rodent research on this topic over the next
two decades (Setchell et al. 2002; Ju et al. 2001; Ju et al.
2006; Santell, Kieu, and Helferich 2000; Ju et al. 2002; Du
et al. 2012; Ju et al. 2008; Allred et al. 2001 2004; Zhang
et al. 2017). It is worth noting however, that when Onoda
et al. (Onoda et al. 2011) slightly tweaked the basic model
used for this research, they did not find that genistein
stimulated mammary tumor growth. Onoda et al. (2011)
suggested the reason for the discrepant findings is that in
their model, prior to implantation, cancer cells are main-
tained in culture lacking estrogen whereas in the model in
which genistein stimulates tumor growth, cells are cultured
in medium containing 1 nM 17b-estradiol, which is approxi-
mately 1,000 fold higher than the unbound 17b-estradiol
concentration in women. Onoda et al. (2011) speculated that
this supraphysiologic estrogen concentration enhances the
estrogen dependence of the MCF-7 cells making them
extremely sensitive to the effects of ER agonists.
It should be acknowledged that despite extensive
research, a definitive understanding of the relationship
between isoflavone intake and breast cancer prognosis has
not been achieved. This is because the effects of soy intake
on breast cancer recurrence and/or breast cancer-specific
mortality among breast cancer survivors has not been exam-
ined in a randomized clinical trial. However, considerable
observational and clinical evidence suggests that post-diag-
nosis soy intake is safe for breast cancer survivors. This con-
clusion is consistent with the position of the American
Cancer Society (Rock et al. 2012), American Institute for
Cancer Research (American Institute for Cancer Research
2021), World Cancer Research Fund International (World
Cancer Research Fund International 2014) and the Canadian
Cancer Society (Eating Well After Breast Cancer 2021).
EFSA has concluded from its review of 43 human studies
and 62 animal studies that there is no indication for adverse
effects of isoflavones on the mammary gland of postmeno-
pausal women (EFSA ANS Panel (EFSA Panel on Food
Additives and Nutrient Sources added to Food) 2015).
However, EFSA also noted that in the face of limited data, it
was not possible to reach a conclusion about the risk of con-
suming isoflavone-based food-supplements in postmeno-
pausal women with a current diagnosis or history of
estrogen-dependent cancer. The review by EFSA focused on
the possible health risks associated with the intake of iso-
lated isoflavones in food supplements by peri- and postme-
nopausal women. Three years later, the SKLM concluded
that “The available human studies do not indicate that an
isoflavone exposure as reported in the thoroughly studied
Asian population or as investigated in clinical studies (i.e.,
about 100mg/day) negatively influences breast cancer risk
…” (H€user et al. 2018) However, as a precautionary meas-
ure, the SKLM recommended that high-risk groups abstain
from the intake of isoflavone-containing supplements and
that isoflavone intake via the consumption of soyfoods not
exceed the median intake of Asian countries of about
50mg/d.
Clinical studies
Primary studies that have examined the safety of soy on
breast health have done so through measurement of bio-
logical markers such as mammographic density (Boyd et al.
2011; Rice et al. 2016). Hooper et al. (2010) meta-analyzed
clinical trials that examined the effect of isoflavone exposure
(ranging from 40 to 120mg/d) for at least 6months on
mammographic density in postmenopausal women (five
studies), premenopausal women (five studies) or both (two
studies). Interventions included red clover-based isoflavone
supplements (two studies), soy-based isoflavone supplements
(three studies; isolated genistein, soy germ based isoflavones
and mixed soy isoflavones), additional soyfoods (one study)
and soy protein powder compared with milk protein powder
(two studies). Results showed no effect of isoflavones on
mammographic density in all women combined [mean dif-
ference (MD) 0.69%, 95% CI: 0.78, 2.17] or postmeno-
pausal women (MD 1.10%, 95% CI: 3.22, 1.03).
However, there was a modest increase in mammographic
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density in premenopausal women (MD 1.83%, 95% CI: 0.25,
3.40) without heterogeneity, but this effect was lost in one
of three sensitivity analyses. Hooper et al. (2010) were
unable to determine the potential clinical significance of a
small increased mammographic density in premeno-
pausal women.
Mammographic density was also examined in three sub-
sequently published isoflavone intervention studies. In one,
Wu et al. (2015) found no evidence that 50mg/d soy isofla-
vones significantly affected mammographic density or breast
MRI fibroglandular tissue density in high-risk women and
previously treated breast cancer patients over a one-year
period. In another one-year study, which involved Greek
postmenopausal women experiencing climacteric symptoms,
a soy extract found no effect on mammographic density,
although this was also true for low-dose hormone therapy
(Labos et al. 2013). However, the isoflavone content of the
intervention product, DT56a (Tofupill/Femarelle, Se-cure
Pharmaceuticals, Dalton, Israel) was not indicated although
it has been described as a “unique enzymatic isolate of
soybeans” (Somjen et al. 2007). Finally, in a two-year study
involving premenopausal women treated surgically for breast
cancer, mammographic density significantly decreased in
both the placebo group and in women ingesting 80mg/d
isoflavones (p< 0.0001), although there were no differences
between groups (Ferraris et al. 2020).
In vivo breast cell proliferation is another commonly
used biological marker that is a better predictor of breast
cancer risk than mammographic density (Hanahan and
Weinberg 2011). The most widely practiced measurement of
proliferation involves immunohistochemical detection of the
nuclear non-histone protein Ki67, which is thought to be
involved in ribosomal RNA synthesis (Rahmanzadeh et al.
2007; Scholzen and Gerdes 2000). Combined hormone ther-
apy (CHT, estrogen plus progestin) has been shown to
increase proliferation four to 10-fold within just 12weeks
(Conner et al. 2003; Murkes et al. 2011; Conner 2007).
In contrast to the proliferative effects of CHT, none of
the six studies that evaluated the effects of isoflavones on
in vivo breast cell proliferation showed an increase
(Table 10) (Khan et al. 2012; Hargreaves et al. 1999;
Sartippour et al. 2004; Palomares et al. 2004; Cheng et al.
2007; Shike et al. 2014). These studies included healthy
women, women at high-risk of developing breast cancer and
breast cancer survivors. The duration of these studies ranged
from two weeks (Hargreaves et al. 1999) to one year
(Palomares et al. 2004) and daily isoflavone intake
(expressed in aglycone equivalents) ranged from 36 (Cheng
et al. 2007) to 235 (Khan et al. 2012) mg. For comparison,
one serving of a traditional soyfood (e.g. 100 g tofu or
250ml soymilk) contains 25mg isoflavones and as noted
previously, mean daily isoflavone intake among older adults
in Japan ranges from 30 to 50mg (Messina, Nagata, and
Wu 2006).
In the study by Palomares et al. (2004), which included
breast cancer survivors, the contralateral breast was used to
assess cell proliferation and in the study by Sartippour et al.
(2004), the ratio of the number of apoptotic to mitotic cells
was used as an assessment of proliferation. It is noteworthy
that in the studies by Shike et al. (2014) and Khan et al.
(2012), women were exposed to approximately 62 and
150mg/d genistein, which equates to amounts provided by
approximately five and 12 servings of traditional soyfoods,
respectively. Interestingly, three of the six studies found that
gene expression was modified in a way suggestive of an
increased breast cancer risk and similar to that which might
be expected from exposure to estrogen (Khan et al. 2012;
Hargreaves et al. 1999; Shike et al. 2014). Nevertheless, cell
proliferation was unaffected even in response to pharmaco-
logic doses of genistein.
Soy exposure has also been studied to determine whether
it regulates gene expression in the breast through epigenetic
mechanisms. Coussement et al. (2018) reported no major
general epigenetic reprogramming in the breast following 5
d of soymilk consumption. Participants in this exploratory
study were randomized to consume 250ml soymilk
(approximately 25mg isoflavones) at breakfast, lunch and
dinner (N¼ 6) or their usual diet (control, N¼ 5) before
their esthetic breast reduction surgery, after which the breast
tissue was examined for global DNA methylation. However,
the findings of Coussement et al. (2018) contrast with an
earlier study from Qin et al. (2009), who found that after
healthy premenopausal women consumed 40 or 140mg/d
supplemental isoflavones for one menstrual cycle, there was
Table 10. Selected characteristics and results of intervention studies evaluating the effects of isoflavone exposure on breast cell proliferation.








Hargreaves et al. (1999) Control 53 0 Healthy premenopausal 14 days
(8-14)
Ki67 3.16 ± 3.081 6.03 ± 4.271
Soy 28 45 4.76 ± 6.161 6.17 ± 7.001
Palomares et al. (2004) Placebo 9 0 Postmenopausal breast cancer survivors 11.7 months Ki67 NA 4.1 ± 9.01
Isoflavones 9 100 NA 4.9 ± 11.51
Sartippour et al. (2004) Placebo 26 0 Postmenopausal breast cancer survivors2 23 days
(13-45)
AI/MI 6.5 ± 7.01 4.4 ± 4.71
Isoflavones 17 120 3.3 ± 3.41 5.8 ± 8.31
Cheng et al. (2007) Placebo 25 0 Healthy
postmenopausal
12 weeks Ki67 NA No change
Isoflavones 26 36 NA No change
Khan et al. (2012) Placebo 49 0 At risk pre- and post-menopausal 6 months Ki67 0.97 (0.70-1.90)3 0.92 (0.59-1.09)3
Isoflavones 49 235 1.17 (0.66-1.93)3 1.09 (0.75-2.33)3
Shike et al. (2014) Control 50 0 Pre- and post-menopausal breast
cancer survivors
6 months Ki67 16.5 (0-80)4 20.0 (1-72)4
Isoflavones 54 62 15.5 (1.6-80)4 21.0 (4-80)4
1Mean ± SD. 2Isoflavone and placebo groups included 12% and 19% premenopausal breast cancer survivors, respectively. 3Median (interquartile range).
4Mean (range).
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an increase in breast cancer-related gene RARb2 hyperme-
thylation that correlated with serum genistein in those
receiving 140mg isoflavones (r¼ 0.68, p¼ 0.021) and in
both groups combined (r¼ 0.67, p¼ 0.0017). There was also
an increase in breast cancer-related gene CCND2 (connect-
ive tissue growth factor) hypermethylation that was corre-
lated with serum genistein in those receiving 40mg
(r¼ 0.79, p¼ 0.011) but not 140mg isoflavones, although
the authors questioned the biological significance of these
methylation changes. The study also showed no changes in
breast cytology and an inverse correlation between serum
levels of the estrogenic marker complement (C)3 and the
change in serum genistein (r ¼ 0.76, p¼ 0.0045) in
women consuming 40mg, but not 140mg isoflavones, sug-
gesting an anti-estrogenic effect. Finally, there was also no
change in nipple aspirate fluid C3 levels in response to iso-
flavone intake, indicating the lack of an estrogenic effect
based on this one marker, which contrasts with the change
Petrakis et al. (1996) observed in nipple aspirate fluid in
response to isoflavone-rich soy protein.
Observational studies (post-diagnosis intake)
Considerable evidence from observational studies supports
the safety of soy consumption after a breast cancer diagno-
sis. The first such study was the Shanghai Breast Cancer
Survival Study (SBCSS, N¼ 5033), which assessed dietary
intake four times following a diagnosis of breast cancer (Shu
et al. 2009). After an average follow up of 3.9 y, there were
444 deaths and 534 recurrences or breast cancer-related
deaths. Mean isoflavone intake among all women was
45.9mg/d. The hazard ratio (HR, 95% CI) for recurrence/
breast cancer-specific mortality was 0.77 (0.60, 0.98) for
women in the fourth isoflavone intake quartile (cutoff, >
62.7mg/d; mean, 85.09mg/d) compared to those in the first
intake quartile (cutoff, < 20mg/d; mean 11.5mg/d). The
HR was below 1.0 even at intakes approaching 25 g/d soy
protein (Shu et al. 2009).
US observational studies have also examined soy isofla-
vone intake by breast cancer survivors, namely, two pro-
spective studies published in 2009 (Guha et al. 2009) and
2011 (Caan et al. 2011) that were analyzed together with the
SBCSS (Shu et al. 2009) in a pooled analysis that included
9514 breast cancer survivors (Nechuta et al. 2012). After an
average of 7.4 y of follow up, there were 1171 deaths (881
from breast cancer) and 1348 recurrences. The HR (95% CI)
for recurrence was 0.75 (0.61, 0.92) for all women in the
highest vs the lowest isoflavone group with similar results
among Chinese (HR, 0.69; 95% CI: 0.47, 1.01) and non-
Asian US women (HR, 0.74; 95 CI: 0.56, 0.97) (Nechuta
et al. 2012). Due to the relatively low isoflavone intakes of
US women, the isoflavone intake cutoffs (mg/d) for the low,
medium and high intake groups were <4.0, 4.0–9.99 and
10.0, respectively. This study also stratified the analysis by
breast cancer subtype and menopausal status with results
showing the HR (95% CI) for breast cancer recurrence as
0.81 (0.63, 1.01) for ERþ, 0.64 (0.44, 0.94) for ER-, 0.93
(0.69, 1.26), for premenopausal women and 0.64 (0.48, 0.87)
for postmenopausal women, all comparing the highest to
the lowest isoflavone intakes.
As more observational studies that examined soy expos-
ure in breast cancer survivors were published, Chi et al.
(2013) completed a meta-analysis that included the three
studies in the aforementioned pooled analysis (Nechuta
et al. 2012) plus two additional Chinese prospective studies
(Kang et al. 2010; Zhang et al. 2012) to total 11,206 partici-
pants. The analysis found that the highest post-diagnosis
soyfood intake was associated with decreased breast cancer
recurrence (HR, 0.74; 95% CI: 0.64, 0.85) and mortality
(HR, 0.84; 95% CI: 0.71, 0.99) when compared with the low-
est post-diagnosis soyfood intake. This analysis, which also
stratified by breast cancer subtype and menopausal status,
found that when comparing highest versus lowest soyfood
intake, the risk [HR þ (95% CI)] for breast cancer recur-
rence was 0.81 (0.63, 1.04) for ERþ, 0.64 (0.44, 0.94) for
ER-, 0.91 (0.72, 1.14) for premenopausal women and 0.67
(0.56, 0.80) for postmenopausal women.
In 2019, a meta-analysis by Qiu and Jiang (2019)
included a focus on post-diagnosis soy intake by summariz-
ing the pooled analysis of the three studies by Nechuta et al.
(2012) and an additional study by Zhang et al. (2017) that
involved an international Breast Cancer Family Registry
with six sites from the United States, Canada, and Australia.
Results showed when comparing highest versus lowest soy-
foods intake, the HR (95% CI) for overall survival was 0.80
(0.62, 1.04) based on all four studies, and for breast cancer
specific survival it was 0.83 (0.64, 1.07), based on the three
studies from the Nechuta pooled analysis (Nechuta et al.
2012). More recently, when Micek et al. (2021) examined
the impact of isoflavone intake on breast cancer recurrence,
they found the overall HR (95% CI) was 0.73 (0.64, 0.84),
and ranged from 0.66 to 0.91 for the four subpopulations
(pre- and postmenopausal, ERþ and ER) analyzed, but of
those four, only the HR for postmenopausal women was
statistically significant.
Finally, a recent prospective case-control study went
beyond dietary intake to examine circulating levels of isofla-
vones in breast cancer survivors. The MARIE (Mamma
Carcinoma Risk factor InvEstigation) was conducted in two
German study regions, the Free and Hanseatic City of
Hamburg (HH) and the Rhine–Neckar–Karlsruhe (RNK)
region (Jaskulski et al. 2019). The study related baseline cir-
culating isoflavones from 1,686 breast cancer survivors fol-
lowed up for a median of 5.3 y at which time 142 (8.4%)
women had died, 73 (51.4%) of which was due to breast
cancer. Neither circulating genistein and daidzein was
related to risk of overall or breast cancer specific mortality,
but genistein (not daidzein) was positively related to risk of
recurrence (HR 1.17, 95% CI: 1.01, 1.36, p¼ 0.04). It should
be noted however that the mean genistein concentration was
only 10 ng/ml (37 nmol/l), indicating extremely low isofla-
vone intake and raising doubt about the relevance of the
findings. Parenthetically, circulating resveratrol was related
to risk of recurrence (HR, 1.19; 95% CI: 1.02, 1.40, p¼ 0.03)
and circulating luteolin to breast cancer specific mortality
(HR, 1.96; 95% CI: 1.07, 3.58, p¼ 0.03).
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Conclusions
In summary, the safety of soy intake related to breast cancer
stems from concern that the phytoestrogenic isoflavones
would exacerbate an estrogen-dependent tumor, a hypoth-
esis confirmed in several animal model studies (Setchell,
Brown, and Lydeking-Olsen 2002; Ju et al. 2001; Ju et al.
2006; Santell, Kieu, and Helferich 2000; Ju et al. 2002; Du
et al. 2012; Ju et al. 2008; Allred et al. 2001; Allred et al.
2004; Zhang et al. 2017), although the human representa-
tiveness of these models has been questioned (Onoda et al.
2011). Human studies focused on biological markers of
breast health have found no significant effects of soy isofla-
vones on mammographic density (Hooper et al. 2010; Wu
et al. 2015; Labos et al. 2013) or breast cell proliferation
(Khan et al. 2012; Hargreaves et al. 1999; Sartippour et al.
2004; Palomares et al. 2004; Cheng et al. 2007; Shike
et al. 2014).
Exploratory studies have examined effects of soy on
breast cancer-related DNA methylation with one finding no
effect of soymilk on the human mammary gland epigenome
(Coussement et al. 2018) and another finding positive asso-
ciations between serum genistein and hypermethylated
breast cancer related genes following isoflavone supplements,
yet no changes in breast cytology and suggestions of an
anti-estrogenic effect were noted. More direct, yet not
causal, evidence from observational studies indicates that
post-diagnosis soy intake is safe for breast cancer survivors
with consumption associated with decreased risk of breast
cancer recurrence and mortality (Nechuta et al. 2012; Chi
et al. 2013; Qiu and Jiang 2019). It is important to again
emphasize that there have not been any randomized clinical
trials that have examined the effects of soy on recurrence or
mortality of cancer survivors and therefore, although
national and international organizations advise that breast
cancer survivors can safely consume soy (Rock et al. 2012;
American Institute for Cancer Research 2021; World Cancer
Research Fund International 2014; Eating Well After Breast
Cancer 2021), it is prudent to remain conservative and sup-
port continued research in this area.
Endometrium
Concern about the susceptibility of the endometrium to iso-
flavones is logical given their classification as phytoestro-
gens. The publication of several case reports supporting this
concern emphasize the importance of evaluating the results
from clinical studies. Regarding the former, Chandrareddy
et al. (2008) described three case reports involving an assort-
ment of uterine/endometrial abnormalities, including leio-
myoma, severe dysmenorrhea, uterine bleeding, and
endometriosis, that were ascribed to excessive soy intake. In
all three cases symptoms resolved upon discontinuation of
soy consumption. One case involved a 56 y old women who
reported an “… unusually high intake of soy milk, equiva-
lent to 40 g of soy isoflavones every day for the last 3 years
for control of her climacteric symptoms.” It should be
noted, however, that it is not possible to consume gram
quantities of isoflavones from soymilk. Another case was a
43 y old women who reported “… regularly consuming
excessive amounts of soy (soy milk, tofu and baloney) as a
health supplement over the last 5 years, every day.”
Isoflavone intake was not reported. A third case was a 35 y
old women who reported “… an extremely high intake of
soy in various forms (milk, tofu, soy granules and soy pro-
tein concentrate) since the age of 14 years, every day.”
Isoflavone intake was again not reported. It was noted that
withholding soy intake resulted in a dramatic improvement
in her symptoms and a subsequent pregnancy. Finally, there
is a case report of a woman diagnosed with grade 1 endo-
metrioid adenocarcinoma of the endometrium whose history
was notable for extensive use of supplemental phytoestro-
gens although none were actually derived from soy (Johnson
et al. 2001). These included dong quai, vitex berry, black
cohosh root, licorice root and motherwort plus 24 other
supplements. Given that these case reports are of individu-
als, there is a need to examine the role of soy in endometrial
health more rigorously. The impact of soy on the endomet-
rium has been studied regarding both endometriosis and
endometrial cancer.
Endometriosis
Endometriosis is a common, benign gynecologic condition
characterized by the presence of endometrial-like lesions in
areas outside of the uterus. It affects approximately 10% of
reproductive-age women and 20% of infertile women
(Eskenazi and Warner 1997). In the US, endometriosis is
the third leading cause of gynecologic hospitalizations after
pelvic inflammatory disease and benign ovarian cysts
(Velebil et al. 1995). The most well-accepted theory to
explain the development and progression of peritoneal endo-
metriotic lesions is retrograde menstruation (Halme et al.
1984). However, the fact that most women experience retro-
grade menstruation but only a small minority develop endo-
metriosis indicates that other factors are involved in the
pathogenesis of this disease.
Diet is one of the factors that has been identified as being
involved in the pathology of endometriosis. For example,
data from the Nurse’s Health Study II found red meat
(more than >2 servings/d) was associated with a 56%
increased risk of endometriosis (when compared with 1
serving red meat/week) (Yamamoto et al. 2018). Soy is
another dietary factor that has been studied in relation to
endometriosis. Some evidence (Miyazawa 1976; Arumugam
and Templeton 1992; Sangi-Haghpeykar and Poindexter
1995), but not all (Missmer et al. 2004), indicates that Asian
women have higher rates of endometriosis than
Caucasian women.
Furthermore, use of SIF has been linked with increased
risk of endometriosis. A US case-control study (n¼ 310
cases, n¼ 727 controls) found women who were regularly
fed SIF as infants had more than twice the risk of endomet-
riosis compared those that were not fed SIF (OR, 2.4; 95%
CI: 1.2, 4.9) (Upson et al. 2015). In agreement, African-
American women ever-fed SIF as infants were more likely
to report ever use of hormonal contraception for menstrual
pain (relative risk (RR), 1.4; 95% CI: 1.1, 1.9) and moderate/
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severe menstrual discomfort/pain with ’most periods’, but
not ’every period’, during early adulthood (ages 18–22 when
not using hormonal contraception) than those who were not
fed SIF (Upson et al. 2019). However, another study that
focused on moderate-severe menstrual pain (a common
symptom of endometriosis) found that SIF use was not sig-
nificantly associated with ever or current use of any medica-
tion for menstrual pain (DiVasta et al. 2018).an
Adult consumption of isoflavones has also been studied
in relation to endometriosis. For example, a case-report
which described a 75 y old women who had been taking
supplements providing 75mg/d isoflavones for five years con-
cluded that there is the possibility that “… phytoestrogens at
least in concentrated form may play a role not only in main-
tenance of endometriosis but also in its malignant trans-
formation.” (Noel et al. 2006) However, in contrast to this
case report and the aforementioned SIF studies, other studies
do not provide support for a role of soy consumption in the
etiology of endometriosis. One US study found that although
rates of endometriosis were higher among Asian relative to
non-Asian women, the connection to soy consumption was
not clear since the comparison was true for Asian women of
Filipino, Indian, Japanese and Korean origin, despite the fact
that soyfoods are consumed by only the latter two groups
(Yamamoto et al. 2017). Another cross-sectional study, this
time focused on Japanese women, reported inverse associa-
tions between urinary genistein and daidzein and advanced
endometriosis (genistein OR, 0.21; 95% CI: 0.06, 0.76 and
daidzein OR, 0.29; 95% CI: 0.08, 1.03) as well as severity of
endometriosis (p for trend ¼ 0.01 for genistein and 0.07 for
daidzein) (Tsuchiya et al. 2007). More recently, isoflavone
intake was inversely related to endometriosis risk in a small
Iranian case-control study, although the low intakes of this
population question the utility of the results (Youseflu
et al. 2020).
Finally, there is a Japanese prospective study involving
1,172 female participants of the Takayama Study who were
premenopausal at enrollment (Nagata et al. 2001). During
the six year follow up period, 31 women underwent preme-
nopausal hysterectomies; since endometriosis is a prominent
reason for hysterectomy (Treloar et al. 1999), its relation to
isoflavone intake was examined. Results showed that the
second isoflavone intake tertile (median, 32.8mg/d) was sig-
nificantly associated with a decreased risk of premenopausal
hysterectomy compared to the lowest intake tertile (median,
20.4mg/d) after controlling for age and total energy (rate
ratio, 0.35, 95% CI: 0.13, 0.97), although the dose-response
relationship was not statistically significant.
The conflicting evidence for the role of soy in endometri-
osis is also seen in rodent studies with some studies having
implicated early soy exposure as a causative factor in experi-
mental endometriosis (Mvondo et al. 2019) whereas other
rodent models have shown isoflavones to have a protective
role (Yavuz et al. 2007; Takaoka et al. 2018; Sutrisno et al.
2018). Overall, the human and animal work indicates
conflicting results for the role of soy in the etiology of endo-
metriosis. Since it is clear that endometriosis is estrogen-
dependent (Anderson 2019) continued research in the role
of soy isoflavones is warranted.
Endometrial cancer
Endometrial cancer (cancer of the corpus uteri) represents
the most common gynecological malignancy in the industri-
alized world and is the seventh most common cancer among
females, although incidence and mortality rates vary mark-
edly among geographical regions and countries (Pisani,
Bray, and Parkin 2002). The highest rates are in the US and
Europe and the lowest in Asia and Africa (Parkin, Pisani,
and Ferlay 1999). Migration data suggest that the inter-
national variation in endometrial cancer rates is due to
environmental (lifestyle), not genetic factors (Liao et al.
2003). It is clear that estrogen contributes to the etiology of
endometrial cancer. Ever-users of unopposed estrogen ther-
apy are about two to three times more likely to develop
endometrial cancer as never-users (Weiderpass et al. 1999;
North American Menopause Society 2003; Grady et al.
1995). Consequently, there is concern that isoflavone-
containing foods could increase risk of developing
endometrial cancer and stimulate the growth of existing
endometrial tumors.
Epidemiology
Several epidemiological studies have examined the role of
soy isoflavones in endometrial cancer. These data were sum-
marized in a meta-analysis of 10 observational studies (eight
case-control, two prospective) that found soy intake was
inversely associated with endometrial cancer risk with an
overall risk estimate (RE) of 0.81 (95% CI: 0.72, 0.91)
(Zhang et al. 2015). Although the cohort (RE, 0.80; 95% CI:
0.51, 1.26) and case-control (RE, 0.83; 95% CI: 0.73, 0.94)
studies produced similar REs, only the latter was statistically
significant. Subgroup analyses found statistically significant
protective effects for both Asian (n¼ 3, RE, 0.79; 95% CI:
0.66, 0.95) and non-Asian (n¼ 7, RE, 0.83; 95% CI: 0.71,
0.96) populations. Of the three Asian studies, the Japanese
case-control study evaluated only tofu intake (Hirose et al.
1996), the Chinese case-control study estimated total isofla-
vone intake (Xu et al. 2008) and the Japanese prospective
study reported total and individual soyfood intake and
intake of isoflavones (Budhathoki et al. 2015).
Clinical studies
The impact of soy isoflavone intake and endometrial cancer
risk has also been examined in clinical studies that have
used high-resolution transvaginal ultrasound (TVU) to
measure endometrial thickness and screen for endometrial
cancer risk (Smith-Bindman, Weiss, and Feldstein 2004). In
general, the thickness of the menopausal endometrium is
normally 5 mm, which is consistent with atrophy
(Nalaboff et al. 2001). After menopause, increased endomet-
rial thickness may indicate proliferative endometrium
(Wolfman et al. 2010) and increased endometrial thickness
even without bleeding is predictive of endometrial cancer.
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The relation of endometrial thickness to endometrial cancer
was shown in the Prostate, Lung, Colorectal and Ovarian
Cancer Screening Trial that completed TVU in 1,018 post-
menopausal women (55–74 y) and found that those with
endometrial thickness 5.0mm had a 5-fold increased risk
of endometrial carcinoma (RR, 5.02; 95% CI: 0.96, 26.36) in
models adjusted for menopausal hormone use and BMI
when compared to women with baseline endometrial thick-
ness of 1.0–2.99mm (Felix et al. 2014). During the 12.5 y
(range: 0.3–13.8 y) follow-up period, however, only 14
women developed endometrial carcinoma. More recently, a
systematic review found that the risk of endometrial cancer/
endometrial hyperplasia was 2.6 times greater in women
with endometrial thickness 11mm vs women with endo-
metrial thickness 5–10mm, although there was significant
heterogeneity in estimates across studies (Alcazar et al. 2018).
In 2015, EFSA reviewed 25 clinical studies (n¼ 1484)
that examined the effect of soy isoflavones on endometrial
thickness (EFSA ANS Panel (EFSA Panel on Food Additives
and Nutrient Sources added to Food) 2015); no studies of
isoflavones and endometrial cancer were identified. Results
showed no statistically significant changes in endometrial
thickness in any of the studies which included the use of
food supplements containing soy isoflavones/soy extract
(60–120mg isoflavones/d, 3–36months), soy protein
(90–120mg isoflavones/d, 4–36months), daidzein-rich iso-
flavones (80–120mg isoflavones/d, 24months), glycitein-rich
isoflavones (114mg isoflavones/d, 3months), genistein
(30–54mg/d, 3–36months) and red clover extract
(40–120mg isoflavones/d, 12–36months). A two-year trial
not included in the EFSA review also found no effect on
endometrial thickness; in this case postmenopausal women
were randomized to receive either a placebo or 54mg/d gen-
istein (Atteritano et al. 2007). A two-year study published
after the EFSA review also found no change in endometrial
thickness in premenopausal women in response to 80mg/d
isoflavones derived from red clover (Ferraris et al. 2020).
EFSA also reviewed 9 studies (n¼ 677) that examined the
effect of isoflavones on histo(patho)logical changes in the
endometrium. These studies intervened with a variety of iso-
flavone-containing products including soy isoflavones/soy
extract (60–120mg/d, 3–6months), soy protein (65–154mg
isoflavones/d, 3–36months), daidzein-rich isoflavones
(80–120mg/d, 24months), glycitein-rich isoflavones (114mg/
d isoflavones/d, 3months) and red clover extract (50mg/d
isoflavones, 3months duration). Results were again insignifi-
cant with only one study, which is discussed below, reporting
significant histo(patho)logical changes in the uterus (Unfer
et al. 2004). EFSA concluded that based on the human and
animal studies, isoflavone exposure does not cause adverse
effects on the uterus in postmenopausal women when taken
in the doses and for the durations examined.
EFSA’s conclusion is consistent with a recent meta-ana-
lysis of clinical studies which found that when all 23 studies
(n¼ 2,167) were included in the analysis there was no effect
of isoflavones on endometrial thickness whereas when only
the seven North American studies (n¼ 726) were analyzed,
there was a statistically significant decrease in endometrial
thickness (Liu et al. 2016). Thus, among North American
women, the clinical data suggest that soy consumption may
reduce risk of developing endometrial cancer. On the other
hand, when the three Asian studies were analyzed, there was
a small increase in endometrial thickness, although none of
these studies intervened with isoflavones derived from soy-
beans. One of the studies in the meta-analysis, which was
not cited in the EFSA review, is notable for its size
(N¼ 224) and duration (3 y) (Quaas et al. 2013). This study
randomized US postmenopausal women to consume either
25 g/d soy protein containing 91mg isoflavones or 25 g/d
milk protein and found that the rate of endometrial hyperpla-
sia/malignancy was lower in the soy group (0% vs 14.3%);
however, the difference was not statistically significant.
The only clinical study to find a significant effect of iso-
flavones on endometrial histo(patho)logical change is also
notable for its size (N¼ 319) and duration (5 y) (Unfer et al.
2004). This Italian study conducted by Unfer et al. (2004),
randomized postmenopausal women to consume either a
placebo or an isoflavone supplement (150mg/d, unclear if
value represents aglycone equivalent or glycoside weight)
and examined endometrial histology from biopsies at base-
line, 30months, and 5 y after treatment. Results showed no
cases of endometrial cancer over the 5 y period and no
effects on endometrial tissue at 30months; however, at 5 y,
there were 5 women (3.2%) in the isoflavone group who
developed simple hyperplasia and 1 (0.6%) who developed
complex hyperplasia whereas none of the women in the pla-
cebo group developed hyperplasia. Simple endometrial
hyperplasia is reversible and rarely progresses to endometrial
cancer (M€unstedt et al. 2004; Kurman, Kaminski, and
Norris 1985).
The study by Unfer et al. (2004), had several notable
weaknesses. For example, as noted by Foth and Nawroth
(2005), women with inaccessible endometrium samples at
baseline (25% of all participants) were not excluded for
evaluation at future time points. Thus, it is unclear whether
the endometrial hyperplasia found in the isoflavone group
was also present at baseline, questioning whether it occurred
because of isoflavone exposure. This point was also noted by
the EFSA (EFSA ANS Panel (EFSA Panel on Food Additives
and Nutrient Sources added to Food) 2015) and the US
National Toxicology Program (National Toxicology Program
UDoHaHS, Center for the Evaluation of Risks to Human
Reproduction 2006) in their evaluations of the safety of iso-
flavones. The study is also limited in its lack of information
on endometrial thickness or bleeding patterns and lack of a
biological measure (i.e. urinary or plasma isoflavones) or
subjective (i.e. asking participants) of compliance to the iso-
flavone supplement. Finally, although not a design weakness,
the results of this study warrant cautious interpretation since
should even a few cases of endometrial hyperplasia in the
placebo group have occurred, which would not have been
unexpected, the differences between groups would likely not
have been statistically significant. For comparison, in the
Postmenopausal Estrogen/Progestin Interventions (PEPI)
Trial, 1.6% of the women in the placebo group developed
hyperplasia over a three-year period (The Writing Group for
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the PEPI Trial 1996). It is logical to speculate that this per-
centage would have been higher at 5 y.
Isoflavones have also been studied for their ability to
inhibit the effects of agents, such as estrogen, that cause
endometrial tissue proliferation. For example, a study by
Bitto et al. (Bitto et al. 2010), found that 54mg/d genistein
consumed for 6months by premenopausal women (n¼ 19)
with non-atypical endometrial hyperplasia improved symp-
toms to approximately the same degree as the drug norethis-
terone acetate (n¼ 19), leading the authors to conclude that
genistein might be useful for the management of endomet-
rial hyperplasia in women who cannot be treated with pro-
gestin (Bitto et al. 2010).
Another study showed that SPI was able to attenuate the
effect of estradiol on increasing endometrial thickness over
6months. This study randomized 39 postmenopausal women
to daily treatment of either estradiol at 2 doses (0.5mg estra-
diolþ placebo or 1.0mg estradiolþ placebo) or estradiol at the
same 2 doses but combined with SPI (0.5mg estradiol þ 25 g
ISP providing 120mg isoflavones, or 1.0mg estradiol þ 25 g
ISP with 120mg isoflavones). Endometrial thickness increases
over the six months were from 3.6 to 12.0mm and from 3.6
to 11.6mm in the 0.5mg and 1.0mg estradiol and placebo
groups, respectively. This increase was attenuated, specifically
from 3.0 to 6.8mm and 3.0 to 7.1mg in the 0.5mg and 1.0mg
estradiol and SPI groups, respectively (comparison among all
groups, p¼ 0.08) (Murray et al. 2003).
Finally, in a third study, Unfer et al. (2004), which was
previously cited, found that co-administration of isoflavones
and CC reversed the deleterious effects of CC on endomet-
rial thickness and contributed to higher pregnancy rates
than CC alone. The 134 women in this study were aged
25–35 y, infertile for at least two years and had oligomenor-
rhea or amenorrhea associated with a positive menstrual
response to the intramuscular progesterone-challenge test. In
an accompanying editorial, Casper (2004) attributed the
likely mechanism of isoflavones to their ability to displace
CC from ERs. However, a pharmacologic dose of isoflavones
was used in this study.
Conclusions
Soy isoflavones have been studied in relation to endometrial
health through their effects on endometriosis and endomet-
rial cancer risk. Rationale for concern comes from the role
of estrogen in the etiology of these conditions and adverse
effects of excessively high intakes of soy isoflavones reported
from individual case reports (Chandrareddy et al. 2008;
Johnson et al. 2001; Noel et al. 2006). Building upon the
higher rates of endometriosis among Asian women relative
to Western women (Miyazawa 1976; Arumugam and
Templeton 1992; Sangi-Haghpeykar and Poindexter 1995),
some studies have suggested an increased risk of endometri-
osis with early soy exposure (SIF) (Upson et al. 2015; Upson
et al. 2019). In contrast, studies focused on adult exposure
have raised doubt about the connection between soy and
endometriosis (Yamamoto 2017 #23084) or even found a
protective association (Tsuchiya et al. 2007). With respect to
endometrial cancer risk, results seem more consistent for a
protective or null role for soy isoflavones with meta-analysis
finding an inverse association between soy isoflavones and
endometrial cancer risk (Zhang et al. 2015) and a review of
clinical studies showing no adverse effects of soy isoflavones
on endometrial thickness or histo(patho)logy (EFSA ANS
Panel (EFSA Panel on Food Additives and Nutrient Sources
added to Food) 2015), although these effects may be ethni-
city-specific (Liu et al. 2016). In addition to individual
effects on the endometrium, there is evidence that soy isofla-
vones can attenuate the proliferative effects of estrogen on
the endometrium (Unfer et al. 2004; Murray et al. 2003).
The epidemiological and clinical studies do not corroborate
the case reports and instead point to a protective or null
effect with consideration required for core factors like estro-
gen exposure, timing of soy exposure and ethnicity.
Uterine fibroids
Uterine fibroids (UF), also called leiomyomata, are benign,
hormonally-dependent tumors that grow in the walls of the
uterus, and are detected in 70–80% of women by age 50 y
(Taylor and Leppert 2012). UF are responsible for causing
symptoms such as heavy and irregular menstrual periods,
infertility, and spontaneous abortions and are listed as a
leading risk factor for hysterectomy (Harding et al. 2008;
Merrill 2008).
UF tend to shrink during menopause and often become
asymptomatic, thus most such patients require no treatment
(Segars et al. 2014; Sener et al. 1996). Specific therapy is
reserved only for large fibroids or leiomyomas that continue
to grow after menopause and, in this age group, usually
result in total hysterectomy. Estrogen-containing contracep-
tives and menopausal hormone therapy have been associated
with an increased risk of fibroids (Sabry and Al-Hendy
2012; Templeman et al. 2009; Pavone et al. 2018; Stewart
et al. 2017; Wise and Laughlin-Tommaso 2016). However,
Moro et al. (2019) concluded that progestin, rather than
estrogen component of menopausal hormone therapy, may
be the more important risk factor.
Recently, Qin et al. (2019) meta-analyzed the epidemio-
logic studies that examined both infant (n¼ 4) and adult
(n¼ 7) soy/isoflavone exposure and risk of UF among pre-
menopausal women. The infant studies, all of which were
conducted in the US, included 2,908 cases. There was a
non-statistically significant positive association between SIF
consumption and risk of UF (OR, 1.19; 95% CI, 0.99-
1.43; p¼ 0.06).
With respect to adults, there were a total of 3,136 cases;
of the seven studies, five were case-control and one each
was a cohort and cross-sectional study. Exposure in five
studies was based on the ingestion of soyfoods whereas in
two it was based on urinary isoflavone excretion. When all
seven studies were considered in the analysis, there was a
positive, but non-statistically significant relationship between
soy exposure and UF risk (OR, 1.92; 95% CI: 0.92, 4.03;
p¼ 0.08). However, the results showed high heterogeneity
with an I2 of 94.3%.
Of the seven studies, three involved non-Asian, low-soy
intake populations. When the three studies involving non-
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Asians were analyzed separately by Qin et al. (2019), there
was no relationship between exposure and risk (OR, 0.99;
95% CI: 0.78, 1.26; p¼ 0.94). In contrast, among the four
Asian studies involving 940 cases, three of which were from
China and one from Japan, there was a significant increased
risk (OR, 2.50; 95% CI: 1.09, 5.74; p¼ 0.03). In addition, the
dose-response analysis showed an accumulating positive
association of soy isoflavone intake with the risk of UF. The
pooled ORs (95% CIs) of UF risk for low vs occasional,
moderate vs occasional, and high vs occasional soy isofla-
vone intake were 1.00 (0.87, 1.14), 1.08 (0.94, 1.24), and 1.23
(0.99, 1.53), respectively. However, in the high-consumption
subgroup, the heterogeneity was high, with an I2 of 92.4%.
Furthermore, in three of the four Asian studies, soy/isofla-
vone exposure was not comprehensively and/or not inde-
pendently assessed.
In the study by Gao and Wang (2018), frequent (four or
more  4 times/wk) consumption of cow’s milk or soybean
consumption was compared with infrequent (<4 times/wk)
consumption. However, portion size was not considered and
cow’s milk and soybean consumption were included in a
combined category; these foods were not assessed independ-
ently (Gao and Wang 2018). In the study by He et al.
(2013), three soy intake categories were compared: low
(never/less than one day per week), intermediate (two days
per week) and high (more than three days per week) (He
et al. 2013), but portion size again was not considered. In
the study by Shen et al. (2013), only the intake of soymilk
was assessed and again without consideration of portion
size; also, no definition of the intake categories (none, occa-
sional and frequent) was provided. Only the Japanese study,
which did not find a statistically significant association with
isoflavones (high vs low isoflavone intake; OR, 1.82; 95% CI:
0.79, 4.17), comprehensively evaluated isoflavone intake
(Nagata et al. 2009). Isoflavone intake categories (mean, mg/
d) were low (21.2), medium (35.4) and high (61.1) (Nagata
et al. 2009). Isoflavone intake in this study was almost cer-
tainly higher than in the Chinese studies given what is
known about Chinese and Japanese soy intake (Messina,
Nagata, and Wu 2006).
Another observational study that was previously dis-
cussed, did not include UF as an endpoint but still may be
relevant to the discussion. The results of this Japanese pro-
spective study involving 1,172 female participants of the
Takayama Study who were aged 35–54 y and premenopausal
at the time they were enrolled suggest that isoflavone intake
is protective against the development of UF (Nagata et al.
2001). As noted previously, UF are a reason for hysterec-
tomy (Treloar et al. 1999). The only clinical study identified
that examined the impact of isoflavone exposure on UF was
conducted by Steinberg et al. (2011) In this two-year study
involving 403 postmenopausal women who were random-
ized to consume either a placebo or 80 or 120mg/d isofla-
vones, no effect on the development or growth of UF was
observed. Two limitations of this study include the involve-
ment of postmenopausal rather than premenopausal women
and the use of isoflavones derived from soygerm, which is
low in genistein.
Conclusions
Given the limited data and the limitations of the existing
studies, it is not possible to reach conclusions about the
impact of isoflavone exposure on the risk of developing UF.
More research is warranted.
Research involving children
Puberty onset
The possible impact of soy on puberty onset is a relationship
that has garnered attention in part because pubertal charac-
teristics are occurring at an earlier age in children through-
out the world as evidenced by a number of changes
including the advance in the age at which menarche occurs
(Euling et al. 2008; Biro et al. 2010; Junqueira Do Lago et al.
2003; Harris, Prior, and Koehoorn 2008; Hosokawa,
Imazeki, and Mizunuma 2012; Cho et al. 2010; Morris et al.
2011; Cabanes et al. 2009; Herman-Giddens 2006; Himes
2006; Talma et al. 2013). In addition, children may absorb
isoflavones to a greater extent than adults (Halm, Ashburn,
and Franke 2007; Maskarinec et al. 2005). However, the
trend toward earlier puberty onset is occurring in countries
where soy is not a traditional part of the diet as well as in
those where soy is (Messina et al. 2017). In comparison to
girls, less evidence is available in support of a secular trend
for earlier pubertal timing for boys although recently
Ohlsson et al. (2019) found that among Swedish boys born
between 1947 and 1996, after adjusting for childhood BMI,
age at peak height velocity was 1.2months earlier per decade
increase in birth year.
Among women, early menarche is associated with shorter
stature, a relationship which has been shown in both high-
and low-income countries (Kang et al. 2019; Onland-Moret
et al. 2005). Earlier menarche has also been implicated in
the etiology of breast and ovarian cancer so the trend
toward earlier puberty is a health concern (Ruder et al.
2008; Barker et al. 2008) as well as a social concern (De
Genna, Larkby, and Cornelius 2011; Graber 2013). On the
other hand, older age at puberty may be associated with
lower bone mineral density (Elhakeem et al. 2019). Many
factors potentially contribute to the trend toward earlier
puberty such as increasing adiposity (Biro et al. 2003) and
xenoestrogen exposure (Wolff et al. 2010; Buck Louis et al.
2008). Diet may also play a role as epidemiological studies
have found that both total protein and animal protein intake
is associated with earlier menarche and earlier development
pubertal characteristics (Rogers et al. 2010; G€unther
et al. 2010).
There has been only limited investigation of the effects of
soy on pubertal development. This issue received some
attention as a result of a case report from Brazil describing a
nearly 5-y-old girl who presented with premature thelarche
that was attributed to an intake of 40mg/d isoflavones
from soyfoods (Fortes et al. 2007). Blood isoflavone levels
were not measured, however. The parents were advised to
limit their daughter’s soy consumption to once per week.
While this case report is certainly intriguing, its informative
value is limited because no follow up examination is
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described until the patient is almost nine years of age, when
it is said that the patient was at the same stage of pubertal
development as her peers and maintained the growth rate
and bone development compatible with chronological age.
More relevant are two Korean case-control studies which
found urinary isoflavones in girls with precocious puberty
were higher than in children serving as controls (Kim et al.
2011; Yum, Lee, and Kim 2013). In one, 108 girls (aged
8.6 ± 0.8 y) with central precocious puberty were compared
with 91 age-matched controls (aged 8.5 ± 0.8 y) (Kim et al.
2011). Serum mean (± SD) total isoflavone concentrations
(nmol/l) were significantly greater in the central precocious
puberty group than in the control children (77.9 ± 57.2 vs
62.9 ± 40.2; p¼ 0.0009). However, the actual difference in
means between groups was relatively small, especially con-
sidering the large standard deviations, which indicates there
was considerable overlap. In addition to the differing means,
the prevalence of precocious puberty was significantly higher
in children with a serum isoflavone level 30 nmol/l than it
was for those with a serum level <30 nmol/l (p¼ 0.0008).
However, this cutoff was arbitrarily chosen by the research-
ers after the data had been tabulated. Also, when assessing
the risk between central precocious puberty and serum iso-
flavones the only factors adjusted for were age, height, and
body weight. Finally, neither estradiol nor peak FSH levels
differed between normal girls and girls with precocious
puberty although peak LH was higher in the latter group.
The other Korean study involved 150 girls (age,
8.91 ± 1.40 y) with precocious puberty and 90 control sub-
jects (age, 8.50 ± 1.68 y) (Yum, Lee, and Kim 2013). The
plasma genistein concentration (ng/ml) was significantly
higher in the girls with precocious puberty compared with
the control girls (8.12 ± 12.71 vs 3.04 ± 4.21, p¼ 0.0008), but
there were no differences between groups for daidzein or
the daidzein metabolite equol (Setchell and Clerici 2010).
Further, it appears that no statistical adjustments were made
for potentially confounding variables when comparing
groups. It is noteworthy that the serum isoflavone levels
among the children in this study (Kim et al. 2011) and the
previous one (Yum, Lee, and Kim 2013) were very low rela-
tive to older Japanese adults, and much lower than infants
consuming SIF (Setchell et al. 1997).
In Korea, there has been an ongoing trend for girls to
begin menstruating at younger ages (Cho et al. 2010). One
analysis identified a host of factors that appear to influence
age of menses (AOM) onset in Korean girls (Cho et al.
2010). These included maternal menarcheal age, BMI,
maternal age at birth, and diet. Importantly, since there is
no evidence that soy consumption has increased over the
past several decades in Korea, it would appear unlikely that
soy intake is contributing to the trend in the AOM (Kim,
Moon, and Popkin 2000).
In contrast to the two Korean studies (Kim et al. 2011;
Yum, Lee, and Kim 2013), a study with a stronger prospect-
ive design involving 1,239US girls aged 6-8 at enrollment
who were followed for seven years found no relationship
between pubertal development and urinary isoflavone excre-
tion (Wolff et al. 2015). Another US study involving 192
healthy 9-year-old girls residing in New York City, but
which utilized a cross-sectional design, found isoflavone
exposure was associated with delayed breast development
(Wolff et al. 2008). This finding agrees with the results of a
German longitudinal study involving 227 girls (Cheng et al.
2010). Girls whose diet was in the highest dietary isoflavone
intake tertile experienced Tanner stage 2 for breast develop-
ment 0.7 y later and reached peak height velocity 0.6 y
later than did girls whose diet was in the lowest isoflavone
tertile adjusted for BMI z score and fiber intake. In boys,
dietary isoflavones were not associated with pubertal
markers. Finally, urinary isoflavone levels were not associ-
ated with pubertal markers in girls or boys. However,
because of the low isoflavone intake of these Western popu-
lations (Wolff et al. 2008, 2015; Cheng et al. 2010), their
informative value is limited.
One US cross-sectional study that avoids the limitations
of the Western studies cited above involved Seventh-day
Adventist (SDA) girls (N¼ 327; age range 12 to 18; mean
age, 15 y) (Segovia-Siapco et al. 2014). Since 40% of SDAs
practice some form of vegetarianism (Orlich et al. 2013),
their soy consumption is much higher than the general US
population (Rizzo et al. 2013). For this study, current soy
intake was used as a surrogate for intake prior to menses
onset, an approach used by other researchers (Cutler
et al. 2009).
The mean number of servings of soyfoods among the
adolescent girls was 12.9 per week and 21.1% of the girls
consumed soyfoods 4x/d. The mean AOM of all girls in
the study was 12.5 y. The consumption of total soyfoods
(p¼ 0.77) and the intake of three specific types of soyfoods
(meat alternatives, tofu/traditional soy, and soy beverages; p
values ¼ 0.838, 0.401, 0.759, respectively) was not signifi-
cantly associated with AOM nor was total soy intake signifi-
cantly associated with the odds of early (<12 y of age) or
late (14 y of age) AOM (Segovia-Siapco et al. 2014).
A similarly designed study involving SDA boys was pub-
lished four years later (Segovia-Siapco et al. 2018). In this
case, the measure of puberty onset was the first onset of
pubic hair (Tanner stage 2). Among the 248 boys aged 12-
18 attending SDA schools, moderate and high total soy iso-
flavone intake was significantly associated with earlier
adjusted median age at pubarche: 12.58 y [RR (95% CI): 1.58
(1.06, 2.36)] for moderate and 12.50 y [RR (95% CI): 1.63
(1.03, 2.60)] for high vs. 13.00 years for low soy consumers.
However, no significant associations were noted between
isoflavone intake and facial hair onset, which was used as a
secondary measure of puberty onset. Also, it is notable that
even among high-soy-consuming boys, puberty onset was
much later than is typical for US boys (Herman-Giddens
et al. 2012). To this point, Herman-Giddens et al. (2012)
reported that among 4,131 boys, puberty onset (Tanner
stage 2) was 11.47, 10.25, and 11.43 y for non-Hispanic
white, African American, and Hispanic boys, respectively. In
these two cross-sectional analyses involving SDAs, soy pro-
tein contributed about 15% (10 g/day) of total protein
intake. More specifically, among the 299 girls and 231 boys,
mean (SD) soy protein was 10.8 ± 9.9 and 9.9 ± 10.1 g/d,
respectively (Segovia-Siapco et al. 2019).
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Indirectly arguing against soy intake advancing puberty
onset in girls are animal (Lamartiniere et al. 1995;
Lamartiniere, Zhao, and Fritz 2000; Peng et al. 2010) and
observational (Shu et al. 2001; Wu et al. 2009; Korde et al.
2009; Baglia et al. 2016) data indicating soy consumption
during childhood and/or adolescence reduces breast cancer
risk later in life. As noted previously, earlier menarche is
associated with an increased risk of breast cancer (Ruder
et al. 2008; Barker et al. 2008), although not all data are sup-
portive of this relationship (Schoemaker et al. 2017).
Furthermore, an increased breast cancer risk may be more
closely tied to earlier thelarche than to earlier AOM onset
(Bodicoat et al. 2014). Isoflavone exposure early in life
appears to cause breast cells in the developing breast to
become permanently less likely to be transformed into can-
cer cells (Messina and Hilakivi-Clarke 2009). The effect of
isoflavones may be similar to that of early pregnancy, which
also reduces breast cancer risk (Russo et al. 2005). Proposed
mechanisms for the protective effect of early isoflavone
exposure include increasing cell differentiation (Russo et al.
2005; Brown et al. 2010) and increasing BRCA1 gene expres-
sion (de Assis et al. 2011) and ERb levels (Rahal and
Simmen 2011).
Finally, no relationship was identified in a prospective
study between use of SIF and signs of early puberty involv-
ing 89 infants (29 SIF-fed, 60 controls) (Sinai et al. 2019).
The use of soy products is common in young children with
cow milk allergy (CMA). Infants who consumed only SIF
were followed from birth until three years of age. Study par-
ticipants were reevaluated between ages 7.8 and 10.5 y by an
interview, nutritional intake by three-day food diaries, and
height, weight, and pubertal signs by physical examination.
The groups had comparable height and BMI z scores. No
association was detected between puberty and infantile
nutrition, after controlling for BMI and family data.
Conclusions
Current evidence suggests no clear relationship between a
high habitual intake of soyfoods with advanced puberty
onset. Although an early case-study raised concerns of pre-
cocious pubertal development linked to high soy isoflavone
intake, subsequent cross-sectional, case-control, and pro-
spective cohort studies have not shown a consistent associ-
ation with early development in girls or boys. Other lines of
evidence from observational studies and animal models link-
ing soy to lower risk of breast cancer provide evidence that
any potential effect is not associated with long-term harm.
To address the uncertainties, more high-quality evidence is
needed from prospective cohort studies that provide large
ranges of soy exposure and randomized controlled trials of
soy-based interventions in peri-pubertal children.
Hormones
Two clinical studies and one population-based study were
identified that examined the impact of soy intake on hor-
mone levels in children. The cross-sectional study of 230
Japanese boys and 198 Japanese girls aged 3-6 y, found that
after adjusting for potential confounding, a higher soy intake
was inversely related to urinary estrone (p for trend, 0.013)
and estradiol (p for trend, 0.026) in boys and positively
related to urinary testosterone (p for trend, 0.003) and
androstenediol (p for trend, 0.027) in girls (Wada et al.
2011). Similar findings were reported for isoflavone intake.
The highest (fourth quartile) median isoflavone intake in
boys and girls was 26.5 and 24.0mg/d, respectively.
In contrast to this cross-sectional study, no effects of iso-
flavone exposure were noted in the two clinical intervention
studies, although both involved small numbers of partici-
pants. In one, Maskarinec et al. (2005) enrolled 17US girls
aged 8–14 for eight weeks during which time they were
instructed to consume one daily serving of soy (average iso-
flavone intake was 27mg/d). They observed an increase in
dehydroepiandrosterone but no change in levels of all other
urinary hormones (5 androgens and 6 estrogens). The
authors noted that in their study since sex steroid levels
were associated with pubertal development based on Tanner
stages, their results support the validity of the sex steroid
measurements (Maskarinec et al. 2005).
The other intervention trial was a small 8-week random-
ized controlled trial with a cross-over design involving 12
hypercholesterolemic Israeli children (8 females) aged
5.3–11.2 y, who received in random order a placebo or 16 or
48mg/d isoflavones in tablet form separated by a two-week
washout period (Zung et al. 2010). Despite the high dose of
isoflavones, there were no effects on serum levels of estradiol
(measured in girls only), testosterone (measured in boys
only), FSH, LH, TSH, free T4 or total T3 (Zung et al. 2010).
Limitations of this study are the small sample size and that
the data were not presented separately for boys and girls.
Data on thyroid hormones come from three studies
including two observational studies and one intervention
study. (Note that two of these studies were previously dis-
cussed in the section on thyroid hormones). In a study
involving 139 girls and 129 boys aged 8–15 y from the
Czech Republic, a very modest association was found
between circulating isoflavone levels and measurements of
thyroid function (Milerova et al. 2006). However, when chil-
dren were divided into two groups (soyfood eaten within
the past 24 h, yes or no), TSH and free T3 levels did not dif-
fer between groups, although free T4 levels were higher in
the soyfood consumers. In the other observational study,
which involved nearly 600 Iranian children ages 6–12 y, risk
of goiter (thyroid hormones were not assessed) was unre-
lated to soy intake (Mousavi, Tavakoli, and Mardan 2006).
Although the findings from these two epidemiologic studies
are mentioned here, they are likely of limited utility because
appreciable amounts of soy are not consumed in either the
Czech Republic or Iran.
Finally, Helk and Widhalm (2020) recently conducted a
randomized controlled trial in pediatric age patients with
heterozygous familial hypercholesterolemia. Children were
assigned to consume a low saturated fat therapeutic diet
(n¼ 13, 8.0 ± 3.46 y) or the same diet enriched with soy pro-
tein (n¼ 13, aged, 9.46 ± 4.05 y) for 13weeks. Children in
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the soy group were instructed to consume 0.25 g/kg bw soy
protein. In comparison to the therapeutic diet only group,
low density lipoprotein-cholesterol was significantly reduced
in the soy group. There were no clinically significant
changes in thyroid hormones (TSH, T4 and T3) in any of
the patients. Average isoflavone intake in the soy group was
0.341mg/kg bw. In addition to this study, Mejia et al.
(Mejia et al. 2019) examined the effects of a one-year soy
protein intervention on bone formation markers, lipid pro-
file and insulin-like growth factor-1 in Columbian children
aged 2–9 y. No differences between groups were noted but
the intervention provided only 7 g protein and minimal iso-
flavones (0.13mg/kg bw/d). Because of the low intake, and
the limited data on hormones, this study does not provide
meaningful insight into the effects of isoflavones.
Conclusions
The available evidence does not support a meaningful rela-
tionship between soy intake and hormone levels in children.
Although some weak evidence from cross-sectional studies
have shown limited associations of soy intake with sex hor-
mones and thyroid hormones, these have not been repli-
cated in intervention studies of soy and soy isoflavones.
As the intervention studies have been small and of short
duration, there remains a need for more high-quality evi-
dence from prospective cohort studies that provide large
ranges of soy exposure over long durations of follow up and
randomized controlled trials of soy-based interventions. The
difficulty of conducting such studies warrants mentions
because differences in growth rates among similarly aged
children will result in considerable variations in hormone
levels which might mask any effects of an intervention,
unless vary large numbers of participants are involved.
Furthermore, in the case of intervention studies, compliance
is also likely to be problematic in young people. Finally, bet-
ter insight may be gained by focusing on more clinically
relevant endpoints, such as puberty onset, rather than on
hormone levels.
Fetal effects of maternal soy/isoflavone intake
In Asian countries, including Japan and China, soy is com-
monly consumed during pregnancy (Li et al. 2011; Miyake
et al. 2005). Ishitsuka et al., (2020) recently reported that
among Japanese women, during pregnancy, pulse intake,
which in Japan is represented primarily by soy products, is
similar to the intake prior to pregnancy. Miyake et al.
(2005) reported that the genistein and daidzein intake
(mean ± SD) of 1,002 pregnant Japanese women participat-
ing in the Japan Osaka Maternal and Child Health Study
was 15.0 ± 10.1mg/d and 9.0 ± 6.1mg/d, respectively. These
values are similar to the value of 21.7 ± 13.7mg/d, which
was the total isoflavone intake of 194 pregnant Japanese
women reported by Nagata, Oba, and Shimizu (2006) And
also similar to the value of 26.4mg/d, which was the quintile
3 mean intake among 84,948 Japanese singleton pregnant
women (median gestational age 12weeks) as recently
reportedly by Dong et al. (2021). For this particular study,
dietary intake was recorded during the 12months preceding
study enrollment. However, although women may alter their
diet because of vomiting and appetite change during early
pregnancy, the food frequency questionnaire used for this
study has been suggested as a useful instrument, regardless
of nausea (Ogawa et al. 2017).
Despite the common practice among Asians of consum-
ing soy while pregnant, concern has been raised that the
resulting in utero isoflavone exposure could adversely
impact the fetus (Yang et al. 2000; Shibayama et al. 2001).
In some sense, this concern is predictable given the well-
studied case of diethylstilbestrol (DES), a potent synthetic
nonsteroidal estrogen that was taken by pregnant women
from the 1940s to 1975 to prevent miscarriage and other
complications (Hilakivi-Clarke, de Assis, and Warri 2013;
Dieckmann et al. 1953), but which was eventually shown to
cause harmful effects in the offspring (Herbst, Ulfelder, and
Poskanzer 1971; Troisi et al. 2007; Herbst 1976; Troisi et al.
2013; Harris and Waring 2012; Titus-Ernstoff et al. 2008;
Swan 2000). However, depending upon the assay, DES can
be 1000-fold more estrogenic than genistein (Song,
Hendrich, and Murphy 1999; Lewis et al. 2003).
Interest in the relationship between the in utero environ-
ment and chronic disease later in life was spurred by the
work of Barker (Barker 1990, 1995), who in 1990 wrote that
“The old model of adult degenerative disease was based on
the interaction between genes and an adverse environment
in adult life. The new model that is developing will include
programming by the environment in fetal and infant life”
(Barker 1990). Research has shown that prenatal exposure to
famine is associated with increased adiposity (Stein et al.
2007), metabolic syndrome (Correia-Branco, Keating, and
Martel 2015), hyperglycemia (Li et al. 2010) and hyperten-
sion (Stein et al. 2006) in adulthood.
In the early 2000s, rodent data led several researchers to
express caution about in utero isoflavone exposure. For
example, Shibayama et al. (2001) concluded that “… it
might be better for … pregnant women to refrain from
ingesting large quantities of soy foods” and Yang et al.
(Yang et al. 2000) concluded that “… the ingestion of soy
during pregnancy … must be done with caution.” It is not-
able that these two research groups are from Japan.
Balakrishnan et al. (2010) demonstrated in an ex-vivo
human placental perfusion model that genistein can transfer
across the human placenta at environmentally relevant con-
centrations. However, it was already known that maternal
isoflavone exposure leads to quantifiable amounts of isofla-
vones in amniotic fluid. In 2002, after evaluating amniotic
fluid isoflavone levels, Foster et al. (Foster et al. 2002) com-
mented that “in utero exposure to dietary phyto-estrogens
may be a risk factor for developmental abnormalities of the
male reproductive tract.” Their concern was based on a
British observational study (North and Golding 2000), which
is discussed below, that found women who ate a vegetarian
diet during pregnancy were more likely to have male infants
affected by hypospadias than non-vegetarian women.
However, after reviewing the literature, Tan, Zhao, and
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Wang (2019) recently concluded that findings regarding the
association between Asian women who consumed a vegetar-
ian diet during pregnancy and hypospadias were inconclu-
sive. The discussion below highlights studies that examined
the relationship between soy intake during pregnancy and
vegetarian diet during pregnancy and risk of hypospadias.
Although vegetarian diet per se does not necessarily inform
about the impact of soy, several of the studies reporting on
vegetarianism also reported soy intake.
Hypospadias – background
Hypospadias is a common genitourinary anomaly in which
the opening of the urethra is on the underside of the penis.
Springer, van den Heijkant, and Baumann (2016) concluded
that hypospadias may be on the rise and cited prevalence
rates ranging from 5 to 50/10,000 births with high rates in
European and North America and low rates in China,
Japan, South-East Asia, and South America. In the US, the
mean prevalence rate is reported to be 34.2/10,000 (approxi-
mately 1 in 300 male children).
The etiology of hypospadias remains uncertain although
some have argued that it is a component of a larger disorder
referred to as testicular dysgenesis syndrome, which com-
prises a set of genitourinary malformations (including hypo-
spadias, cryptorchidism, hypospermatogenesis, and testicular
cancer) linked with genetic as well as environmental factors
(Toppari et al. 2010; Main et al. 2010; Wohlfahrt-Veje,
Main, and Skakkebaek 2009). Qiao et al. (2012) concluded
that aberrant estrogenic effects have a role in the etiology of
hypospadia and Krysiak-Baltyn et al. (Krysiak-Baltyn et al.
2010) suggested that the higher rates of male reproductive
disorders, including cryptorchidism and hypospadias in
Denmark compared with Finland, might be due to the
greater exposure to endocrine disrupting chemicals in the
former. Other evidence implicates industrial chemical
agents, some of which are classified as endocrine disruptors,
as possible etiological factors in hypospadias (Nordenvall
et al. 2014; Czeizel 1985; Paulozzi, Erickson, and Jackson
1997; Giordano et al. 2010; Nordkap et al. 2012; Botta,
Cunha, and Baskin 2014).
One might expect that if isoflavone exposure increased
risk of hypospadias, prevalence rates would be higher in
Japan than in non-soyfood-consuming countries, but the
opposite appears to be the case (Paulozzi 1999; Kurahashi
et al. 2004). Furthermore, one report suggested Japanese
rates had increased over a recent 20 y period (Paulozzi
1999), a time during which soy protein (and therefore isofla-
vone exposure) as a percentage of total protein intake
decreased (Messina, Nagata, and Wu 2006). While note-
worthy, since there are likely multiple factors involved in
the etiology of hypospadias (Yiee and Baskin 2010), these
types of epidemiologic observations are of only modest util-
ity in addressing the concerns initial raised by the previously
referenced British study (North and Golding 2000).
Regarding isoflavones, a review by Botta, Cunha, and
Baskin (2014) cited three rodent studies implicating genis-
tein as a possible risk factor for hypospadias (Ross et al.
2011; Padilla-Banks et al. 2012; Vilela et al. 2007). However,
there is reason for skepticism about the utility of animal
models for studying this condition. More than 40 years ago,
Robinson et al. (Robinson et al. 1977) highlighted the high
concentrations of estrogen to which the human fetus is nat-
urally exposed. And according to Witorsch (2002), “… cir-
culating levels of estrogen attained during pregnancy in the
rat and mouse compared to human are vastly different,
those of the latter far exceeding those of the former.” This
difference in in utero estrogen concentration suggests that
isoflavones are more likely to exert an estrogenic effect in
utero in rodents compared to humans. Hollier et al. (2014)
commented that “Due to the many developmental differen-
ces between species (e.g., duration of pregnancy, maturity at
birth, and susceptibility to a variety of environmental condi-
tions), it is difficult to extrapolate animal model findings to
human development.”
Observational data: soy/vegetarian diet and hypospadias
The previously cited British prospective study, which
included 7928 boys born to mothers taking part in the Avon
Longitudinal Study of Pregnancy and Childhood, was the
first observational study to examine the relationship between
maternal soy intake and risk of hypospadias (North and
Golding 2000). Compared with omnivores who did not
supplement their diet with iron, there was an approximate
5-fold increased risk (OR, 4.99; 95% CI: 2.10, 11.88) of
hypospadias in sons of mothers who ate a vegetarian diet
during pregnancy (North and Golding 2000). A total of 51
boys had hypospadias. These results agree with those of a
case–control study by Akre et al. (2008) that included 292
cases and 427 controls from Sweden and Denmark, which
found that a diet during pregnancy lacking both fish and
meat (4.8 and 1.9% of cases and controls, respectively, fell
into this category) was associated with a more than 4-fold
increased risk of hypospadias (OR, 4.6; 95% CI: 1.56, 13.07).
The study by Akre et al. (2008) did not report soy intake
but in the British study, mothers who drank soymilk [yes or
no; OR, 3.67; 95% CI: 0.87, 15.44)] or who ate soy “meat”
(1x/wk versus never; OR, 2.95; 95% CI: 0.90, 9.68) during
pregnancy were about 3-fold more likely to give birth to
boys with hypospadias (North and Golding 2000). However,
these associations were not statistically significant; further-
more, 2% of the >6000 mothers enrolled in this study
consumed soy during pregnancy (North and Golding 2000).
Also, although the authors speculated that isoflavones might
be responsible for the apparent association with soy intake,
legume (dried peas, beans, lentils, and chick peas) intake
was associated with a 7-fold increased risk of hypospadias
(4x/wk versus never; OR, 7.56; 95% CI: 2.25, 25.42), des-
pite non-soy legumes containing negligible amounts of iso-
flavones (Franke et al. 1998; Murphy et al. 1999). Soy meat
analogs, which as noted previously are also typically low in
isoflavones, were also associated with an increased risk
(Murphy et al. 1999).
A Dutch case–control study nested within a cohort of
8,698 male births that included 313 controls and 78 and 56
cases of cryptorchidism (a condition in which one or both
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of the testes fail to descend from the abdomen into the scro-
tum) and hypospadias, respectively, found the ORs for
cryptorchidism and hypospadias for the first (0 g/d), second
(>0–20 g/d) and third (20 g/d) soy protein intake tertiles
were 1.0, 1.1, and 0.6 and 1.0, and 1.1 and 1.0, respectively
(Pierik et al. 2004). Thus, these results provide no evidence
soy intake is linked to hypospadias. However, there is reason
to question the findings. In this study, 16% of the controls
fell into the third soy protein intake tertile, which had a cut-
off of 20 g/d. This intake level, which is similar that found
in Japan (Messina, Nagata, and Wu 2006), is inconsistent
with several reports showing relatively little soy is consumed
by the Dutch population (Boker et al. 2002; Kreijkamp-
Kaspers et al. 2004).
Somewhat parenthetically, this Dutch study (Pierik et al.
2004) found no association between a vegetable-rich diet
and risk of hypospadias, which concurs with the results of a
Dutch study published three years later involving 583 cases
and 251 controls; 10 of the mothers of cases and seven of
the mothers of controls were vegetarian (Brouwers et al.
2007). Also in agreement, are the results of two case–control
studies; one a British study involving 471 cases and 490 con-
trols (Ormond et al. 2009) and the other, a US study (dis-
cussed below) involving 1250 cases and 3118 controls
(Carmichael et al. 2012). In the former, there was no rela-
tionship between vegetarianism and hypospadias (OR, 0.85;
95% CI; 0.61, 1.19); of the total number of participants, 168
(17.5%) were classified as vegetarian or vegan. However, in
a later report from this British cohort (Ormond et al. 2009),
only about 3% of the participants were classified as vegetar-
ian (de Kort, Nieuwenhuijsen, and Mendez 2011). This later
analysis found that mothers consuming diets that were clas-
sified as ‘non-health conscious’ (low frequency of consump-
tion of yogurt, cheese, eggs, fruit and vegetables, fish, beans
and pulses, olive oil and organic food) had a higher risk of
hypospadias (OR, 1.54; 95% CI: 1.06, 2.26) compared with
‘health conscious’ participants who frequently consumed
fresh fruit and vegetables, dried fruit, fresh or frozen fish,
beans, pulses, soy products, olive oil and organic food.
Intakes of individual foods were not strongly associated with
hypospadias. The percentage of participants consuming soy
products 1x/mo in the health-conscious, mixed, and non-
health-conscious categories was 32.9, 5.5 and 6.5, respect-
ively (p< 0.0001) (de Kort, Nieuwenhuijsen, and
Mendez 2011).
Two small Indian studies reported contrasting results
regarding vegetarian diets and hypospadias as one (80 cases,
120 controls) (Shekharyadav et al. 2011) found no associ-
ation whereas the other (101 cases, 110 controls) (Samtani
et al. 2014) found a more than two-fold increased risk (OR
2.47; 95% CI: 1.4, 4.3). Ghosh et al. (2016), who also studied
this relationship in India, found a very high percentage of
mothers with infants with hypospadias were vegetarians, but
this work did not include a control group and no statistical
model was used to evaluate the findings.
The most direct examination of a possible association
between isoflavone intake and risk of hypospadias may be a
nationwide birth cohort study, which recruited women as
early in pregnancy as possible throughout Japan between
2011 and 2014 (Michikawa et al. 2019). Daily genistein
intake (as the representative isoflavone) was estimated from
the response to a self-administered food-frequency question-
naire. Information on cases that were diagnosed until the
first month after birth was obtained from medical records.
Among 41,578 mothers who delivered singleton live male
births, 51 cases of hypospadias were identified, and the
median genistein intake was 15.3mg/d. Compared with
mothers in the reference group (genistein intake 11th-89th
percentiles), those in the low intake group (10th percent-
ile) had an elevated risk of their sons having hypospadias
(multivariable-adjusted OR, 2.8; 95% CI: 1.4, 5.8). Neither
adverse nor beneficial effects of genistein on hypospadias
were observed in the high intake group (90th percentile)
(OR, 0.9, 95% CI: 0.4, 2.4). The authors concluded that low
maternal isoflavone intake in early pregnancy was associated
with an elevated risk of hypospadias. Low natto and tofu
intake were each associated with about a 2-fold
increased risk.
Finally, no relationship was found between meat intake
and risk of hypospadias in the National Birth Defects
Prevention Study, a US study which included 1250 cases
with second- or third-degree hypospadias and 3118 male,
liveborn, non-malformed controls (Carmichael et al. 2012).
The authors concluded that their study “does not support
an association of a vegetarian diet … with hypospadias.”
This study did find that maternal intake of total phytoestro-
gens (isoflavones, lignans and coumestrol) was associated
with a statistically significant 60% decrease in the risk of
hypospadias although after adjustment for possible con-
founding factors (maternal age, parity, race/ethnicity, educa-
tion, BMI, study center, folic acid-containing supplement
intake, and energy intake) the association was no longer
statistically significant (Carmichael et al. 2013). Similarly,
isoflavone intake alone was associated with a statistically sig-
nificant 60% decreased risk, but after adjustment, the 30%
decreased risk was no longer significant. However, because
the cutoff for the third isoflavone intake cutoff was 103.5
mg/d, the utility of this finding for informing about the
health effects of isoflavones is doubtful.
Conclusions
Although limited, the existing evidence does not suggest
that maternal isoflavone intake increases risk of hypospadias.
Although a British study found a non-significant association
with soy intake (North and Golding 2000), as highlighted
there are reasons to question the findings. Furthermore,
there was no association in three other non-Asian studies
(Pierik et al. 2004; de Kort, Nieuwenhuijsen, and Mendez
2011; Carmichael et al. 2013), although the low soy intake of
these populations limits the utility of the findings. More
importantly, there was no association between isoflavone
exposure and hypospadias in a Japanese study despite much
higher maternal isoflavone intake (Michikawa et al. 2019).
Also, rates of hypospadias are lower in Japan than in
Europe and the US, despite Japanese women consuming soy
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during pregnancy (Springer et al. 2016; Paulozzi 1999;
Kurahashi et al. 2004).
Outcomes other than hypospadias
Six studies were identified that assessed the impact of soy
intake during pregnancy on offspring outcomes other than
hypospadias. Three of these involved non-Asian populations
(Marks et al. 2017; Schmitt, Dekant, and Stopper 2001;
Starling et al. 2017), two involved a Chinese population (Liu
et al. 2020; Chen et al. 2021) and one a Japanese population
(Suzuki et al. 2012), although only the latter examined an
outcome possibly related to hypospadias.
A British longitudinal study by Marks et al. (2017)
involving 367 mother-daughter dyads found no association
between gestational urinary genistein, daidzein or equol lev-
els and risk of early puberty. In contrast, urinary levels of
O-desmethylangolensin (ODMA), an intestinally derived
metabolite of the soybean isoflavone daidzein, were associ-
ated with an increased likelihood of girls entering puberty
before the age of 11.5 years. In utero exposure to endocrine
disruptors has been proposed as advancing the age of
puberty onset in girls (Harley et al. 2019).
The link with ODMA, but not the other isoflavones, is
inconsistent with a possible estrogenic effect since ODMA is
considered to be less estrogenic than genistein, daidzein and
equol (Schmitt, Dekant, and Stopper 2001). Marks et al.
(2017) suggested that earlier puberty may simply be the
result of a specific phenotype, which is also characterized by
the ability to make large amounts of ODMA. Although
puberty onset in girls is a much different endpoint than
hypospadias in boys, the lack of effect on the latter informs
about the possible impact of isoflavones on the developing
fetus. However, the low isoflavone intake of the British
population raises doubts about the utility of this study. This
limitation also applies to the next study.
A US study conducted between 1999 and 2005 involving
387 partners of pregnant women found that beef consump-
tion during pregnancy of the mothers of the male partners
was inversely related to sperm concentration and the pro-
portion of men with sperm concentration <20 million/ml
(Swan et al. 2007). In contrast, maternal consumption dur-
ing pregnancy of fish, chicken, soy products and vegetables
was unrelated to the son’s sperm concentration (all p val-
ues, 0.225–0.655).
And in another US study, which involved 764 mothers, a
pattern characterized by starchy vegetables, eggs, non-whole
grains, and a low intake of dairy, dark-green vegetables,
whole grains, and soy was associated with greater maternal
fasting glucose and greater newborn birth weight and adi-
posity (Starling et al. 2017). In a study from Northwest
China, which used data from 7194 women from a large-scale
cross-sectional survey, medium and high adherence to a
dietary pattern that included soy products were less likely to
give birth to low birth weight and small for gestational age
(SGA) infants (Liu et al. 2020). Also from China is a study
that found among 1188 mother-infant pairs, sometimes or
frequent consumption of soy during weeks 12–16weeks of
pregnancy was associated with higher birth weight among
girls, whereas no association between soy intake and birth-
weight among boys was found (Chen et al. 2021).
In research published in 2012, spot urine samples taken
from 111 pregnant Japanese women were used to determine
whether phthalate ester metabolites were related to birth
outcomes and anogenital distance (AGD), the distance from
the center of the anus to external genitalia. A recent meta-
analysis found that boys with hypospadias or cryptorchidism
have shorter AGD (Hua et al. 2018). In a multiple regression
model, the log-transformed mono-2-ethylhexyl phthalate
concentration (specific gravity-corrected) was negatively, and
maternal smoking status, positively related, to the anogenital
index (AGI, AGD expressed in mm ⁄ kg). Urinary daidzein
(genistein was not measured) concentrations were unrelated
to AGI (Suzuki et al. 2012). Urinary daidzein levels (cor-
rected for creatinine) were similar to those reported by
Nagata, Oba, and Shimizu (2006) but about 50-fold higher
than reported for US adults (Centers for Disease Control
and Prevention 2019).
Finally, only one study was identified that intervened
with soy protein in pregnant women. For this study, Indian
women presenting with gestational diabetes were random-
ized to a high fiber complex carbohydrate diet (n¼ 30) or
the same diet in which 25% of the cereal component of the
high fiber, complex carbohydrate diet was replaced by soy
(n¼ 32) (Sarathi et al. 2016). At the end of the intervention,
patients in the non-soy group had significantly higher post-
prandial blood glucose levels whereas fasting pre-meal blood
glucose values tended to be lower in the soy group. In add-
ition, 12 (40%) women in the non-soy group failed to
achieve the glycemic targets compared to four (12.5%) in
the soy group. Thyroid function did not differ between
groups. Regarding infants, there were no significant differen-
ces between groups in neonatal TSH levels; none of the neo-
nates in either group had TSH >15 lIU/ml. While this
study is unique, its findings are of somewhat limited value
with respect to both the women and their infants because
the intervention was only one week in duration and the
amount of protein and isoflavones provided by soy products
(beans, chunks, granules or flour) isn’t clear from the study
description.
In utero isoflavone concentrations
Assessing the impact of maternal soy intake on birth out-
comes is the most direct way of determining the extent to
which, if any, in utero isoflavone exposure affects the fetus.
However, by comparing fetal isoflavone exposure with fetal
estrogen exposure, some insight is potentially gained about
the likelihood of maternal soy intake having an impact on
the fetus, assuming isoflavones exert an effect through an
estrogen-related mechanism.
Amniotic samples provide an approximation of circulat-
ing fetal hormones by gauging the hormone levels that have
entered the amniotic fluid via fetal urination or diffusion
through fetal skin (Nagamani et al. 1979). While amniotic
hormones are thought to relate to hormone levels in fetal
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blood, the strength of the relationship remains unclear.
Currently, there is no “gold standard” approach to the meas-
urement of prenatal hormone exposure (van de Beek et al.
2004). Umbilical cord blood is typically collected after deliv-
ery near term, and so cord plasma or serum hormone con-
centrations are thought to reflect the levels in the fetal
circulation at late gestation (Keelan et al. 2012).
According to recent reviews, umbilical cord blood 17b-
estradiol concentrations range from about 20 to 40 nmol/l
(Hollier et al. 2014; Kuijper et al. 2013). In two of the stud-
ies in Table 11, one reported cord blood estriol levels of
>7000 nmol/l (Nagata, Oba, and Shimizu 2006) and the
other reported a level >3,000 nmol/l (Adlercreutz et al.
1999). Amniotic estradiol concentrations at mid pregnancy
are about 1 nmol/l (van de Beek et al. 2004; Forest et al.
1980; van de Beek et al. 2009) and estrone levels are only
about 20% of that (Forest et al. 1980). As to whether there
are differences between Asian and non-Asian women,
Lagiou et al. (2011) found that cord blood levels of estradiol
and estriol in US women were 129.9 and 1328.6 nM,
respectively, and women from China, 292.5 and 1411.9 nM,
respectively.
When considering isoflavone levels in cord blood, it is
important to recognize that the half-life of genistein and
daidzein is approximately eight hours (Setchell et al. 2003).
Thus, cord blood isoflavone levels will likely be impacted by
the timing of the mother’s last meal containing isoflavones
prior to delivery. To this point, Todaka et al. (2005), found
much higher blood isoflavone levels of Japanese volunteers
who consumed a breakfast (isoflavone content not indicated)
a few hours prior to sampling than maternal blood levels
at delivery.
Jarrell, Foster, and Kinniburgh (2012) showed that amni-
otic fluid genistein and daidzein levels were higher (3–5
fold) in daily vs weekly soyfood consumers, indicating levels
respond to isoflavone intake. This point is also illustrated by
the higher amniotic fluid isoflavone levels among Japanese
(Adlercreutz et al. 1999) in comparison to US women
(Foster et al. 2002; Engel et al. 2006), which also is true for
cord levels as evidenced by the higher cord blood




Sampling time (gestation) Estradiol (nM) Estriol (nM)
Amniotic Fluid
Hill/Czech Republic/ (Hill et al. 2010) 12/28-41 wk 2.1 90.5




Cho/Korea// (Cho et al. 2006) 22/8–15 wk
.
3-sulfate, 18.9 ± 11.2
3-glucuronide, 8.4 ± 3
16-glucuronide, 19.8
van de Beck/USA/ (van de Beek et al. 2004) 75/2nd trimester
78/2nd trimester
0.89 ± 0.003 (from males)
1.01 ± 0.004 (from females)
Robinson/USA/ (Robinson et al. 1977) 48 male/14–20weeks
72 female/14–20weeks
64 ± 4 pg/ml (M) (235 pM)
96 ± 9 pg/ml (F) (352 pM)
Cord Levels
















Troisi/USA/ (Troisi et al. 2003) 86/Delivery 34.9 774






Troisi/USA/ (Troisi et al. 2003) 86/ (38–39 gestation wk) 35.0 0.81
Faupel-Badger/ (Faupel-Badger et al. 2009) 75/ (2nd tertile for pregnancy wt gain)32.1 708
Savarese/USA/ (Savarese et al. 2007) 289/Delivery 34.2 1,149 (unconjugated)
van de Beck/USA/ (van de Beek et al. 2004) 18 mothers with males













Adlercreutz/Japan/ (Adlercreutz et al. 1999; Adlercreutz and Luukkainen 1970) 7/Delivery 165 58.8
Todaka/Japan/ (Todaka et al. 2005) 51/Delivery 71.9 19.9
Nagata/Japan/ (Nagata, Oba, and Shimizu 2006) 194/Delivery 126.9 38.6
Dalais/Indonesia (Dalais, Meliala, and Wahlqvist 2000) 30/Delivery 91.7 ± 12.5 33.9 ± 5.62
Jarrell/Canada/ (Jarrell, Foster, and Kinniburgh 2012) 300/2nd trimester 9.93 9.01
Mustafa/Malaysia/ (Mustafa et al. 2007) 103 57.0 13.8
Amniotic Fluid (nmol/l)
Adlercreutz/Japan/ (Adlercreutz et al. 1999; Adlercreutz and Luukkainen 1970) 7/At delivery 64.0 67.8
Foster/USA/ (Foster et al. 2002) 53/15-23 wk gestation 6.3 5.7
Engel/USA/ (Engel et al. 2006) 21/<20 wks gestation 5.1 37.5
Jarrell/Canada/ (Jarrell, Foster, and Kinniburgh 2012) 300/2nd trimester 2.85 2.36
Conversions: Estrone pg/ml  3.699¼ pmol/l, estradiol pg/ml  3.67¼ pmol/l, estriol ng/ml  3.47¼ nmol/l (Robinson et al. 1977).
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isoflavones levels in the Japanese studies (Nagata, Oba, and
Shimizu 2006; Todaka et al. 2005) vs the Canadian study
(Jarrell, Foster, and Kinniburgh 2012) listed in Table 11.
On the other hand, Mustafa et al. (2007) commented that
“Analysis of cord plasma and corresponding maternal
plasma did not produce linear relationship” and that “no
correlation on the relevance of mothers’ diet to the phytoes-
trogens level in cord could be derived.” However, despite
these comments, in their study involving 300 Malaysian
women, total mean levels of soybean isoflavones plus cou-
mestrol in maternal and cord plasma were 18.3 ng/ml and
18.6 ng/ml, respectively.
Todaka et al. (2005) found a weak correlation between
maternal and cord serum (genistein, r2 ¼ 0.32; daidzein, r2
¼ 0.29; equol, r2 ¼ 0.22) among 51 Japanese mothers who
underwent a cesarean section. Adlercreutz et al. (1999)
reported that cord plasma genistein levels from seven
Japanese women were about twice as high as maternal
plasma genistein levels (165 vs 89 nmol/l) whereas daidzein
levels were more similar (59 vs 46 nmol/l). Food consump-
tion based on three-day dietary records from 97 women in
the area from which the pregnant women resided was
reported to include 77 g of bean products, mainly soybeans,
tofu, and miso. Dalais, Meliala, and Wahlqvist (2000)
reported very similar maternal and cord plasma levels
among Indonesian women (maternal plasma genistein and
daidzein, 83.1 ± 11.7 and 28.9 ± 6.49, respectively; cord
plasma genistein and daidzein, 91.7 ± 12.5 and
33.9 ± 5.62 nmol/L, respectively).
If one considers only the three studies involving Japanese
women (Nagata, Oba, and Shimizu 2006; Adlercreutz et al.
1999; Todaka et al. 2005), cord blood genistein and daidzein
levels ranged from approximately 72 to 165 nmol/l and from
approximately 20 to 39 nmol, respectively (Table 11). In the
only study involving Japanese women that measured amni-
otic fluid levels, genistein, daidzein and equol levels ranged
from 42 to 46 nmol/l (Adlercreutz et al. 1999). For the sake
of simplicity, if one adds genistein and daidzein levels
together (despite dissimilar potency) and takes an average of
the three studies, cord blood isoflavone levels are approxi-
mately 3–6 times higher than estradiol levels. However, this
comparison ignores the contribution of estriol and estrone.
Even estriol is considerably more estrogenic than isoflavones
(Dang et al. 2011).
If one arbitrarily doubles or triples isoflavone levels to
account for higher steady state levels (vs levels at delivery),
it would appear that the estrogenic influence of endogen-
ously produced estrogens will dwarf the influence of isofla-
vones, assuming the fetus responds to isoflavones in a
manner similar to adults. A direct comparison comes from
Adlercreutz et al. (1999), who found that mean total estro-
gens in maternal plasma, cord plasma and amniotic fluid
were 1093, 5579 and 3800 nmol/l, whereas mean total isofla-
vone levels in maternal plasma, cord plasma and amniotic
fluid were 232, 299 and 233 nmol/l, respectively.
Finally, there is need for information on in utero a-feto-
protein protein (AFP) in relation to isoflavones. AFP is
glycoprotein that is formed in the yolk sack and in the fetal
liver that plays an important role in the regulation of fetal
growth (Vakharia and Mizejewski 2000). Keel et al. (1992)
reported that human AFP does not bind estradiol; however,
Vakharia and Mizejewski (2000) showed that AFP peptides
have an anti-estrogenic effect. Garreau et al. (1991) found
that in vitro AFP binds isoflavones. The interaction between
AFP and estrogen and AFP and isoflavones could influence
the potential for each of these compounds to impact fetal
development.
Conclusions
Evidence indicates that maternal isoflavone intake results in
exposure of the fetus to isoflavones. However, in utero iso-
flavone concentrations are markedly lower than estrogen
concentrations. The difference in concentrations suggests,
although does not prove, that isoflavones are unlikely to
exert an estrogenic effect on the fetus.
Breastfeeding
In 1996, an editorial in Clinical Chemistry pondered whether
phytoestrogens (isoflavones) in human milk might be
another advantage of breast feeding (Slavin 1996). This
question has not been addressed clinically or via observa-
tional studies. Nevertheless, as discussed, there is evidence
upon which one can reasonably speculate as to whether
breast-fed infants are likely to be impacted by maternal iso-
flavone intake.
As background, normal concentrations of estrogens and
progesterone in breast milk exhibit a broad range of physio-
logical functions ranging from modulation of bone density,
promoting the conversion of linolenic acid to docosahexae-
noic acid, improvement of brain function, improvement of
the morphology and motility of cell types and the promo-
tion of cholesterol mobilization (Shang 2006; Shang 2007;
Burdge and Wootton 2002; Mulac-Jericevic et al. 2000; Pi~na-
Medina et al. 2016; Barros, Tufik, and Andersen 2015).
Conversely, high breast milk estrogen and progesterone con-
centrations may cause sexual precocity of children (Main
et al. 2007).
Cruz et al. (1994) were the first to demonstrate that
infants are capable of absorbing isoflavones, but in their
study the delivery vehicle was SIF, not human milk.
Although isoflavones are detectable in breastfed infants (Cao
et al. 2009), the bioavailability of isoflavones may differ
between SIF and human milk because isoflavones are found
as glucuronide conjugates in the latter (Franke and Custer
1996) whereas they are present mostly as glycosidic conju-
gates in the former (Coward et al. 1993).
More than 20 years ago, Huggett et al. (1997) suggested
isoflavones are biologically inactive in infants because their
analysis revealed that none of the plasma samples from four
infants fed SIF contained detectable “free” (unconjugated)
isoflavones, even after continuous feeding for more than
4weeks. However, in their pilot observational study, Adgent
et al. (2018) found that infants who consume SIF present
36 M. MESSINA ET AL.
with changes to tissue consistent with those seen with
exogenous estrogen.
Several studies have determined the isoflavone concentra-
tion of human milk in women after consuming soy as well
as in women from soyfood-consuming countries. In addition
to reviewing these studies, the isoflavone concentration in
human milk is compared to human milk estrogen concen-
trations and to the isoflavone content of SIF. Also compared
are the circulating isoflavone concentrations in infants con-
suming human milk from mothers consuming soyfoods
with isoflavone levels in infants consuming SIF.
Franke and Custer (1996) were the first to report on the
human milk isoflavone content following a soy intervention.
For this pilot study, milk was collected from a Caucasian
woman at 0, 24 and 72 h following the consumption of 5,
10, and 20 g of roasted soybeans containing approximately
10, 20 and 40mg isoflavones, respectively. Milk from a
Chinese woman consuming her usual diet was also collected
at these times. In the Caucasian woman, human milk isofla-
vone concentration increased in a dose response fashion.
Maximum milk concentrations were reached 10–14 h after
soy intake and returned to baseline values two to four days
later, depending upon the intake. The concentrations of gen-
istein and daidzein in milk (30–50 and 80–110 nmol/L,
respectively) from the Chinese woman consuming her usual
diet were similar to those observed in the milk of the
Caucasian women after challenge with roasted soybeans.
In contrast to the study by Franke and Custer (1996),
Zhou et al. (2020) found that after a Chinese woman con-
sumed 500ml soymilk, maximum isoflavone breastmilk con-
centrations were reached much earlier, after only six h. At
this time point, mean genistein and daidzein concentrations
were approximately 99 (270 nM) and 104 ug/kg (260 nM),
respectively. These concentrations are similar to those
reported by Min, Wang, and Liang (2020) for Chinese
women, as genistein and daidzein concentrations in breast-
milk were 144 nmol/l (38.92 ug/l) and 52 nmol/l (13.09 ug/l),
respectively. The urinary genistein and daidzein concentra-
tions of the breastfed infants were 96 nmol/l and 44 nmol/l,
respectively.
These values for Chinese women are similar to the
human milk isoflavone concentrations in healthy Korean
women (age 37 ± 4 y) as shown in Table 12. No information
about the isoflavone intake of these women or the number
of women sampled was reported, although the plasma values
indicate soy was consumed (Choi et al. 2002). As can be
seen, the isoflavone concentration of human milk is only
approximately twice the concentration of 17b-estradiol
whereas in plasma, isoflavone concentration is 10 to 40
times higher. In 32 Chinese women, Lu et al. (2017)
reported 17b-estradiol concentrations of 1.60 ± 0.96 lg/l,
0.83 ± 0.36 lg/l and 1.26 ± 0.48 lg/L in colostrum (day 1),
transitional milk (day 14) and mature human milk (day 42),
respectively. The concentrations of estriol were
2.09 ± 1.66 lg/L, 2.23 ± 1.74lg/L and 4.64 ± 2.15lg/L,
respectively.
Morton et al. (1998) reported that the genistein and daid-
zein concentration of breast milk from five women from
Hong Kong was 4.8 (17.8 nmol/l) and 3.6 ng/ml (14.2 nmol/
l), respectively, which is at the very low end of the range
reported for the Korean women. However, this report was
published in abstract form only and genistein and daidzein
were detected in only four and three of the milks, respect-
ively. In contrast to the concentrations in Asian women,
Jarrell, Foster, and Kinniburgh (2012) reported that breast
milk genistein (n¼ 84) and daidzein (n¼ 0.25) concentra-
tions from Canadian women were only 0.61 ng/ml
(2.3 nmol/l) and 0.25 ng/ml (0.98 nmol/l), respectively. The
difference between the Asian and non-Asian women sup-
ports the notion that habitual isoflavone intake impacts
breast milk isoflavone concentrations.
Franke et al. (2006) determined the breast milk isoflavone
concentrations in seven mothers who consumed one daily
serving (36.5 g) of a soy protein beverage for 2–4 d that con-
tained approximately 55mg isoflavones. Breast milk isofla-
vone concentrations increased from 5.1 ± 2.2 to
70.7 ± 19.2 nmol/L after the mothers consumed soy. The lat-
ter value is consistent with the previously cited studies
(Franke and Custer 1996; Choi et al. 2002). For this study,
after the soy beverage was consumed on the last day in the
early morning, sample collection was performed that after-
noon and was completed within 1–2 h. Mothers collected
their milk and urine as well as the infant’s urine.
This study by Franke et al. (2006) also provides data
about the impact of isoflavone exposure via human milk on
infant plasma isoflavone concentrations. The mean total iso-
flavone concentration in plasma obtained from 11 infants
that were breastfed by mothers consuming soy daily was
19.7 ± 13.2 nmol/L. In contrast, in three children aged
9–25months who ate 15–90 g tofu, mean plasma isoflavone
value was 1048.6 nmol/L (median: 663.1 nmol/L; range:
629.1–1853.6 nmol/L). Blood was collected for 2-4 h after the
infants consumed on average 44 g tofu (equivalent to 7.4mg
isoflavones). Franke et al. (2006) also found that urinary iso-
flavone excretion per hour adjusted for dose per bw was
81% lower for breastfed infants and 24% higher for tofu-fed
infants than for their mothers after eating soy.
Jochum et al. (2017) determined breast milk isoflavone
concentrations in 18 German women who were advised to
consume one daily serving (250mL) of a soy drink. The soy
drink increased the average daily isoflavone (daidzein plus
genistein) intake from 0.2mg to 12.7mg. Milk samples
Table 12. Estrogen and isoflavone concentrations in breast milk and plasma of Korean women (Choi et al. 2002).
Concentration (ug/l)/nmol/l
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(>10mL) were taken before intervention (day 1), during
intervention (days 4 and 7), and after intervention (day 8)
five min after the start of a given breastfeeding interval in
the evening (about 10 h after study drink ingestion) using a
breast pump. As can be seen from Table 13, isoflavones
were not detected in breast milk prior to the intervention
and increased to a peak of 4.3 nmol/l and 9.1 nmol/l for gen-
istein and daidzein, respectively, on study day seven. These
levels are much lower than the levels reported in the study
by Franke et al. (2006) of 70.7 ± 19.2 nmol/L, but in the lat-
ter, women consumed 55mg/d isoflavones versus only
12.7mg/d in the former.
Jochum et al. (2017) estimated that the isoflavone (genis-
tein and daidzein) intake of an infant breast fed by the
mothers consuming 250ml soy drink (12.5 isoflavones)
would be 11 nmol (2.8 ug), assuming a daily average breast
milk volume of 800mL for a 4-month old infant. In con-
trast, they noted that infants consuming SIF containing an
isoflavone concentration of 32–47mg/L (0.12–0.18mmol/L)
(Setchell et al. 1997) would result in about 1,000-fold higher
intake (4.5–8.0mg/kg bw/d) compared with breastmilk feed-
ing. These values for infant intake are similar to those
reported by Irvine, Fitzpatrick, and Alexander (1998), who
estimated that the daily dose of isoflavones (genistein plus
daidzein) was 3.2 ± 0.2mg/kg body weight in infants on SIF.
Finally, Setchell et al. (1997) found that the mean ± SD
plasma concentrations of genistein and daidzein in seven
infants fed SIF were 684 ± 443 ng/mL (2.53 ± 1.64mmol/l)
and 295 ± 60 ng/mL (1.16 ± 0.23mmol/l), respectively. These
plasma values are roughly 200 times greater than the values
reported Frank and Custer (Franke et al. 2006) in 11 infants
who were breastfed by mothers consuming soy. Accordingly,
Setchell et al. (1997) concluded that there is “… little rea-
son for concern about phyto-estrogens from human breast-
milk, even when mothers consume soy during lactation.”
Conclusions
Maternal soy consumption increases breastmilk isoflavone
concentrations in a dose-response fashion. However, the
relatively low concentration, especially in comparison to SIF,
suggests breastfed infants are unlikely to be affected by
maternal soy consumption.
Kawasaki disease
Kawasaki disease (KD) is an acute, self-limited vasculitis
that affects small- and medium-sized vessels that can lead to
severe cardiac complications (Burns et al. 2000) that is
responsible for more cases of acquired heart disease among
children than any other condition (Newburger et al. 2004).
KD most commonly affects children between ages six
months and five years (peak incidence occurs between the
ages of 6 and 11months) (Nakamura et al. 2012). There are
approximately 6000 new cases of KD each year in the US
(Huang et al. 2013). The occurrence incidence of KD in the
US is estimated to be between 17.5 and 20.8 per 100,000
children <5 y (Lin and Wu 2017).
Asian ethnicity appears to be an important risk factor for
KD (Nakamura et al. 2012) and genetic studies have indi-
cated a major role for Fcc receptors (FcGRs) in KD patho-
genesis (Shrestha et al. 2012; Shrestha et al. 2011). These
receptors bind to antibodies that are attached to infected
cells or invading pathogens. Based on the knowledge that
in vitro, genistein inhibits FcGR function (Huang et al.
2006), the prevalence of KD in Japan and Asia is elevated
relative to Western countries (Holman et al. 2010) and soy
is a commonly consumed food among Japanese, Portman
(2013) hypothesized that soy consumption increases KD
risk. A possible association with maternal soy consumption
was first tentatively identified in a pilot observational study
published more than 20 years ago (Ross 1998).
To examine this hypothesis, Portman et al. (2016) eval-
uated soyfood intake and isoflavone consumption in nearly
200US KD cases (age, 4.0 ± 3.7) and 200 age-matched con-
trols (age, 5.2 ± 4.2) using a food frequency questionnaire for
children and their mothers. The assessed intake period was
three months prior to diagnosis. Maternal soy intake during
pregnancy and nursing showed no significant differences in
isoflavone consumption between groups. In contrast, isofla-
vone intake among children was associated with a two-fold
increased risk of KD (OR, 2.33; 95% CI: 1.37, 3.96) when
comparing high-soy consumers vs nonconsumers.
When the data were sub-analyzed, the increased risk
associated with isoflavone intake was primarily found in
Asian children. Risk among Asian-American children with
the highest intake was increased nearly seven-fold (OR, 7.29;
95% CI: 1.73, 30.75) whereas among white children risk was
not significantly increased (OR, 1.61; 95% CI: 0.86, 3.01).
While these findings are certainly intriguing and warrant
additional research, it is important to recognize that this
study included only 51 Asian children. In addition, the low
mean isoflavone intake (27.6mg/week) even among the cases
raises doubt about the biological plausibility of the findings.
In fact, risk was increased nearly threefold (OR, 4.09; 95%
CI: 0.46, 36.18), although non-significantly so, even among
those whose isoflavone intake was <16.6mg/week.
Furthermore, although Huang et al. (2006) found that
FccRIIA-mediated phagocytosis is more sensitive to a reduc-
tion in tyrosine phosphorylation in response to genistein
than is endocytosis, the genistein concentration showing
even minor inhibitory effects (18.5 mmol/l) is far greater
than can be reached in children in response to the con-
sumption of soyfoods. Portman et al. (Portman 2013) also
Table 13. Isoflavone concentrations (nmol/L, mean ± SD) in human breast milk samples before (day 1), during (days 3 and 6), and after (day 7) intervention with
soy drink (Jochum et al. 2017).
Study day 1 Study day 4 Study day 7 Study day 8
Daidzein Not detected 9.3 ± 4.2 9.1 ± 4.8 7.3 ± 3.3
Genistein Not detected 4.9 ± 7.2 4.3 ± 2.7 3.5 ± 2.3
Detection limit: daidzein: 6.25 nmol/L; genistein: 2.5 nmol/L.
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cited as evidence in support of a role for genistein a marked
reduction in thymic mass in mice in vivo with plasma genis-
tein levels that approximate those obtained in humans by
dietary ingestion (Cimafranca et al. 2010). However, in this
study (Cimafranca et al. 2010), genistein was administered
neonatally (postnatal days 1–5). Also, although serum genis-
tein levels were in the low micromolar range, which can be
achieved in humans, the aglycone fraction in the serum of
mice ranged from 20% to 40% of the total serum genistein
concentration, whereas in humans, the aglycone fraction
represents <2% of the total concentration (Setchell
et al. 2011).
Finally, in Japan, KD prevalence rates (incidence/100,000
children age 0–4) have increased dramatically over the past
30 years, a time during which soy consumption has not
increased and may have declined somewhat (Makino et al.
2015). Some evidence suggests that the causative agent of
KD is a preformed windborne toxin or environmental agent
rather than an organism requiring replication (Rodo et al.
2014; Ballester et al. 2019). Nagata recently concluded that
among the numerous proposed etiologies, the most credible
theory is that bacterial infection triggers KD, but the possi-
bility of fungi and new types of viruses also playing a role
was not excluded (Nagata 2019).
Conclusions
The notion that soy intake increases risk of KD has been
investigated to only a limited extent and thus this hypothesis
remains speculative. No conclusions about this hypothesis
can be drawn at this time.
Summary and conclusions
Isoflavones and soyfoods have been rigorously investigated
over the past 30 years. Early on, there was considerable
excitement about the possible role of isoflavones in prevent-
ing and treating a variety of chronic diseases (Messina
1995). Some of that enthusiasm faded as subsequently pub-
lished research produced equivocal findings (Balk et al.
2005). Nevertheless, research into the benefits of soy and
isoflavones – with results often supportive of efficacy – con-
tinue to be published at an impressive rate (Man et al. 2021;
Sansai et al. 2020; Cui et al. 2020; Li et al. 2020). However,
concerns about the safety of isoflavones have led to these
soybean constituents, and as a result, to soyfoods, becoming
controversial. These concerns, are, for the most part, based
on rodent studies.
The conclusion of the current technical review, which
consists of a comprehensive evaluation of the clinical and
observational literature, is that there is little evidence to sug-
gest that isoflavones, when consumed at levels not exceeding
Asian intake (100mg/d), exert untoward effects in adults.
This evidence includes a lack of significant effect of isofla-
vones on reproductive hormone levels in men and women,
a possible modest effect on menstrual cycle length, and a
lack of effect on thyroid function and on markers of breast
cancer risk.
Furthermore, evidence does not support the notion that
isoflavone exposure is contraindicated for breast cancer sur-
vivors; in fact, the observational data suggest the opposite
may be the case. There is also evidence that soy may reduce
the risk of developing endometrial cancer. However, because
data related to the development of uterine fibroids are
inconsistent, and limited, more research in this area is war-
ranted. Overall, based on research in adults, the evidence
does not warrant classifying isoflavones (or soyfoods) as
endocrine disruptors.
Note that the upper intake figure of 100mg/d isoflavones
is not meant to imply that when intake exceeds this level,
there is evidence of harm. In fact, adverse effects have not
been reported in long-term trials in which study participants
consumed >100mg/d isoflavones. Rather, this figure is sug-
gested because there is no historical precedent for habitual
consumption higher than this amount. Besides, consuming
>100mg/d isoflavones from traditional soyfoods, requires
the consumption of >4 servings/d. Consuming >4 servings/
d of any food is inconsistent with the dietetic principles of
moderation and variety.
Not unexpectedly, much less research on the effects of
soy and isoflavone intake in children has been conducted.
Because when expressed on a bw basis, there is the potential
for isoflavone exposure to be higher in children than adults,
and isoflavone absorption may be greater in children, more
research involving children is certainly warranted. This
research should not be limited to safety concerns but should
also explore potential benefits. Regarding the latter, there is
substantial observational evidence that soy intake early in
life reduces later risk of developing breast cancer. More
research aimed at evaluating this hypothesis is needed.
The existing data, although limited, are generally support-
ive of safety of isoflavone intake in children. No clinically
relevant hormonal effects have been observed in young peo-
ple consuming soyfoods or isoflavones. Regarding puberty
onset, the data are mixed. The largest study to examine this
issue, which involved SDAs, found no relationship between
soyfood intake and AOM, although in boys, in one study,
there was a modest effect on the age of onset of pubic hair
(primary endpoint), but not on facial hair (secondary end-
point). The clinical implications, if any, of this effect, even if
confirmed by future research, are unclear. Especially because
puberty onset among the high-soy-consuming SDA boys
was later than average for non-SDA US boys.
To address this issue more definitively requires data from
large prospective studies, which would need to involve either
Western vegetarians or Asians, to assure soy intake is suffi-
ciently high. It is difficult to make intake recommendations,
but in keeping with the previously mentioned dietetic princi-
ples, a reasonable upper isoflavone limit for younger people, is
50mg/d. Again, this upper limit is not to suggest that when
intake exceeds 50mg/d, evidence of harm has been observed.
Finally, no clinical studies have evaluated the effects of
isoflavone intake on the developing fetus or of infants
exposed to isoflavones as a result of maternal soy consump-
tion, but given the low concentration of isoflavones in breast
milk and the high in utero estrogen concentrations, adverse
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effects would not be expected. These exposures periods are
difficult to study prospectively because of the long follow up
period and large sample size that would be required.
Certainly though, the historical precedence of Asian women
consuming soy during pregnancy and lactation provide a
considerable measure of comfort.
In closing, the conclusion of this review of the observa-
tional and clinical studies covering a broad range of health
outcomes likely to be affected by endocrine active substances
is that neither soyfoods nor isoflavones warrant classification
as endocrine disruptors. Future research exploring the bio-
logical effects of soy its constituent isoflavones should
be encouraged.
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Ferreira, and D. P. de Carvalho. 2011. Impact of flavonoids on thy-
roid function. Food and Chemical Toxicology: An International
Journal Published for the British Industrial Biological Research
Association 49 (10):2495–502. doi: 10.1016/j.fct.2011.06.074.
Decroos, K., S. Vanhemmens, S. Cattoir, N. Boon, and W. Verstraete.
2005. Isolation and characterisation of an equol-producing mixed
microbial culture from a human faecal sample and its activity under
gastrointestinal conditions. Archives of Microbiology 183 (1):45–55.
doi: 10.1007/s00203-004-0747-4.
Delmanto, A., J. Nahas-Neto, P. Traiman, G. Uemura, E. C. Pessoa,
and E. A. P. Nahas. 2013. Effects of soy isoflavones on mammo-
graphic density and breast parenchyma in postmenopausal women:
A randomized, double-blind, placebo-controlled clinical trial.
Menopause (New York, N.Y.) 20 (10):1049–54. doi: 10.1097/GME.
0b013e3182850270.
Department of Health and Human Services. 2017. Food Labeling:
Health Claims; Soy Protein and Coronary Heart Disease. Federal
Register 82:50324–46.
Dieckmann, W. J., M. E. Davis, L. M. Rynkiewicz, and R. E. Pottinger.
1953. Does the administration of diethylstilbestrol during pregnancy
have therapeutic value? American Journal of Obstetrics and
Gynecology 66 (5):1062–81. doi: 10.1016/S0002-9378(16)38617-3.
Direito, A., S. Bailly, A. Mariani, and R. Ecochard. 2013. Relationships
between the luteinizing hormone surge and other characteristics of
the menstrual cycle in normally ovulating women. Fertility and
Sterility 99 (1):279–85. doi: 10.1016/j.fertnstert.2012.08.047.
DiVasta, A. D., A. F. Vitonis, M. R. Laufer, and S. A. Missmer. 2018.
Spectrum of symptoms in women diagnosed with endometriosis
during adolescence vs adulthood. American Journal of Obstetrics and
Gynecology 218:324 e1–e11. doi: 10.1016/j.ajog.2017.12.007.
Divi, R. L., and D. R. Doerge. 1996. Inhibition of thyroid peroxidase by
dietary flavonoids. Chemical Research in Toxicology 9 (1):16–23. doi:
10.1021/tx950076m.
Divi, R. L., H. C. Chang, and D. R. Doerge. 1997. Anti-thyroid isofla-
vones from soybean: Isolation, characterization, and mechanisms of
action. Biochemical Pharmacology 54 (10):1087–96. doi: 10.1016/
s0006-2952(97)00301-8.
Dixon, R. A., and L. W. Sumner. 2003. Legume natural products:
Understanding and manipulating complex pathways for human and
animal health. Plant Physiology 131 (3):878–85. doi: 10.1104/pp.102.
017319.
Doerge, D., and H. Chang. 2002. Inactivation of thyroid peroxidase by
soy isoflavones, in vitro and in vivo. Journal of Chromatography B
777 (1-2):269–79. doi: 10.1016/S1570-0232(02)00214-3.
Dong, J.-Y., T. Kimura, S. Ikehara, M. Cui, Y. Kawanishi, T. Kimura,
K. Ueda, and H. Iso. 2021. Soy consumption and incidence of gesta-
tional diabetes mellitus: The Japan Environment and Children’s
Study. European Journal of Nutrition 60 (2):897–904. doi: 10.1007/
s00394-020-02294-1.
Dorjgochoo, T., K. Gu, Y. Zheng, A. Kallianpur, Z. Chen, W. Zheng,
W. Lu, and X. O. Shu. 2011. Soy intake in association with meno-
pausal symptoms during the first 6 and 36 months after breast can-
cer diagnosis. Breast Cancer Research and Treatment 130 (3):879–89.
doi: 10.1007/s10549-010-1096-4.
Du, M., X. Yang, J. A. Hartman, P. S. Cooke, D. R. Doerge, Y. H. Ju,
and W. G. Helferich. 2012. Low-dose dietary genistein negates the
therapeutic effect of tamoxifen in athymic nude mice. Carcinogenesis
33 (4):895–901. doi: 10.1093/carcin/bgs017.
Eating Well After Breast Cancer. Accessed February 08, 2021. https://
www.cancer.ca/en/cancer-information/cancer-type/breast/supportive-
care/eating-well-after-breast-cancer/?region=on.)
EFSA ANS Panel (EFSA Panel on Food Additives and Nutrient
Sources added to Food). 2015. Scientific opinion on the risk assess-
ment for peri- and post-menopausal women taking food supple-
ments containing isolated isoflavones. EFSA Journal 13 (4246):342.
Eldridge, A. C., and W. F. Kwolek. 1983. Soybean isoflavones: Effect of
environment and variety on composition. Journal of Agricultural
and Food Chemistry 31 (2):394–6. doi: 10.1021/jf00116a052.
Elhakeem, A., M. Frysz, K. Tilling, J. H. Tobias, and D. A. Lawlor.
2019. Association between age at puberty and bone accrual from 10
to 25 years of age. JAMA Network Open 2 (8):e198918. doi: 10.1001/
jamanetworkopen.2019.8918.
Engel, S. M., B. Levy, Z. Liu, D. Kaplan, and M. S. Wolff. 2006.
Xenobiotic phenols in early pregnancy amniotic fluid. Reproductive
Toxicology 21 (1):110–2. doi: 10.1016/j.reprotox.2005.07.007.
Esaki, H., S. Kawakishi, Y. Morimitsu, and T. Osawa. 1999. New potent
antioxidative o-dihydroxyisoflavones in fermented Japanese soybean
products. Bioscience, Biotechnology, and Biochemistry 63 (9):1637–9.
doi: 10.1271/bbb.63.1637.
Eskenazi, B., and M. L. Warner. 1997. Epidemiology of endometriosis.
Obstetrics and Gynecology Clinics of North America 24 (2):235–58.
doi: 10.1016/S0889-8545(05)70302-8.
Euling, S. Y., M. E. Herman-Giddens, P. A. Lee, S. G. Selevan, A. Juul,
T. I. A. Sørensen, L. Dunkel, J. H. Himes, G. Teilmann, and S. H.
Swan. 2008. Examination of US puberty-timing data from 1940 to
1994 for secular trends: Panel findings. Pediatrics 121 Suppl 3
(Suppl 3):S172–S91. doi: 10.1542/peds.2007-1813D.
European Food Safety Authority. 2010. Scientific report of the endo-
crine active substances task force. EFSA Journal 8:1–59. https://efsa.
onlinelibrary.wiley.com/doi/pdf/10.2903/j.efsa.2010.1932.
Evans, M., J. G. Elliott, P. Sharma, R. Berman, and N. Guthrie. 2011.
The effect of synthetic genistein on menopause symptom
44 M. MESSINA ET AL.
management in healthy postmenopausal women: A multi-center,
randomized, placebo-controlled study. Maturitas 68 (2):189–96. doi:
10.1016/j.maturitas.2010.11.012.
Fang, N., S. Yu, and T. M. Badger. 2004. Comprehensive phytochem-
ical profile of soy protein isolate. Journal of Agricultural and Food
Chemistry 52 (12):4012–20. doi: 10.1021/jf049842y.
Fanti, P., B. P. Sawaya, L. J. Custer, et al. 1999. Serum levels and meta-
bolic clearance of the isoflavones genistein and daidzein in hemodi-
alysis patients. J Am Soc Nephrol 10:864–71. https://pubmed.ncbi.
nlm.nih.gov/10203372/.
Faupel-Badger, J. M., R. N. Hoover, N. Potischman, J. M. Roberts, and
R. Troisi. 2009. Pregnancy weight gain is not associated with mater-
nal or mixed umbilical cord estrogen and androgen concentrations.
Cancer Causes & Control : CCC 20 (2):263–7. doi: 10.1007/s10552-
008-9235-5.
Felix, A. S., J. L. Weissfeld, R. M. Pfeiffer, F. Modugno, A. Black, L. M.
Hill, J. Martin, A. S. Sit, M. E. Sherman, and L. A. Brinton. 2014.
Endometrial thickness and risk of breast and endometrial carcino-
mas in the prostate, lung, colorectal and ovarian cancer screening
trial. International Journal of Cancer 134 (4):954–60. doi: 10.1002/
ijc.28404.
Fernandez-Lopez, A., V. Lamothe, M. Delample, M. Denayrolles, and
C. Bennetau-Pelissero. 2016. Removing isoflavones from modern
soyfood: Why and how? Food Chemistry 210:286–94. doi: 10.1016/j.
foodchem.2016.04.126.
Ferraris, C., B. Ballestra, C. Listorti, V. Cappelletti, C. Reduzzi, G. P.
Scaperrotta, I. Pulice, E. G. A. Ferrari, S. Folli, L. Mariani, et al.
2020. Red clover and lifestyle changes to contrast menopausal symp-
toms in premenopausal patients with hormone-sensitive breast can-
cer receiving tamoxifen. Breast Cancer Research and Treatment 180
(1):157–65. doi: 10.1007/s10549-020-05534-4.
Fleshner, N. E., L. Kapusta, B. Donnelly, S. Tanguay, J. Chin, K.
Hersey, A. Farley, K. Jansz, D. R. Siemens, K. Trpkov, et al. 2011.
Progression from high-grade prostatic intraepithelial neoplasia to
cancer: A randomized trial of combination vitamin-E, soy, and sel-
enium. Journal of Clinical Oncology: Official Journal of the American
Society of Clinical Oncology 29 (17):2386–90. doi: 10.1200/JCO.2010.
32.0994.
Folman, Y., and G. S. Pope. 1966. The interaction in the immature
mouse of potent oestrogens with coumestrol, genistein and other
utero-vaginotrophic compounds of low potency. The Journal of
Endocrinology 34 (2):215–25. doi: 10.1677/joe.0.0340215.
Folman, Y., and G. S. Pope. 1969. Effect of norethisterone acetate,
dimethylstilboestrol, genistein and coumestrol on uptake of
[3H]oestradiol by uterus, vagina and skeletal muscle of immature
mice. The Journal of Endocrinology 44 (2):213–8. doi: 10.1677/joe.0.
0440213.
Food Labeling: Health Claims; Soy Protein and Coronary Heart
Disease. 1999. Food and Drug Administration, HHS. Final rule.
Federal Register 64:57700–33. https://pubmed.ncbi.nlm.nih.gov/
11010706/.
Forest, M. G., E. DE Peretti, A. Lecoq, E. Cadillon, M.-T. Zabot, and
J.-M. Thoulon. 1980. Concentration of 14 steroid hormones in
human amniotic fluid of midpregnancy. Journal of Clinical
Endocrinology and Metabolism 51 (4):816–22. doi: 10.1210/jcem-51-
4-816.
Fortes, E. M., M. I. Malerba, P. D. Luchini, E. K. Sugawara, L.
Sumodjo, L. M. Ribeiro Neto, and I. T. N. Verreschi. 2007. [High
intake of phytoestrogens and precocious thelarche: Case report with
a possible correlation.]. Arquivos Brasileiros de Endocrinologia e
Metabologia 51 (3):500–3. doi: 10.1590/s0004-27302007000300021.
Foster, W. G., S. Chan, L. Platt, and C. L. Hughes. 2002. Detection of
phytoestrogens in samples of second trimester human amniotic
fluid. Toxicology Letters 129 (3):199–205. doi: 10.1016/s0378-
4274(02)00018-8.
Foth, D., and F. Nawroth. 2005. Effect of phytoestrogens on the endo-
metrium? Fertility and Sterility 83 (1):256–7. doi: 10.1016/j.fertn-
stert.2004.10.021.
Franke, A. A., and L. J. Custer. 1996. Daidzein and genistein concen-
trations in human milk after soy consumption. Clinical Chemistry
42 (6 Pt 1):955–64. doi: 10.1093/clinchem/42.6.955.
Franke, A. A., B. M. Halm, L. J. Custer, Y. Tatsumura, and S. Hebshi.
2006. Isoflavones in breastfed infants after mothers consume soy.
The American Journal of Clinical Nutrition 84 (2):406–13. doi: 10.
1093/ajcn/84.1.406.
Franke, A. A., J. F. Lai, and B. M. Halm. 2014. Absorption, distribu-
tion, metabolism, and excretion of isoflavonoids after soy intake.
Archives of Biochemistry and Biophysics 559:24–8. doi: 10.1016/j.abb.
2014.06.007.
Franke, A. A., L. J. Custer, and S. A. Hundahl. 2004. Determinants for
urinary and plasma isoflavones in humans after soy intake.
Nutrition and Cancer 50 (2):141–54. doi: 10.1207/s15327914nc5002_
3.
Franke, A. A., L. J. Custer, W. Wang, and C. Y. Shi. 1998. HPLC ana-
lysis of isoflavonoids and other phenolic agents from foods and
from human fluids. Proceedings of the Society for Experimental
Biology and Medicine. Society for Experimental Biology and Medicine
(New York, N.Y.) 217 (3):263–73. doi: 10.3181/00379727-217-44231.
Franke, A. A., M. C. Yu, G. Maskarinec, P. Fanti, W. Zheng, and L. J.
Custer. 1999. Phytoestrogens in human biomatrices including breast
milk. Biochemical Society Transactions 27 (2):308–18. doi: 10.1042/
bst0270308.
Franke, A. A., S. M. Hebshi, I. Pagano, N. Kono, W. J. Mack, and
H. N. Hodis. 2010. Urine accurately reflects circulating isoflavonoids
and ascertains compliance during soy intervention. Cancer
Epidemiology Biomarkers & Prevention 19 (7):1775–83. doi: 10.1158/
1055-9965.EPI-10-0116.
Franke, A. A., Y. Morimoto, L. M. Yeh, and G. Maskarinec. 2006.
Urinary isoflavonoids as a dietary compliance measure among pre-
menopausal women. Asia Pacific Journal of Clinical Nutrition 15 (1):
88–94. https://pubmed.ncbi.nlm.nih.gov/16500883/.
Fruzza, A. G., C. Demeterco-Berggren, and K. L. Jones. 2012.
Unawareness of the effects of soy intake on the management of con-
genital hypothyroidism. Pediatrics 130 (3):e699-702–e702. doi: 10.
1542/peds.2011-3350.
Fujimoto, K., M. Tanaka, Y. Hirao, Y. Nagata, M. Mori, N. Miyanaga,
H. Akaza, and W.-J. Kim. 2008. Age-stratified serum levels of isofla-
vones and proportion of equol producers in Japanese and Korean
healthy men. Prostate Cancer and Prostatic Diseases 11 (3):252–7.
doi: 10.1038/sj.pcan.4501030.
Fukutake, M., M. Takahashi, K. Ishida, H. Kawamura, T. Sugimura,
and K. Wakabayashi. 1996. Quantification of genistein and genistin
in soybeans and soybean products. Food and Chemical Toxicology:
An International Journal Published for the British Industrial
Biological Research Association 34 (5):457–61. doi: 10.1016/0278-
6915(96)87355-8.
Gaitan, E. 1990. Goitrogens in food and water. Annual Review of
Nutrition 10:21–39. doi: 10.1146/annurev.nu.10.070190.000321.
Gao, M., and H. Wang. 2018. Frequent milk and soybean consumption
are high risks for uterine leiomyoma: A prospective cohort study.
Medicine 97 (41):e12009. doi: 10.1097/MD.0000000000012009.
Garber, J. R., R. H. Cobin, H. Gharib, J. V. Hennessey, I. Klein, J. I.
Mechanick, R. Pessah-Pollack, P. A. Singer, and K. A. Woeber.
2012. Clinical practice guidelines for hypothyroidism in adults:
Cosponsored by the American Association of Clinical
Endocrinologists and the American Thyroid Association. Thyroid:
Official Journal of the American Thyroid Association 22 (12):
1200–35. doi: 10.4158/EP12280.GL.
Gardner, C. D., B. Oelrich, J. P. Liu, D. Feldman, A. A. Franke, and
J. D. Brooks. 2009. Prostatic soy isoflavone concentrations exceed
serum levels after dietary supplementation. The Prostate 69 (7):
719–26. doi: 10.1002/pros.20922.
Gardner-Thorpe, D., C. O’Hagen, I. Young, and S. J. Lewis. 2003.
Dietary supplements of soya flour lower serum testosterone concen-
trations and improve markers of oxidative stress in men. European
Journal of Clinical Nutrition 57 (1):100–6. doi: 10.1038/sj.ejcn.
1601495.
CRITICAL REVIEWS IN FOOD SCIENCE AND NUTRITION 45
Garreau, B., G. Vallette, H. Adlercreutz, K. W€ah€al€a, T. M€akel€a, C.
Benassayag, and E. A. Nunez. 1991. Phytoestrogens: New ligands for
rat and human alpha-fetoprotein. Biochimica et Biophysica Acta
1094 (3):339–45. doi: 10.1016/0167-4889(91)90095-f.
Ghosh, S., R. Shukla, V. S. Mujalde, V. Chaturvedi, and D. K. Barolia.
2016. Maternal vegetarian diet in pregnancy, a predisposition to
hypospadias? International Journal of Research in Medical Sciences 5
(1):344–5. doi: 10.18203/2320-6012.ijrms20164575.
Ginsburg, J. 1996. Tackling environmental endocrine disrupters. Lancet
(London, England) 347 (9014):1501–2. doi: 10.1016/s0140-
6736(96)90667-4.
Giordano, F., A. Abballe, E. De Felip, A. di Domenico, F. Ferro, P.
Grammatico, A. M. Ingelido, V. Marra, G. Marrocco, S. Vallasciani,
et al. 2010. Maternal exposures to endocrine disrupting chemicals
and hypospadias in offspring. Birth Defects Research. Part A, Clinical
and Molecular Teratology 88 (4):241–50. doi: 10.1002/bdra.20657.
Glover, A., and S. J. Assinder. 2006. Acute exposure of adult male rats
to dietary phytoestrogens reduces fecundity and alters epididymal
steroid hormone receptor expression. The Journal of Endocrinology
189 (3):565–73. doi: 10.1677/joe.1.06709.
Gomes-Lima, C., and K. D. Burman. 2018. Reverse T3 or perverse T3?
Still puzzling after 40 years. Cleveland Clinic Journal of Medicine 85
(6):450–5. doi: 10.3949/ccjm.85a.17079.
Goodin, S., F. Shen, W. J. Shih, N. Dave, M. P. Kane, P. Medina, G. H.
Lambert, J. Aisner, M. Gallo, and R. S. DiPaola. 2007. Clinical and
biological activity of soy protein powder supplementation in healthy
male volunteers. Cancer Epidemiology, Biomarkers & Prevention: a
Publication of the American Association for Cancer Research,
Cosponsored by the American Society of Preventive Oncology 16 (4):
829–33. doi: 10.1158/1055-9965.EPI-06-0882.
Gore, A. C., V. A. Chappell, S. E. Fenton, J. A. Flaws, A. Nadal, G. S.
Prins, J. Toppari, and R. T. Zoeller. 2015. EDC-2: The endocrine
society’s second scientific statement on endocrine-disrupting chemi-
cals. Endocrine Reviews 36 (6):E1–E150. doi: 10.1210/er.2015-1010.
Govind, A. P., and R. V. Thampan. 2003. Membrane associated estro-
gen receptors and related proteins: Localization at the plasma mem-
brane and the endoplasmic reticulum. Molecular and Cellular
Biochemistry 253 (1-2):233–40. doi: 10.1023/a:1026068017309.
Graber, J. A. 2013. Pubertal timing and the development of psycho-
pathology in adolescence and beyond. Hormones and Behavior 64
(2):262–9. doi: 10.1016/j.yhbeh.2013.04.003.
Grace, P. B., J. I. Taylor, Y. L. Low, et al. 2004. Phytoestrogen concen-
trations in serum and spot urine as biomarkers for dietary phyto-
estrogen intake and their relation to breast cancer risk in European
prospective investigation of cancer and nutrition-norfolk. Cancer
Epidemiology, Biomarkers & Prevention 13:698–708. https://
pubmed.ncbi.nlm.nih.gov/15159299/.
Grady, D., T. Gebretsadik, K. Kerlikowske, V. Ernster, and D. Petitti.
1995. Hormone replacement therapy and endometrial cancer risk: A
meta-analysis. Obstetrics and Gynecology 85 (2):304–13. doi: 10.
1016/0029-7844(94)00383-O.
Gramec Skledar, D., V. Tvrdy, M. Kenda, A. Zega, M. Pour, P. Horky,
P. Mladenka, M. Sollner Dolenc, and L. Peterlin Masic. 2020.
Applicability of the OECD 455 in-vitro assay for determination of
hERa agonistic activity of isoflavonoids. Toxicology and Applied
Pharmacology 386:114831. doi: 10.1016/j.taap.2019.114831.
Gu, D., J. He, X. Duan, et al. 2006. Body weight and mortality among
men and women in China. JAMA 295 (7):776–83. doi: 10.1001/
jama.295.7.776.
Gu, L., S. E. House, R. L. Prior, N. Fang, M. J. J. Ronis, T. B. Clarkson,
M. E. Wilson, and T. M. Badger. 2006. Metabolic phenotype of iso-
flavones differ among female rats, pigs, monkeys, and women. The
Journal of Nutrition 136 (5):1215–21. doi: 10.1093/jn/136.5.1215.
Guha, N., M. L. Kwan, C. P. Quesenberry, E. K. Weltzien, A. L.
Castillo, and B. J. Caan. 2009. Soy isoflavones and risk of cancer
recurrence in a cohort of breast cancer survivors: The life after can-
cer epidemiology study. Breast Cancer Research and Treatment 118
(2):395–405. doi: 10.1007/s10549-009-0321-5.
G€unther, A. L. B., N. Karaolis-Danckert, A. Kroke, T. Remer, and A. E.
Buyken. 2010. Dietary protein intake throughout childhood is
associated with the timing of puberty. The Journal of Nutrition 140
(3):565–71. doi: 10.3945/jn.109.114934.
Halm, B. M., L. A. Ashburn, and A. A. Franke. 2007. Isoflavones from
soya foods are more bioavailable in children than adults. British
Journal of Nutrition 98 (5):998–1005. doi: 10.1017/
S0007114507771866.
Halme, J., M. G. Hammond, J. F. Hulka, S. G. Raj, and L. M. Talbert.
1984. Retrograde menstruation in healthy women and in patients
with endometriosis. Obstetrics and Gynecology 64 (2):151–4. https://
pubmed.ncbi.nlm.nih.gov/6234483/.
Hamilton-Reeves, J. M., G. Vazquez, S. J. Duval, W. R. Phipps, M. S.
Kurzer, and M. J. Messina. 2010. Clinical studies show no effects of
soy protein or isoflavones on reproductive hormones in men:
Results of a meta-analysis. Fertility and Sterility 94 (3):997–1007.
doi: 10.1016/j.fertnstert.2009.04.038.
Hanahan, D., and R. A. Weinberg. 2011. Hallmarks of cancer: The
next generation. Cell 144 (5):646–74. doi: 10.1016/j.cell.2011.02.013.
Hara, A., S. Sasazuki, M. Inoue, M. Iwasaki, T. Shimazu, N. Sawada, T.
Yamaji, and S. Tsugane. 2012. Isoflavone intake and risk of gastric
cancer: A population-based prospective cohort study in Japan. The
American Journal of Clinical Nutrition 95 (1):147–54. doi: 10.3945/
ajcn.111.020479.
Hara, A., S. Sasazuki, M. Inoue, T. Miura, M. Iwasaki, N. Sawada, T.
Shimazu, T. Yamaji, and S. Tsugane. 2013. Plasma isoflavone con-
centrations are not associated with gastric cancer risk among
Japanese men and women. The Journal of Nutrition 143 (8):1293–8.
doi: 10.3945/jn.113.175505.
Harding, G., K. S. Coyne, C. L. Thompson, and J. B. Spies. 2008. The
responsiveness of the uterine fibroid symptom and health-related
quality of life questionnaire (UFS-QOL). Health and Quality of Life
Outcomes 6 (1):99. doi: 10.1186/1477-7525-6-99.
Hargreaves, D. F., C. S. Potten, C. Harding, et al. 1999. Two-week diet-
ary soy supplementation has an estrogenic effect on normal preme-
nopausal breast. Journal of Clinical Endocrinology and Metabolism
84 (11):4017–24. doi: 10.1210/jcem.84.11.6152.
Harley, K. G., K. P. Berger, K. Kogut, K. Parra, R. H. Lustig, L. C.
Greenspan, A. M. Calafat, X. Ye, and B. Eskenazi. 2019. Association
of phthalates, parabens and phenols found in personal care products
with pubertal timing in girls and boys. Human Reproduction
(Oxford, England) 34 (1):109–17. doi: 10.1093/humrep/dey337.
Harmon, S. M., and C. F. Seifert. 1991. Levothyroxine-cholestyramine
interaction reemphasized. Annals of Internal Medicine 115 (8):658–9.
doi: 10.7326/0003-4819-115-8-658_2.
Harrigan, G. G., W. P. Ridley, S. G. Riordan, M. A. Nemeth, R. Sorbet,
W. A. Trujillo, M. L. Breeze, and R. W. Schneider. 2007. Chemical
composition of glyphosate-tolerant soybean 40-3-2 grown in Europe
remains equivalent with that of conventional soybean (Glycine max
L.). Journal of Agricultural and Food Chemistry 55 (15):6160–8. doi:
10.1021/jf0704920.
Harris, M. A., J. C. Prior, and M. Koehoorn. 2008. Age at menarche in
the Canadian population: secular trends and relationship to adult-
hood BMI. The Journal of Adolescent Health: Official Publication of
the Society for Adolescent Medicine 43 (6):548–54. doi: 10.1016/j.
jadohealth.2008.07.017.
Harris, R. M., and R. H. Waring. 2012. Diethylstilboestrol-a long-term
legacy. Maturitas 72 (2):108–12. doi: 10.1016/j.maturitas.2012.03.002.
Hasanah, Y., T. C. Nisa, H. Armidin, and H. Hanum. 2015. Isoflavone
content of soybean [Glycine max (L). Merr.] cultivars with different
nitrogen sources and growing season under dry land conditions.
JAEID 109:5–17. doi: 10.12895/jaeid.20151.216.
Hatena Blog. How much is it in Tokyo? Hatena Blog. Accessed
February 09, 2021. http://nbakki.hatenablog.com/entry/Kids_
Average_Height_and_Weight_by_Age_in_Japan.
He, Y., Q. Zeng, S. Dong, L. Qin, G. Li, and P. Wang. 2013.
Associations between uterine fibroids and lifestyles including diet,
physical activity and stress: A case-control study in China. Asia
Pacific Journal of Clinical Nutrition 22 (1):109–17. doi: 10.6133/
apjcn.2013.22.1.07.
Hedlund, T. E., P. D. Maroni, P. G. Ferucci, R. Dayton, S. Barnes, K.
Jones, R. Moore, L. G. Ogden, K. W€aH€aL€a, H. M. Sackett, et al.
46 M. MESSINA ET AL.
2005. Long-term dietary habits affect soy isoflavone metabolism and
accumulation in prostatic fluid in Caucasian men. The Journal of
Nutrition 135 (6):1400–6. doi: 10.1093/jn/135.6.1400.
Helk, O., and K. Widhalm. 2020. Effects of a low-fat dietary regimen
enriched with soy in children affected with heterozygous familial
hypercholesterolemia. Clinical Nutrition Espen 36:150–6. doi: 10.
1016/j.clnesp.2019.09.009.
Herbst, A. L. 1976. Summary of the changes in the human female geni-
tal tract as a consequence of maternal diethylstilbestrol therapy.
Journal of Toxicology and Environmental Health. Supplement 1:
13–20. https://pubmed.ncbi.nlm.nih.gov/994230/.
Herbst, A. L., H. Ulfelder, and D. C. Poskanzer. 1971. Adenocarcinoma
of the vagina. Association of maternal stilbestrol therapy with tumor
appearance in young women. The New England Journal of Medicine
284 (15):878–81. doi: 10.1056/NEJM197104222841604.
Herman-Giddens, M. E. 2006. Recent data on pubertal milestones in
United States children: The secular trend toward earlier develop-
ment. International Journal of Andrology 29 (1):241–6. doi: 10.1111/
j.1365-2605.2005.00575.x.
Herman-Giddens, M. E., J. Steffes, D. Harris, E. Slora, M. Hussey, S. A.
Dowshen, R. Wasserman, J. R. Serwint, L. Smitherman, and E. O.
Reiter. 2012. Secondary sexual characteristics in boys: Data from the
Pediatric Research in Office Settings Network. Pediatrics 130 (5):
e1058-68–e1068. doi: 10.1542/peds.2011-3291.
Hilakivi-Clarke, L., S. de Assis, and A. Warri. 2013. Exposures to syn-
thetic estrogens at different times during the life, and their effect on
breast cancer risk. Journal of Mammary Gland Biology and
Neoplasia 18 (1):25–42. doi: 10.1007/s10911-013-9274-8.
Hill, M., A. Parızek, R. Kancheva, M. Duskova, M. Velıkova, L. Krız,
M. Klımkova, A. Paskova, Z. Zizka, P. Matucha, et al. 2010. Steroid
metabolome in plasma from the umbilical artery, umbilical vein,
maternal cubital vein and in amniotic fluid in normal and preterm
labor. The Journal of Steroid Biochemistry and Molecular Biology 121
(3-5):594–610. doi: 10.1016/j.jsbmb.2009.10.012.
Himes, J. H. 2006. Examining the evidence for recent secular changes
in the timing of puberty in US children in light of increases in the
prevalence of obesity. Molecular and Cellular Endocrinology 254-255:
13–21. doi: 10.1016/j.mce.2006.04.013.
Hirose, K., K. Tajima, N. Hamajima, T. Takezaki, M. Inoue, T.
Kuroishi, K. Kuzuya, S. Nakamura, and S. Tokudome. 1996. Subsite
(cervix/endometrium)-specific risk and protective factors in uterus
cancer. Japanese Journal of Cancer Research 87 (9):1001–9. doi: 10.
1111/j.1349-7006.1996.tb02132.x.
Ho, S. C., J. Woo, S. Lam, Y. Chen, A. Sham, and J. Lau. 2003. Soy
protein consumption and bone mass in early postmenopausal
Chinese women. Osteoporosis International 14 (10):835–42. doi: 10.
1007/s00198-003-1453-9.
Hodis, H. N., W. J. Mack, N. Kono, S. P. Azen, D. Shoupe, J. Hwang-
Levine, D. Petitti, L. Whitfield-Maxwell, M. Yan, A. A. Franke, et al.
2011. Isoflavone soy protein supplementation and atherosclerosis
progression in healthy postmenopausal women: A randomized con-
trolled trial. Stroke 42 (11):3168–75. doi: 10.1161/STROKEAHA.111.
620831.
Hollier, L. P., J. A. Keelan, M. Hickey, M. T. Maybery, and A. J. O.
Whitehouse. 2014. Measurement of androgen and estrogen concen-
trations in cord blood: Accuracy, biological interpretation, and
applications to understanding human behavioral development.
Frontiers in Endocrinology 5:64. doi: 10.3389/fendo.2014.00064.
Holman, R. C., E. D. Belay, K. Y. Christensen, A. M. Folkema, C. A.
Steiner, and L. B. Schonberger. 2010. Hospitalizations for Kawasaki
syndrome among children in the United States, 1997-2007. Pediatric
Infectious Disease Journal 29 (6):483–8. doi: 10.1097/INF.
0b013e3181cf8705.
Hong, S. J., S. I. Kim, S. M. Kwon, J. R. Lee, and B. C. Chung. 2002.
Comparative study of concentration of isoflavones and lignans in
plasma and prostatic tissues of normal control and benign prostatic
hyperplasia. Yonsei Medical Journal 43 (2):236–41. doi: 10.3349/ymj.
2002.43.2.236.
Hooper, L., G. Madhavan, J. A. Tice, S. J. Leinster, and A. Cassidy.
2010. Effects of isoflavones on breast density in pre- and post-
menopausal women: A systematic review and meta-analysis of
randomized controlled trials. Human Reproduction Update 16 (6):
745–60. doi: 10.1093/humupd/dmq011.
Hooper, L., J. J. Ryder, M. S. Kurzer, J. W. Lampe, M. J. Messina,
W. R. Phipps, and A. Cassidy. 2009. Effects of soy protein and iso-
flavones on circulating hormone concentrations in pre- and post-
menopausal women: A systematic review and meta-analysis. Human
Reproduction Update 15 (4):423–40. doi: 10.1093/humupd/dmp010.
Hosoda, K., T. Furuta, A. Yokokawa, and K. Ishii. 2010. Identification
and quantification of daidzein-7-glucuronide-4’-sulfate, genistein-7-
glucuronide-4’-sulfate and genistein-4’,7-diglucuronide as major
metabolites in human plasma after administration of kinako.
Analytical and Bioanalytical Chemistry 397 (4):1563–72. doi: 10.
1007/s00216-010-3714-8.
Hosokawa, M., S. Imazeki, and H. Mizunuma. 2012. Secular trends in
age at menarche and time to establish regular menstrual cycling in
Japanese women born between 1930 and 1985. BMC Womens
Health 12:19. doi: 10.1186/1472-6874-12-19.
Hozawa, A., Y. Sugawara, Y. Tomata, M. Kakizaki, T. Tsuboya, K.
Ohmori-Matsuda, N. Nakaya, S. Kuriyama, A. Fukao, I. Tsuji, et al.
2013. Relationship between serum isoflavone levels and disability-
free survival among community-dwelling elderly individuals: Nested
case-control study of the Tsurugaya project. The Journals of
Gerontology. Series A, Biological Sciences and Medical Sciences 68
(4):465–72. doi: 10.1093/gerona/gls198.
Hsiao, A. K.-F., and P. M. Lyons-Wall. 2000. Soy consumption in
Taiwanese children in Taipei. Journal of Nutrition 130:705S. doi: 10.
1093/jn/130.3.680S.
Hsieh, C. Y., R. C. Santell, S. Z. Haslam, and W. G. Helferich. 1998.
Estrogenic effects of genistein on the growth of estrogen receptor-
positive human breast cancer (MCF-7) cells in vitro and in vivo.
Cancer Research 58 (17):3833–8. https://pubmed.ncbi.nlm.nih.gov/
9731492/.
Hu, X. J., W. R. Song, L. Y. Gao, S. P. Nie, G. Eisenbrand, and M. Y.
Xie. 2014. Assessment of dietary phytoestrogen intake via plant-
derived foods in China. Food Additives & Contaminants. Part A,
Chemistry, Analysis, Control, Exposure & Risk Assessment 31 (8):
1325–35. doi: 10.1080/19440049.2014.930562.
Hua, X.-G., R. Hu, C.-Y. Hu, F.-L. Li, W. Jiang, and X.-J. Zhang. 2018.
Associations between hypospadias, cryptorchidism and anogenital
distance: Systematic review and meta-analysis. Andrologia 50 (10):
e13152 doi: 10.1111/and.13152.
Huang, S.-K., M.-T. Lin, H.-C. Chen, S.-C. Huang, and M.-H. Wu.
2013. Epidemiology of Kawasaki disease: Prevalence from national
database and future trends projection by system dynamics modeling.
Journal of Pediatrics 163 (1):126–31 e1. doi: 10.1016/j.jpeds.2012.12.
011.
Huang, Z.-Y., D. R. Barreda, R. G. Worth, Z. K. Indik, M.-K. Kim, P.
Chien, and A. D. Schreiber. 2006. Differential kinase requirements
in human and mouse Fc-gamma receptor phagocytosis and endo-
cytosis. Journal of Leukocyte Biology 80 (6):1553–62. doi: 10.1189/jlb.
0106019.
Huggett, A. C., S. Pridmore, A. Malno€e, F. Haschke, and E. A. Offord.
1997. Phyto-oestrogens in soy-based infant formula. Lancet (London,
England) 350 (9080):815–6. doi: 10.1016/s0140-6736(05)62613-x.
Hur, H. G., J. O. Lay, R. D. Beger, J. P. Freeman, and F. Rafii. 2000.
Isolation of human intestinal bacteria metabolizing the natural iso-
flavone glycosides daidzin and genistin. Archives of Microbiology 174
(6):422–8. doi: 10.1007/s002030000222.
Husain, D., K. Khanna, S. Puri, and M. Haghighizadeh. 2015.
Supplementation of soy isoflavones improved sex hormones, blood
pressure, and postmenopausal symptoms. Journal of the American
College of Nutrition. 34 (1):42–8. doi: 10.1080/07315724.2013.875434.
H€user, S., S. Guth, H. G. Joost, S. T. Soukup, J. K€ohrle, L. Kreienbrock,
P. Diel, D. W. Lachenmeier, G. Eisenbrand, G. Vollmer, et al. 2018.
Effects of isoflavones on breast tissue and the thyroid hormone sys-
tem in humans: A comprehensive safety evaluation. Archives of
Toxicology 92 (9):2703–48. doi: 10.1007/s00204-018-2279-8.
Hutchins, A. M., J. L. Slavin, and J. W. Lampe. 1995. Urinary isoflavo-
noid phytoestrogen and lignan excretion after consumption of
CRITICAL REVIEWS IN FOOD SCIENCE AND NUTRITION 47
fermented and unfermented soy products. Journal of the American
Dietetic Association 95 (5):545–51. doi: 10.1016/S0002-
8223(95)00149-2.
Hwang, C. S., H. S. Kwak, H. J. Lim, S. H. Lee, Y. S. Kang, T. B. Choe,
H. G. Hur, and K. O. Han. 2006. Isoflavone metabolites and their
in vitro dual functions: They can act as an estrogenic agonist or
antagonist depending on the estrogen concentration. The Journal of
Steroid Biochemistry and Molecular Biology 101 (4-5):246–53. doi:
10.1016/j.jsbmb.2006.06.020.
Ichige, M., E. Fukuda, S. Miida, J-i Hattan, N. Misawa, S. Saito, T.
Fujimaki, M. Imoto, and K. Shindo. 2013. Novel isoflavone gluco-
sides in groundnut (Apios americana Medik) and their antiandro-
genic activities. Journal of Agricultural and Food Chemistry 61 (9):
2183–7. doi: 10.1021/jf305233t.
ILSI range is from ILSI Crop Composition Database. 2019. Accessed
February 9, 2020 (ILSI).
Irvine, C. H., M. G. Fitzpatrick, and S. L. Alexander. 1998.
Phytoestrogens in soy-based infant foods: Concentrations, daily
intake, and possible biological effects. Proceedings of the Society for
Experimental Biology and Medicine. Society for Experimental Biology
and Medicine (New York, N.Y.) 217 (3):247–53. DOI: 10.1073/pnas.
73.7.2275
Irvine, C. H., N. Shand, M. G. Fitzpatrick, and S. L. Alexander. 1998.
Daily intake and urinary excretion of genistein and daidzein by
infants fed soy- or dairy-based infant formulas. The American
Journal of Clinical Nutrition 68 (6):1462S–5S. doi: 10.1093/ajcn/68.6.
1462S.
Irvine, C., M. Fitzpatrick, I. Robertson, and D. Woodhams. 1995. The
potential adverse effects of soybean phytoestrogens in infant feeding.
The New Zealand Medical Journal 108 (1000):208–9. https://
pubmed.ncbi.nlm.nih.gov/7783996/.
Ishitsuka, K., S. Sasaki, K. Yamamoto-Hanada, H. Mezawa, M. Konishi,
and Y. Ohya. 2020. Changes in dietary intake in pregnant women
from periconception to pregnancy in the Japan Environment and
Children’s Study: A nationwide Japanese birth cohort study.
Maternal and Child Health Journal 24 (3):389–400. doi: 10.1007/
s10995-019-02835-z.
Islam, M. A., R. Bekele, J. H. J. Vanden Berg, Y. Kuswanti, O. Thapa,
S. Soltani, F. X. R. van Leeuwen, I. M. C. M. Rietjens, and A. J.
Murk. 2015. Deconjugation of soy isoflavone glucuronides needed
for estrogenic activity. Toxicology in Vitro: An International Journal
Published in Association with BIBRA 29 (4):706–15. doi: 10.1016/j.
tiv.2015.01.013.
Iwasaki, M., M. Inoue, T. Otani, S. Sasazuki, N. Kurahashi, T. Miura,
S. Yamamoto, and S. Tsugane. 2008. Plasma isoflavone level and
subsequent risk of breast cancer among Japanese women: A nested
case-control study from the Japan Public Health Center-based pro-
spective study group. Journal of Clinical Oncology : official Journal of
the American Society of Clinical Oncology 26 (10):1677–83. doi: 10.
1200/JCO.2007.13.9964.
Izumi, T., M. K. Piskula, S. Osawa, A. Obata, K. Tobe, M. Saito, S.
Kataoka, Y. Kubota, and M. Kikuchi. 2000. Soy isoflavone aglycones
are absorbed faster and in higher amounts than their glucosides in
humans. The Journal of Nutrition 130 (7):1695–9. doi: 10.1093/jn/
130.7.1695.
Jacobsen, B. K., K. Jaceldo-Siegl, S. F. Knutsen, et al. 2014. Soy isofla-
vone intake and the likelihood of ever becoming a mother: The
Adventist Health Study-2. International Journal of Women’s Health
6:377–84. doi: 10.2147/IJWH.S57137.
Jakes, R. W., L. Alexander, S. W. Duffy, J. Leong, L. H. Chen, and
W. H. Lee. 2001. Dietary intake of soybean protein and menstrual
cycle length in pre-menopausal Singapore Chinese women. Public
Health Nutrition 4 (2):191–6. doi: 10.1079/phn200063.
Jamilian, M., and Z. Asemi. 2016. The effects of soy isoflavones on
metabolic status of patients with polycystic ovary syndrome. Journal
of Clinical Endocrinology and Metabolism 101 (9):3386–94. doi: 10.
1210/jc.2016-1762.
Jang, C. H., C. S. Park, J. K. Lim, et al. 2008. Metabolism of isoflavone
derivatives during the manufacturing of traditional meju and
doenjang. Food Science and Biotechnology17:442–5. https://www.
koreascience.or.kr/article/JAKO200833338360467.page.
Jang, H.-H., H. Noh, H.-W. Kim, S.-Y. Cho, H.-J. Kim, S.-H. Lee, S.-H.
Lee, M. J. Gunter, P. Ferrari, A. Scalbert, et al. 2020. Metabolic
tracking of isoflavones in soybean products and biosamples from
healthy adults after fermented soybean consumption. Food
Chemistry 330:127317. doi: 10.1016/j.foodchem.2020.127317.
Janulewicz, P. A., J. M. Carlson, A. K. Wesselink, L. A. Wise, E. E.
Hatch, L. M. Edwards, and J. L. Peters. 2019. Urinary isoflavones
levels in relation to serum thyroid hormone concentrations in
female and male adults in the U.S. general population. International
Journal of Environmental Health Research :1–12. doi: 10.1080/
09603123.2019.1663497.
Jarrell, J., W. G. Foster, and D. W. Kinniburgh. 2012. Phytoestrogens
in human pregnancy. Obstetrics and Gynecology International 2012:
850313. doi: 10.1155/2012/850313.
Jaskulski, S., A. Y. Jung, M. Huebner, G. Poschet, R. Hell, A. H€using,
S. Gonzalez-Maldonado, S. Behrens, N. Obi, H. Becher, and J.
Chang-Claude. 2019. Prognostic associations of circulating phytoes-
trogens and biomarker changes in long-term survivors of postmeno-
pausal breast cancer. Nutrition and Cancer :1–15.
Jefferson, W. N., H. B. Patisaul, and C. J. Williams. 2012. Reproductive
consequences of developmental phytoestrogen exposure.
Reproduction (Cambridge, England) 143 (3):247–60. doi: 10.1530/
REP-11-0369.
Jiang, Y., P. Gong, Z. Madak-Erdogan, T. Martin, M. Jeyakumar, K.
Carlson, I. Khan, T. J. Smillie, A. G. Chittiboyina, S. C. K. Rotte,
et al. 2013. Mechanisms enforcing the estrogen receptor b selectivity
of botanical estrogens. FASEB Journal: Official Publication of the
Federation of American Societies for Experimental Biology 27 (11):
4406–18.,doi: 10.1096/fj.13-234617.
Jochum, F., B. Alteheld, P. Meinardus, N. Dahlinger, A. Nomayo, and
P. Stehle. 2017. Mothers’ consumption of soy drink but not black
tea increases the flavonoid content of term breast milk: A pilot
randomized, controlled intervention study. Annals of Nutrition &
Metabolism 70 (2):147–53. doi: 10.1159/000471857.
Jocsak, G., E. Ioja, D. S. Kiss, I. Toth, Z. Barany, T. Bartha, L. V.
Frenyo, and A. Zsarnovszky. 2019. Endocrine disruptors induced
distinct expression of thyroid and estrogen receptors in rat versus
mouse primary cerebellar cell cultures. Brain Sciences 9 (12):359.
doi: 10.3390/brainsci9120359.
Johnson, E. B., M. G. Muto, E. H. Yanushpolsky, and G. L. Mutter.
2001. Phytoestrogen supplementation and endometrial cancer.
Obstetrics and Gynecology 98 (5 Pt 2):947–50. doi: 10.1016/s0029-
7844(01)01542-3.
Ju, Y. H., C. D. Allred, K. F. Allred, K. L. Karko, D. R. Doerge, and
W. G. Helferich. 2001. Physiological concentrations of dietary genis-
tein dose-dependently stimulate growth of estrogen-dependent
human breast cancer (MCF-7) tumors implanted in athymic nude
mice. The Journal of Nutrition 131 (11):2957–62. doi: 10.1093/jn/
131.11.2957.
Ju, Y. H., D. R. Doerge, K. A. Woodling, J. A. Hartman, J. Kwak, and
W. G. Helferich. 2008. Dietary genistein negates the inhibitory effect
of letrozole on the growth of aromatase-expressing estrogen-depend-
ent human breast cancer cells (MCF-7Ca) in vivo. Carcinogenesis 29
(11):2162–8. doi: 10.1093/carcin/bgn161.
Ju, Y. H., D. R. Doerge, K. F. Allred, C. D. Allred, and W. G.
Helferich. 2002. Dietary genistein negates the inhibitory effect of
tamoxifen on growth of estrogen-dependent human breast cancer
(MCF-7) cells implanted in athymic mice. Cancer Research 62 (9):
2474–7. https://pubmed.ncbi.nlm.nih.gov/11980635/.
Ju, Y. H., J. Fultz, K. F. Allred, D. R. Doerge, and W. G. Helferich.
2006. Effects of dietary daidzein and its metabolite, equol, at physio-
logical concentrations on the growth of estrogen-dependent human
breast cancer (MCF-7) tumors implanted in ovariectomized athymic
mice. Carcinogenesis 27 (4):856–63. doi: 10.1093/carcin/bgi320.
Junqueira Do Lago, M., E. Faerstein, C. De Souza Lopes, and G. L.
Werneck. 2003. Family socio-economic background modified secular
trends in age at menarche: Evidence from the Pro-Saude Study (Rio
48 M. MESSINA ET AL.
de Janeiro, Brazil) . Ann Hum Biol 30 (3):347–52. ). doi: 10.1080/
0301446031000091783.
Kang, J., T. M. Badger, M. J. J. Ronis, and X. Wu. 2010. Non-isofla-
vone phytochemicals in soy and their health effects. Journal of
Agricultural and Food Chemistry 58 (14):8119–33. doi: 10.1021/
jf100901b.
Kang, S., Y. M. Kim, J. A. Lee, D. H. Kim, and J. S. Lim. 2019. Early
menarche is a risk factor for short stature in young Korean females:
An epidemiologic study. Journal of Clinical Research in Pediatric
Endocrinology 11 (3):234–9. doi: 10.4274/jcrpe.galenos.2018.2018.
0274.
Kang, X., Q. Zhang, S. Wang, X. Huang, and S. Jin. 2010. Effect of soy
isoflavones on breast cancer recurrence and death for patients
receiving adjuvant endocrine therapy. Canadian Medical Association
Journal 182 (17):1857–62. doi: 10.7314/apjcp.2013.14.4.2407.
Kano, M., T. Takayanagi, K. Harada, S. Sawada, and F. Ishikawa. 2006.
Bioavailability of isoflavones after ingestion of soy beverages in
healthy adults. The Journal of Nutrition 136 (9):2291–6. doi: 10.
1093/jn/136.9.2291.
Karamali, M., M. Kashanian, S. Alaeinasab, and Z. Asemi. 2018. The
effect of dietary soy intake on weight loss, glycaemic control, lipid
profiles and biomarkers of inflammation and oxidative stress in
women with polycystic ovary syndrome: A randomised clinical trial.
Journal of Human Nutrition and Dietetics 31 (4):533–43. Aug doi:
10.1111/jhn.12545.
Kato, N., H. Takimoto, T. Yokoyama, S. Yokoya, T. Tanaka, and H.
Tada. 2014. Updated Japanese growth references for infants and pre-
school children, based on historical, ethnic and environmental char-
acteristics. Acta Paediatrica ( Paediatrica 103 (6):e251–e61. doi: 10.
1111/apa.12587.
Kavlock, R. J., G. P. Daston, C. DeRosa, P. Fenner-Crisp, L. E. Gray, S.
Kaattari, G. Lucier, M. Luster, M. J. Mac, C. Maczka, et al. 1996.
Research needs for the risk assessment of health and environmental
effects of endocrine disruptors: A report of the U.S. EPA-sponsored
workshop. Environmental Health Perspectives 104:715–40. doi: 10.
1289/ehp.96104s4715.
Keel, B. A., K. B. Eddy, S. Cho, B. K. Gangrade, and J. V. May. 1992.
Purified human alpha fetoprotein inhibits growth factor-stimulated
estradiol production by porcine granulosa cells in monolayer cul-
ture. Endocrinology 130 (6):3715–7. doi: 10.1210/endo.130.6.1375908.
Keelan, J. A., E. Mattes, H. Wei Tan, A. Dinan, J. P. Newnham,
A. J. O. Whitehouse, P. Jacoby, and M. Hickey. 2012. Androgen
concentrations in umbilical cord blood and their association with
maternal, fetal and obstetric factors. PloS One 7 (8):e42827. doi: 10.
1371/journal.pone.0042827.
Khan, S. A., R. T. Chatterton, N. Michel, M. Bryk, O. Lee, D. Ivancic,
R. Heinz, C. M. Zalles, I. B. Helenowski, B. D. Jovanovic, et al.
2012. Soy isoflavone supplementation for breast cancer risk reduc-
tion: A randomized phase II trial. Cancer Prevention Research
(Philadelphia, Pa.) 5 (2):309–19. doi: 10.1158/1940-6207.CAPR-11-
0251.
Khani, B., F. Mehrabian, E. Khalesi, et al. 2011. Effect of soy phyto-
estrogen on metabolic and hormonal disturbance of women with
polycystic ovary syndrome. Journal of Research in Medical Sciences:
The Official Journal of Isfahan University of Medical Sciences 16:
297–302.
Kim, J. K., E.-H. Kim, I. Park, B.-R. Yu, J. D. Lim, Y.-S. Lee, J.-H. Lee,
S.-H. Kim, and I.-M. Chung. 2014. Isoflavones profiling of soybean
[Glycine max (L.) Merrill] germplasms and their correlations with
metabolic pathways. Food Chemistry. 153:258–64. doi: 10.1016/j.
foodchem.2013.12.066.
Kim, J., S. Kim, K. Huh, Y. Kim, H. Joung, and M. Park. 2011. High
serum isoflavone concentrations are associated with the risk of pre-
cocious puberty in Korean girls. Clinical Endocrinology 75 (6):831–5.
doi: 10.1111/j.1365-2265.2011.04127.x.
Kim, S., S. Moon, and B. M. Popkin. 2000. The nutrition transition in
South Korea. The American Journal of Clinical Nutrition 71 (1):
44–53. doi: 10.1093/ajcn/71.1.44.
Kim, Y. J., M. Y. Park, N. Chang, and O. Kwon. 2015. Intake and
major sources of dietary flavonoid in Korean adults: Korean
National Health and Nutrition Examination Survey 2010-2012. Asia
Pacific Journal of Clinical Nutrition 24 (3):456–63. doi: 10.6133/
apjcn.2015.24.3.04.
King, R. A., and D. B. Bursill. 1998. Plasma and urinary kinetics of the
isoflavones daidzein and genistein after a single soy meal in humans.
The American Journal of Clinical Nutrition 67 (5):867–72. doi: 10.
1093/ajcn/67.5.867.
King, R. A., J. L. Broadbent, and R. J. Head. 1996. Absorption and
excretion of the soy isoflavone genistein in rats. The Journal of
Nutrition 126 (1):176–82. doi: 10.1093/jn/126.1.176.
Koh, W.-P., J.-M. Yuan, C.-L. Sun, H.-P. Lee, and M. C. Yu. 2005.
Middle-aged and older Chinese men and women in Singapore who
smoke have less healthy diets and lifestyles than nonsmokers. The
Journal of Nutrition 135 (10):2473–7. doi: 10.1093/jn/135.10.2473.
K€ohrle, J. 2004. Low dose competition of flavonoids with endogenous
thyroid transport proteins: Potential relevance to the thyroid hor-
mone axis. In: Functional food: Safety aspects, symposium
Forschungsberichte (DFG) Deutsche Forschungsgemeinschaft, ed. W.-
V. Verlag, 112–37.
Konishi, K., K. Wada, M. Yamakawa, Y. Goto, F. Mizuta, S. Koda, T.
Uji, M. Tsuji, and C. Nagata. 2019. Dietary soy intake is inversely
associated with risk of type 2 diabetes in Japanese women but not
in men. The Journal of Nutrition 149 (7):1208–14. doi: 10.1093/jn/
nxz047.
Korde, L. A., A. H. Wu, T. Fears, A. M. Y. Nomura, D. W. West, L. N.
Kolonel, M. C. Pike, R. N. Hoover, and R. G. Ziegler. 2009.
Childhood soy intake and breast cancer risk in Asian American
women. Cancer Epidemiology, Biomarkers & Prevention: A
Publication of the American Association for Cancer Research,
Cosponsored by the American Society of Preventive Oncology 18 (4):
1050–9. doi: 10.1158/1055-9965.EPI-08-0405.
Kraemer, W. J., G. Solomon-Hill, B. M. Volk, B. R. Kupchak, D. P.
Looney, C. Dunn-Lewis, B. A. Comstock, T. K. Szivak, D. R.
Hooper, S. D. Flanagan, et al. 2013. The effects of soy and whey
protein supplementation on acute hormonal reponses to resistance
exercise in men. Journal of the American College of Nutrition 32 (1):
66–74. doi: 10.1080/07315724.2013.770648.
Kreijkamp-Kaspers, S., L. Kok, M. L. Bots, D. E. Grobbee, and Y. T.
van der Schouw. 2004. Dietary phytoestrogens and vascular function
in postmenopausal women: A cross-sectional study. Journal of
Hypertension 22 (7):1381–8. doi: 10.1097/01.hjh.0000125435.28861.
d2.
Krysiak-Baltyn, K., J. Toppari, N. E. Skakkebaek, T. S. Jensen, H. E.
Virtanen, K.-W. Schramm, H. Shen, T. Vartiainen, H. Kiviranta, O.
Taboureau, et al. 2010. Country-specific chemical signatures of per-
sistent environmental compounds in breast milk. International
Journal of Andrology 33 (2):270–8. doi: 10.1111/j.1365-2605.2009.
00996.x.
Kudou, S., Y. Fleury, D. Welti, D. Magnolato, T. Uchida, K. Kitamura,
and K. Okubo. 1991. Malonyl isoflavone glycosides in soybean seeds
(Glycine max MERRILL). Agricultural and Biological Chemistry 55
(9):2227–33. doi: 10.1080/00021369.1991.10870966.
Kuijper, E. A. M., J. C. F. Ket, M. R. Caanen, and C. B. Lambalk. 2013.
Reproductive hormone concentrations in pregnancy and neonates:
A systematic review. Reproductive Biomedicine Online 27 (1):33–63.
doi: 10.1016/j.rbmo.2013.03.009.
Kuiper, G. G., B. Carlsson, K. Grandien, E. Enmark, J. H€aggblad, S.
Nilsson, and J. A. Gustafsson. 1997. Comparison of the ligand bind-
ing specificity and transcript tissue distribution of estrogen receptors
alpha and beta. Endocrinology 138 (3):863–70. 10.1210/
endo.138.3.4979 doi: 10.1210/endo.138.3.4979.
Kuiper, G. G., E. Enmark, M. Pelto-Huikko, S. Nilsson, and J. A.
Gustafsson. 1996. Cloning of a novel receptor expressed in rat pros-
tate and ovary. Proceedings of the National Academy of Sciences of
the United States of America 93 (12):5925–30. doi: 10.1073/pnas.93.
12.5925.
Kuiper, G. G., J. G. Lemmen, B. Carlsson, J. C. Corton, S. H. Safe,
P. T. van der Saag, B. van der Burg, and J. A. Gustafsson. 1998.
Interaction of estrogenic chemicals and phytoestrogens with
CRITICAL REVIEWS IN FOOD SCIENCE AND NUTRITION 49
estrogen receptor beta. Endocrinology 139 (10):4252–63. doi: 10.
1210/endo.139.10.6216.
Kuo, L.-C., W.-Y. Cheng, R.-Y. Wu, C.-J. Huang, and K.-T. Lee. 2006.
Hydrolysis of black soybean isoflavone glycosides by Bacillus subtilis
natto. Applied Microbiology and Biotechnology 73 (2):314–20. doi:
10.1007/s00253-006-0474-7.
Kurahashi, N., M. Iwasaki, M. Inoue, S. Sasazuki, and S. Tsugane.
2008. Plasma isoflavones and subsequent risk of prostate cancer in a
nested case-control study: The Japan Public Health Center. Journal
of Clinical Oncology : Official Journal of the American Society of
Clinical Oncology 26 (36):5923–9. doi: 10.1200/JCO.2008.16.8807.
Kurahashi, N., M. Murakumo, H. Kakizaki, K. Nonomura, T.
Koyanagi, S. Kasai, F. Sata, and R. Kishi. 2004. The estimated preva-
lence of hypospadias in Hokkaido, Japan. Journal of Epidemiology 14
(3):73–7. doi: 10.2188/jea.14.73.
Kurman, R. J., P. F. Kaminski, and H. J. Norris. 1985. The behavior of
endometrial hyperplasia. A long-term study of "untreated" hyperpla-
sia in 170 patients. Cancer 56 (2):403–12. doi: 10.1002/1097-
0142(19850715)56:2< 403::aid-cncr2820560233> 3.0.co;2-x.
Kurniawan, A.-L., C.-Y. Hsu, J. C.-J. Chao, R. Paramastri, H.-A. Lee,
P.-C. Lai, N.-C. Hsieh, and S.-F V. Wu. 2021. Association of testos-
terone-related dietary pattern with testicular function among adult
men: A cross-sectional health screening study in Taiwan. Nutrients
13 (1):259. doi: 10.3390/nu13010.
Kwack, S. J., K.-B. Kim, H. S. Kim, K. S. Yoon, and B. M. Lee. 2009.
Risk assessment of soybean-based phytoestrogens. Journal of
Toxicology and Environmental Health, Part A 72 (21-22):1254–61.
doi: 10.1080/15287390903212212.
Labos, G., E. Trakakis, P. Pliatsika, A. Augoulea, V. Vaggopoulos, G.
Basios, G. Simeonidis, M. Creatsa, A. Alexandrou, Z. Iliodromiti,
et al. 2013. Efficacy and safety of DT56a compared to hormone
therapy in Greek post-menopausal women. Journal of
Endocrinological Investigation 36:521–6. doi: 10.3275/8926.
Lacey, M., J. Bohday, S. M. R. Fonseka, A. I. Ullah, and S. A.
Whitehead. 2005. Dose-response effects of phytoestrogens on the
activity and expression of 3beta-hydroxysteroid dehydrogenase and
aromatase in human granulosa-luteal cells. The Journal of Steroid
Biochemistry and Molecular Biology 96 (3-4):279–86. doi: 10.1016/j.
jsbmb.2005.03.006. [InsertedFromOnline[pubmedMismatch]]
Lagiou, P., E. Samoli, W. Okulicz, B. Xu, A. Lagiou, L. Lipworth, C.
Georgila, L. Vatten, H. O. Adami, D. Trichopoulos, et al. 2011.
Maternal and cord blood hormone levels in the United States and
China and the intrauterine origin of breast cancer. Annals of
Oncology 22 (5):1102–8. doi: 10.1093/annonc/mdq565.
Lamartiniere, C. A., J. Moore, M. Holland, and S. Barnes. 1995.
Neonatal genistein chemoprevents mammary cancer. Proceedings of
the Society for Experimental Biology and Medicine. Society for
Experimental Biology and Medicine (New York, N.Y.) 208 (1):120–3.
doi: 10.3181/00379727-208-43843.
Lamartiniere, C. A., Y. X. Zhao, and W. A. Fritz. 2000. Genistein:
Mammary cancer chemoprevention, in vivo mechanisms of action,
potential for toxicity and bioavailability in rats. Journal of Women’s
Cancer 2:11–9.
Lampe, J. W., D. R. Gustafson, A. M. Hutchins, M. C. Martini, S. Li,
K. W€ah€al€a, G. A. Grandits, J. D. Potter, and J. L. Slavin. 1999.
Urinary isoflavonoid and lignan excretion on a Western diet:
Relation to soy, vegetable, and fruit intake. Cancer Epidemiology,
Biomarkers & Prevention: A Publication of the American Association
for Cancer Research, Cosponsored by the American Society of
Preventive Oncology 8 (8):699–707. https://pubmed.ncbi.nlm.nih.
gov/10744130/.
Lappe, M. A., E. B. Bailey, C. Childress, and K. D. R. Setchell. 1998.
Alterations in clinically important phytoestrogens in genetically
modified, herbicide-tolerant soybeans. Journal of Medicinal Food 1
(4):241–5. doi: 10.1089/jmf.1998.1.241.
Lee, A., L. Beaubernard, V. Lamothe, and C. Bennetau-Pelissero. 2019.
New evaluation of isoflavone exposure in the French population.
Nutrients 11 (10):2308. doi: 10.3390/nu11102308.
Lee, M. J., and J. H. Kim. 2007. Estimated dietary isoflavone intake
among Korean adults. Nutrition Research and Practice 1 (3):206–11.
doi: 10.4162/nrp.2007.1.3.206.
Lee, S.-A., W. Wen, Y.-B. Xiang, S. Barnes, D. Liu, Q. Cai, W. Zheng,
and X. O. Shu. 2007. Assessment of dietary isoflavone intake among
middle-aged Chinese men. The Journal of Nutrition 137 (4):1011–6.
doi: 10.1093/jn/137.4.1011.
Lepping, M. D., R. A. Herman, and B. L. Potts. 2013. Compositional
equivalence of DAS-444Ø6-6 (AAD-12þ 2mEPSPSþ PAT) herbi-
cide-tolerant soybean and nontransgenic soybean . Journal of
Agricultural and Food Chemistry 61 (46):11180–90. doi: 10.1021/
jf403775d.
Levine, L. D., K. Kim, A. Purdue-Smithe, R. Sundaram, E. F.
Schisterman, M. Connell, E. A. Devilbiss, Z. Alkhalaf, J. G. Radoc,
G. M. Buck Louis, et al. 2020. Urinary phytoestrogens and relation-
ship to menstrual cycle length and variability among healthy, eume-
norrheic women. Journal of the Endocrine Society 4 (2):bvz003. doi:
10.1210/jendso/bvz003.
Levis, S., N. Strickman-Stein, P. Ganjei-Azar, P. Xu, D. R. Doerge, and
J. Krischer. 2011. Soy isoflavones in the prevention of menopausal
bone loss and menopausal symptoms: A randomized, double-blind
trial. Archives of Internal Medicine 171 (15):1363–9. doi: 10.1001/
archinternmed.2011.330.
Lewis, R. W., N. Brooks, G. M. Milburn, A. Soames, S. Stone, M. Hall,
and J. Ashby. 2003. The effects of the phytoestrogen genistein on
the postnatal development of the rat. Toxicological Sciences : An
Official Journal of the Society of Toxicology 71 (1):74–83. doi: 10.
1093/toxsci/71.1.74.
Li, J., X. Teng, W. Wang, Y. Chen, X. Yu, S. Wang, J. Li, L. Zhu, C. Li,
C. Fan, et al. 2011. Effects of dietary soy intake on maternal thyroid
functions and serum anti-thyroperoxidase antibody level during
early pregnancy. Journal of Medicinal Food 14 (5):543–50. doi: 10.
1089/jmf.2010.1078.
Li, N., X. Wu, W. Zhuang, L. Xia, Y. Chen, R. Zhao, M. Yi, Q. Wan,
L. Du, Y. Zhou, et al. 2020. Soy and isoflavone consumption and
multiple health outcomes: Umbrella review of systematic reviews
and meta-analyses of observational studies and randomized trials in
humans. Molecular Nutrition & Food Research 64 (4):e1900751 doi:
10.1002/mnfr.201900751.
Li, Y., Y. He, L. Qi, V. W. Jaddoe, E. J. M. Feskens, X. Yang, G. Ma,
and F. B. Hu. 2010. Exposure to the Chinese famine in early life
and the risk of hyperglycemia and type 2 diabetes in adulthood.
Diabetes 59 (10):2400–6. doi: 10.2337/db10-0385.
Li, Z., W. J. Aronson, J. R. Arteaga, K. Hong, G. Thames, S. M.
Henning, W. Liu, R. Elashoff, J. M. Ashley, and D. Heber. 2008.
Feasibility of a low-fat/high-fiber diet intervention with soy supple-
mentation in prostate cancer patients after prostatectomy. European
Journal of Clinical Nutrition 62 (4):526–36. doi: 10.1038/sj.ejcn.
1602743.
Liao, C. K., K. A. Rosenblatt, S. M. Schwartz, and N. S. Weiss. 2003.
Endometrial cancer in Asian migrants to the United States and their
descendants. Cancer Causes & Control : CCC 14 (4):357–60. doi: 10.
1023/a:1023925010837. [12846367]
Liel, Y., A. D. Sperber, and S. Shany. 1994. Nonspecific intestinal
adsorption of levothyroxine by aluminum hydroxide. The American
Journal of Medicine 97 (4):363–5. doi: 10.1016/0002-9343(94)90303-
4.
Liel, Y., I. Harman-Boehm, and S. Shany. 1996. Evidence for a clinic-
ally important adverse effect of fiber-enriched diet on the bioavail-
ability of levothyroxine in adult hypothyroid patients. The Journal of
Clinical Endocrinology and Metabolism 81 (2):857–9. doi: 10.1210/
jcem.81.2.8636317.
Lin, M. T., and M. H. Wu. 2017. The global epidemiology of Kawasaki
disease: Review and future perspectives. Global Cardiology Science &
Practice 2017 (3):e201720. doi: 10.21542/gcsp.2017.20.
Liu, D., Y. Cheng, B. Mi, L. Zeng, P. Qu, S. Li, R. Zhang, Q. Qi, C.
Wu, X. Gao, et al. 2020. Maternal dietary patterns during pregnancy
derived by reduced-rank regression and birth weight in the Chinese
population. British Journal of Nutrition 123 (10):1176–86. doi: 10.
1017/S0007114520000392.
50 M. MESSINA ET AL.
Liu, J., F. Yuan, J. Gao, B. Shan, Y. Ren, H. Wang, and Y. Gao. 2016.
Oral isoflavone supplementation on endometrial thickness: A meta-
analysis of randomized placebo-controlled trials. Oncotarget 7 (14):
17369–79. doi: 10.18632/oncotarget.7959.
Liu, Z., W. Li, J. Sun, et al. 2004. Intake of soy foods and soy isofla-
vones by rural adult women in China. Asia Pacific Journal of
Clinical Nutrition 13:204–9. https://pubmed.ncbi.nlm.nih.gov/
15228989/.
Liwanpo, L., and J. M. Hershman. 2009. Conditions and drugs interfer-
ing with thyroxine absorption. Best Practice & Research. Clinical
Endocrinology & Metabolism 23 (6):781–92. doi: 10.1016/j.beem.
2009.06.006.
Loukovaara, M., M. Carson, A. Palotie, and H. Adlercreutz. 1995.
Regulation of sex hormone-binding globulin production by isoflavo-
noids and patterns of isoflavonoid conjugation in HepG2 cell cul-
tures. Steroids 60 (9):656–61. doi: 10.1016/0039-128X(95)00089-9.
Lu, M., H. Xiao, K. Li, J. Jiang, K. Wu, and D. Li. 2017.
Concentrations of estrogen and progesterone in breast milk and
their relationship with the mother’s diet. Food & Function 8 (9):
3306–10. doi: 10.1039/C7FO00324B.
Lundh, T. J. O., H. I. Pettersson, and K. A. Martinsson. 1990.
Comparative levels of free and conjugated plant estrogens in blood
plasma of sheep and cattle fed estrogenic silage. Journal of
Agricultural and Food Chemistry 38 (7):1530–4. doi: 10.1021/
jf00097a022.
Lynch, H. M., M. P. Buman, J. M. Dickinson, L. B. Ransdell, C. S.
Johnston, and C. M. Wharton. 2020. No significant differences in
muscle growth and strength development when consuming soy and
whey protein supplements matched for leucine following a 12 week
resistance training program in men and women: A randomized trial.
International Journal of Environmental Research and Public Health
17 (11):3871. doi: 10.3390/ijerph17113871.
Ma, X., A. Beeghly-Fadiel, X.-O. Shu, H. Li, G. Yang, Y.-T. Gao, and
W. Zheng. 2013. Anthropometric measures and epithelial ovarian
cancer risk among Chinese women: Results from the Shanghai
Women’s Health Study. British Journal of Cancer 109 (3):751–5. doi:
10.1038/bjc.2013.384.
Main, K. M., H. Kiviranta, H. E. Virtanen, E. Sundqvist, J. T.
Tuomisto, J. Tuomisto, T. Vartiainen, N. E. Skakkebaek, and J.
Toppari. 2007. Flame retardants in placenta and breast milk and
cryptorchidism in newborn boys. Environmental Health Perspectives
115 (10):1519–26. doi: 10.1289/ehp.9924.
Main, K. M., N. E. Skakkebaek, H. E. Virtanen, and J. Toppari. 2010.
Genital anomalies in boys and the environment. Best Practice &
Research. Clinical Endocrinology & Metabolism 24 (2):279–89. doi:
10.1016/j.beem.2009.10.003.
Makino, N., Y. Nakamura, M. Yashiro, R. Ae, S. Tsuboi, Y. Aoyama,
T. Kojo, R. Uehara, K. Kotani, and H. Yanagawa. 2015. Descriptive
epidemiology of Kawasaki disease in Japan, 2011-2012: From the
results of the 22nd nationwide survey. Journal of Epidemiology 25
(3):239–45. doi: 10.2188/jea.JE20140089.
Man, B., C. Cui, X. Zhang, D. Sugiyama, E. Barinas-Mitchell, and A.
Sekikawa. 2021. The effect of soy isoflavones on arterial stiffness: A
systematic review and meta-analysis of randomized controlled trials.
European Journal of Nutrition 60 (2):603–14. 10.1007/s00394-020-
02300-6. doi: 10.1007/s00394-020-02300-6.
Marks, K. J., T. J. Hartman, E. V. Taylor, M. E. Rybak, K. Northstone,
and M. Marcus. 2017. Exposure to phytoestrogens in utero and age
at menarche in a contemporary British cohort. Environmental
Research 155:287–93. doi: 10.1016/j.envres.2017.02.030.
Martinez, J., and J. E. Lewi. 2008. An unusual case of gynecomastia
associated with soy product consumption. Endocrine Practice:
Official Journal of the American College of Endocrinology and the
American Association of Clinical Endocrinologists 14 (4):415–8. doi:
10.4158/EP.14.4.415.
Maskarinec, G., C. Oshiro, Y. Morimoto, S. Hebshi, R. Novotny, and
A. A. Franke. 2005. Urinary isoflavone excretion as a compliance
measure in a soy intervention among young girls: A pilot study.
European Journal of Clinical Nutrition 59 (3):369–75. doi: 10.1038/sj.
ejcn.1602083.
Maskarinec, G., K. Watts, J. Kagihara, S. M. Hebshi, and A. A. Franke.
2008. Urinary isoflavonoid excretion is similar after consuming soya
milk and miso soup in Japanese-American women. The British
Journal of Nutrition 100 (2):424–9. doi: 10.1017/S0007114508898686.
Maskarinec, G., N. J. Ollberding, S. M. Conroy, Y. Morimoto, I. S.
Pagano, A. A. Franke, E. Gentzschein, and F. Z. Stanczyk. 2011.
Estrogen levels in nipple aspirate fluid and serum during a random-
ized soy trial. Cancer Epidemiology Biomarkers & Prevention 20 (9):
1815–21. doi: 10.1158/1055-9965.EPI-11-0363.
Maskarinec, G., Y. Morimoto, R. Novotny, F. J. Nordt, F. Z. Stanczyk,
and A. A. Franke. 2005. Urinary sex steroid excretion levels during
a soy intervention among young girls: A pilot study. Nutrition and
Cancer 52 (1):22–8. doi: 10.1207/s15327914nc5201_3.
Mathey, J., V. Lamothe, V. Coxam, M. Potier, P. Sauvant, and C.
Bennetau-Pelissero. 2006. Concentrations of isoflavones in plasma
and urine of post-menopausal women chronically ingesting high
quantities of soy isoflavones. Journal of Pharmaceutical and
Biomedical Analysis 41 (3):957–65. doi: 10.1016/j.jpba.2006.01.051.
Matsumura, A., A. Ghosh, G. S. Pope, and P. D. Darbre. 2005.
Comparative study of oestrogenic properties of eight phytoestrogens
in MCF7 human breast cancer cells. The Journal of Steroid
Biochemistry and Molecular Biology 94 (5):431–43. doi: 10.1016/j.
jsbmb.2004.12.041.
Matsushita, Y., Y. Takahashi, T. Mizoue, M. Inoue, M. Noda, and S.
Tsugane. 2008. Overweight and obesity trends among Japanese
adults: A 10-year follow-up of the JPHC Study. International Journal
of Obesity (2005) 32 (12):1861–7. doi: 10.1038/ijo.2008.188.
McCann, M. C., K. Liu, W. A. Trujillo, and R. C. Dobert. 2005.
Glyphosate-tolerant soybeans remain compositionally equivalent to
conventional soybeans (Glycine max L.) during three years of field
testing. Journal of Agricultural and Food Chemistry 53 (13):5331–5.
doi: 10.1021/jf0504317.
McCarrison, R. 1933. The goitrogenic action of soya-bean and ground-
nut. Ind J Med Res XXI:179–81.
McCarver, G., J. Bhatia, C. Chambers, R. Clarke, R. Etzel, W. Foster, P.
Hoyer, J. S. Leeder, J. M. Peters, E. Rissman, et al. 2011. NTP-
CERHR expert panel report on the developmental toxicity of soy
infant formula. Birth Defects Research. Part B, Developmental and
Reproductive Toxicology 92 (5):421–68. doi: 10.1002/bdrb.20314.
McMichael-Phillips, D. F., C. Harding, M. Morton, S. A. Roberts, A.
Howell, C. S. Potten, and N. J. Bundred. 1998. Effects of soy-protein
supplementation on epithelial proliferation in the histologically nor-
mal human breast. The American Journal of Clinical Nutrition 68
(6):1431S–5S. doi: 10.1093/ajcn/68.6.1431S.
Meezan, E., E. M. Meezan, K. Jones, R. Moore, S. Barnes, and J. K.
Prasain. 2005. Contrasting effects of puerarin and daidzin on glucose
homeostasis in mice. Journal of Agricultural and Food Chemistry 53
(22):8760–7. doi: 10.1021/jf058105e.
[InsertedFromOnline[pubmedMismatch]]
Mejia, W., D. Cordoba, P. Duran, Y. Chacon, and D. Rosselli. 2019.
Effect of daily exposure to an isolated soy protein supplement on
body composition, energy and macronutrient intake, bone formation
markers, and lipid profile in children in Colombia. Journal of
Dietary Supplements 16:1–13. doi: 10.1080/19390211.2017.1409851.
Merrill, R. M. 2008. Hysterectomy surveillance in the United States,
1997 through 2005. Medical Science Monitor: International Medical
Journal of Experimental and Clinical Research 14 (1):CR24–31.
https://pubmed.ncbi.nlm.nih.gov/18160941/.
Merritt, R. J., and B. H. Jenks. 2004. Safety of soy-based infant formu-
las containing isoflavones: The clinical evidence. The Journal of
Nutrition 134 (5):1220S–4S. doi: 10.1093/jn/134.5.1220S.
Mesiano, S., S. L. Katz, J. Y. Lee, and R. B. Jaffe. 1999. Phytoestrogens
alter adrenocortical function: Genistein and daidzein suppress gluco-
corticoid and stimulate androgen production by cultured adrenal
cortical cells. The Journal of Clinical Endocrinology and Metabolism
84 (7):2443–8. doi: 10.1210/jcem.84.7.5839.
Messina, M. 1995. Modern applications for an ancient bean: Soybeans
and the prevention and treatment of chronic disease. Journal of
Nutrition 125 (3 Suppl):567S–9S. doi: 10.1093/jn/125.3_Suppl.567S.
CRITICAL REVIEWS IN FOOD SCIENCE AND NUTRITION 51
Messina, M. 2004. Western soy intake is too low to produce health
effects. The American Journal of Clinical Nutrition 80 (2):528–9. doi:
10.1093/ajcn/80.2.528.
Messina, M. 2010. Soybean isoflavone exposure does not have feminiz-
ing effects on men: A critical examination of the clinical evidence.
Fertility and Sterility 93 (7):2095–104. doi: 10.1016/j.fertnstert.2010.
03.002.
Messina, M. 2011. Evidence does not support the conclusion that soy
is an endocrine disruptor. Journal of Pediatric Endocrinology &
Metabolism: JPEM 24 (9-10):859–60. doi: 10.1515/JPEM.2011.271.
Messina, M., and G. Redmond. 2006. Effects of soy protein and soy-
bean isoflavones on thyroid function in healthy adults and hypothy-
roid patients: A review of the relevant literature. Thyroid: Official
Journal of the American Thyroid Association 16 (3):249–58. doi: 10.
1089/thy.2006.16.249.
Messina, M., and L. Hilakivi-Clarke. 2009. Early intake appears to be
the key to the proposed protective effects of soy intake against
breast cancer. Nutrition and Cancer 61 (6):792–8. doi: 10.1080/
01635580903285015.
Messina, M., and S. Barnes. 1991. The role of soy products in reducing
risk of cancer. Journal of the National Cancer Institute 83 (8):541–6.
doi: 10.1093/jnci/83.8.541.
Messina, M., C. Nagata, and A. H. Wu. 2006. Estimated Asian adult
soy protein and isoflavone intakes. Nutrition and Cancer 55 (1):
1–12. doi: 10.1207/s15327914nc5501_1.
Messina, M., H. Lynch, J. M. Dickinson, and K. E. Reed. 2018. No dif-
ference between the effects of supplementing with soy protein versus
animal protein on gains in muscle mass and strength in response to
resistance exercise. International Journal of Sport Nutrition and
Exercise Metabolism 28 (6):674–85. doi: 10.1123/ijsnem.2018-0071.
Messina, M., M. M. Rogero, M. Fisberg, and D. Waitzberg. 2017.
Health impact of childhood and adolescent soy consumption.
Nutrition Reviews 75 (7):500–15. doi: 10.1093/nutrit/nux016.
Messina, M., S. Watanabe, and K. D. Setchell. 2009. Report on the 8th
International symposium on the role of soy in health promotion
and chronic disease prevention and treatment. The Journal of
Nutrition 139 (4):796S–802S. doi: 10.3945/jn.108.104182.
Micek, A., J. Godos, T. Brzostek, A. Gniadek, C. Favari, P. Mena, M.
Libra, D. Del Rio, F. Galvano, and G. Grosso. 2021. Dietary phytoes-
trogens and biomarkers of their intake in relation to cancer survival
and recurrence: A comprehensive systematic review with meta-ana-
lysis. Nutrition Reviews 79 (1):42–65. doi: 10.1093/nutrit/nuaa043.
Michikawa, T., M. Inoue, N. Sawada, Y. Tanaka, T. Yamaji, M.
Iwasaki, T. Shimazu, S. Sasazuki, M. Mizokami, S. Tsugane, et al.
2015. Plasma isoflavones and risk of primary liver cancer in
Japanese women and men with hepatitis virus infection: A nested
case-control study. Cancer Epidemiology, Biomarkers & Prevention:
A Publication of the American Association for Cancer Research,
Cosponsored by the American Society of Preventive Oncology 24 (3):
532–7. doi: 10.1158/1055-9965.EPI-14-1118.
Michikawa, T., S. Yamazaki, M. Ono, T. Kuroda, S. F. Nakayama, E.
Suda, T. Isobe, M. Iwai-Shimada, Y. Kobayashi, J. Yonemoto, et al.
2019. Isoflavone intake in early pregnancy and hypospadias in the
Japan Environment and Children’s Study. Urology 124:229–36. doi:
10.1016/j.urology.2018.11.008.
Milerova, J., J. Cerovska, V. Zamrazil, R. Bılek, O. Lapcık, and R.
Hampl. 2006. Actual levels of soy phytoestrogens in children correl-
ate with thyroid laboratory parameters. Clinical Chemistry and
Laboratory Medicine 44 (2):171–4. doi: 10.1515/CCLM.2006.031.
Min, J., Z. Wang, and C. Liang. 2020. Detection of phytoestrogen
metabolites in breastfed infants’ urine and the corresponding breast
milk by LC-MS/MS. Journal of Agricultural and Food Chemistry.
doi: 10.1021/acs.jafc.9b08107.
Minatoya, M., G. Kutomi, S. Asakura, S. Otokozawa, Y. Sugiyama, H.
Ohnishi, H. Akasaka, T. Miura, M. Mori, K. Hirata, et al. 2015.
Relationship of serum isoflavone, insulin and adiponectin levels with
breast cancer risk. Breast Cancer (Tokyo, Japan) 22 (5):452–61. doi:
10.1007/s12282-013-0502-2.
Mınguez-Alarcon, L., M. C. Afeiche, Y.-H. Chiu, J. C. Vanegas, P. L.
Williams, C. Tanrikut, T. L. Toth, R. Hauser, and J. E. Chavarro.
2015. Male soy food intake was not associated with in vitro fertiliza-
tion outcomes among couples attending a fertility center. Andrology
3 (4):702–8. doi: 10.1111/andr.12046.
Missmer, S. A., S. E. Hankinson, D. Spiegelman, R. L. Barbieri, L. M.
Marshall, and D. J Hunter. 2004. Incidence of laparoscopically con-
firmed endometriosis by demographic, anthropometric, and lifestyle
factors. American Journal of Epidemiology 160 (8):784–96. doi: 10.
1093/aje/kwh275.
Mitchell, J. H., E. Cawood, D. Kinniburgh, A. Provan, A. R. Collins,
and D. S. Irvine. 2001. Effect of a phytoestrogen food supplement
on reproductive health in normal males. Clinical Science (London,
England: 1979) 100 (6):613–8. doi: 10.1042/CS20000212.
Miyake, Y., S. Sasaki, Y. Ohya, S. Miyamoto, I. Matsunaga, T. Yoshida,
Y. Hirota, and H. Oda. 2005. Soy, isoflavones, and prevalence of
allergic rhinitis in Japanese women: The Osaka Maternal and Child
Health Study. The Journal of Allergy and Clinical Immunology 115
(6):1176–83. doi: 10.1016/j.jaci.2005.02.016.
Miyazawa, K. 1976. Incidence of endometriosis among Japanese
women. Obstet Gynecol. 48:407–9. https://pubmed.ncbi.nlm.nih.gov/
967375/
Moro, E., E. Degli Esposti, G. Borghese, F. Manzara, M. Zanello, D.
Raimondo, G. Gava, A. Arena, P. Casadio, M. C. Meriggiola, et al.
2019. The impact of hormonal replacement treatment in postmeno-
pausal women with uterine fibroids: A state-of-the-art review of the
literature. Medicina ( Medicina 55 (9):549. doi: 10.3390/
medicina55090549.
Morris, D. H., M. E. Jones, M. J. Schoemaker, A. Ashworth, and A. J.
Swerdlow. 2011. Secular trends in age at menarche in women in the
UK born 1908-93: Results from the Breakthrough Generations
Study. Paediatric and Perinatal Epidemiology 25 (4):394–400. doi:
10.1111/j.1365-3016.2011.01202.x.
Morton, M. S., O. Arisaka, N. Miyake, L. D. Morgan, and B. A. J.
Evans. 2002. Phytoestrogen concentrations in serum from Japanese
men and women over forty years of age. The Journal of Nutrition
132 (10):3168–71. doi: 10.1093/jn/131.10.3168.
Morton, M. S., S. S. F. Leung, D. P. Davies, et al. 1998. Determination
of isoflavonoids and lignans in human breast milk from British and
Chinese women by gas chromatography-mass spectrometry. Am J
Clinical Nutr 68. 1537S.
Morton, R. W., K. Sato, M. P. B. Gallaugher, S. Y. Oikawa, P. D.
McNicholas, S. Fujita, and S. M. Phillips. 2018. Muscle androgen
receptor content but not systemic hormones is associated with
resistance training-induced skeletal muscle hypertrophy in healthy,
young men. Frontiers in Physiology 9 (1373). doi: 10.3389/fphys.
2018.01373.
Mousavi, S. M., N. Tavakoli, and F. Mardan. 2006. Risk factors for goi-
ter in primary school girls in Qom city of Iran. European Journal of
Clinical Nutrition 60 (3):426–33. doi: 10.1038/sj.ejcn.1602335.
Mueller, N. T., A. O. Odegaard, M. D. Gross, W.-P. Koh, M. C. Yu, J.-
M. Yuan, and M. A. Pereira. 2012. Soy intake and risk of type 2 dia-
betes in Chinese Singaporeans [corrected]. European Journal of
Nutrition 51 (8):1033–40. doi: 10.1007/s00394-011-0276-2.
Mulac-Jericevic, B., R. A. Mullinax, F. J. DeMayo, J. P. Lydon, and
O. M. Conneely. 2000. Subgroup of reproductive functions of pro-
gesterone mediated by progesterone receptor-B isoform. Science
(New York, N.Y.) 289 (5485):1751–4. doi: 10.1126/science.289.5485.
1751.
Mumford, S. L., A. Z. Steiner, A. Z. Pollack, N. J. Perkins, A. C.
Filiberto, P. S. Albert, D. R. Mattison, J. Wactawski-Wende, and
E. F. Schisterman. 2012. The utility of menstrual cycle length as an
indicator of cumulative hormonal exposure. The Journal of Clinical
Endocrinology & Metabolism 97 (10):E1871–9. doi: 10.1210/jc.2012-
1350.
Mumford, S. L., R. Sundaram, E. F. Schisterman, A. M. Sweeney, D. B.
Barr, M. E. Rybak, J. M. Maisog, D. L. Parker, C. M. Pfeiffer, and
G. M. B. Louis. 2014. Higher urinary lignan concentrations in
women but not men are positively associated with shorter time to
pregnancy. The Journal of Nutrition 144 (3):352–8. doi: 10.3945/jn.
113.184820.
52 M. MESSINA ET AL.
Mumford, S. L., S. Kim, Z. Chen, D. B. Barr, and G. M. B. Louis. 2015.
Urinary phytoestrogens are associated with subtle indicators of
semen quality among male partners of couples desiring pregnancy.
The Journal of Nutrition 145 (11):2535–41. doi: 10.3945/jn.115.
214973.
M€unstedt, K., P. Grant, J. Woenckhaus, G. Roth, and H.-R. Tinneberg.
2004. Cancer of the endometrium: Current aspects of diagnostics
and treatment. World Journal of Surgical Oncology 2:24. doi: 10.
1186/1477-7819-2-24.
Murkes, D., P. Conner, K. Leifland, E. Tani, A. Beliard, E. Lundstr€om,
and G. S€oderqvist. 2011. Effects of percutaneous estradiol-oral pro-
gesterone versus oral conjugated equine estrogens-medroxyproges-
terone acetate on breast cell proliferation and bcl-2 protein in
healthy women. Fertility and Sterility 95 (3):1188–91. doi: 10.1016/j.
fertnstert.2010.09.062.
Murkies, A. L., C. Lombard, B. J. G. Strauss, G. Wilcox, H. G. Burger,
and M. S. Morton. 1995. Dietary flour supplementation decreases
post-menopausal hot flushes: Effect of soy and wheat. Maturitas 21
(3):189–95. doi: 10.1016/0378-5122(95)00899-V.
Murphy, P. A., K. Barua, and C. C. Hauck. 2002. Solvent extraction
selection in the determination of isoflavones in soy foods. Journal of
Chromatography. B, Analytical Technologies in the Biomedical and
Life Sciences 777 (1-2):129–38. doi: 10.1016/s1570-0232(02)00342-2.
Murphy, P. A., T. Song, G. Buseman, K. Barua, G. R. Beecher, D.
Trainer, and J. Holden. 1999. Isoflavones in retail and institutional
soy foods. Journal of Agricultural and Food Chemistry 47 (7):
2697–704. doi: 10.1021/jf981144o.
Murray, M. J., W. R. Meyer, B. A. Lessey, R. H. Oi, R. E. DeWire, and
M. A. Fritz. 2003. Soy protein isolate with isoflavones does not pre-
vent estradiol-induced endometrial hyperplasia in postmenopausal
women: a pilot trial. Menopause 10 (5):456–64. 10.1097/
01.GME.0000063567.84134.D1 doi: 10.1097/01.GME.0000063567.
84134.D1.
Mustafa, A. M., N. T. Malintan, S. Seelan, Z. Zhan, Z. Mohamed, J.
Hassan, R. Pendek, R. Hussain, and N. Ito. 2007. Phytoestrogens
levels determination in the cord blood from Malaysia rural and
urban populations. Toxicology and Applied Pharmacology 222 (1):
25–32. doi: 10.1016/j.taap.2007.03.014.
Mvondo, M. A., J. D. Ekenfack, S. Minko Essono, H. Saah Namekong,
C. F. Awounfack, M. W. Laschke, and D. Njamen. 2019. Soy intake
since the prepubertal age may contribute to the pathogenesis of
endometriosis in adulthood. Journal of Medicinal Food. 22 (6):
631–8. doi: 10.1089/jmf.2018.0160.
Nagamani, M., P. G. McDonough, J. O. Ellegood, and V. B. Mahesh.
1979. Maternal and amniotic fluid steroids throughout human preg-
nancy. American Journal of Obstetrics and Gynecology 134 (6):
674–80. doi: 10.1016/0002-9378(79)90649-5.
Nagata, C., H. Shimizu, R. Takami, M. Hayashi, N. Takeda, and K.
Yasuda. 2002. Soy product intake and serum isoflavonoid and estra-
diol concentrations in relation to bone mineral density in postmeno-
pausal Japanese women. Osteoporosis International: A Journal
Established as Result of Cooperation between the European
Foundation for Osteoporosis and the National Osteoporosis
Foundation of the USA 13 (3):200–4. doi: 10.1007/s001980200014.
Nagata, C., K. Nakamura, S. Oba, M. Hayashi, N. Takeda, and K.
Yasuda. 2009. Association of intakes of fat, dietary fibre, soya isofla-
vones and alcohol with uterine fibroids in Japanese women. The
British Journal of Nutrition 101 (10):1427–31. doi: 10.1017/
s0007114508083566.
Nagata, C., N. Takatsuka, N. Kawakami, and H. Shimizu. 2001. Soy
product intake and premenopausal hysterectomy in a follow-up
study of Japanese women. European Journal of Clinical Nutrition 55
(9):773–7. doi: 10.1038/sj.ejcn.1601223.
Nagata, C., S. Iwasa, M. Shiraki, T. Ueno, S. Uchiyama, K. Urata, Y.
Sahashi, and H. Shimizu. 2006. Associations among maternal soy
intake, isoflavone levels in urine and blood samples, and maternal
and umbilical hormone concentrations (Japan). Cancer Causes &
Control : CCC 17 (9):1107–13. doi: 10.1007/s10552-006-0044-4.
Nagata, C., S. Oba, and H. Shimizu. 2006. Associations of menstrual
cycle length with intake of soy, fat, and dietary fiber in Japanese
women. Nutrition and Cancer 54 (2):166–70. doi: 10.1207/
s15327914nc5402_2.
Nagata, S. 2019. Causes of Kawasaki Disease-From past to present.
Front Pediatr 7:18. doi: 10.3389/fped.2019.00018.
Nagata, Y., Y. Sugiyama, F. Fukuta, A. Takayanagi, N. Masumori, T.
Tsukamoto, H. Akasaka, H. Ohnishi, S. Saitoh, T. Miura, et al. 2016.
Relationship of serum levels and dietary intake of isoflavone, and
the novel bacterium Slackia sp. strain NATTS with the risk of pros-
tate cancer: A case-control study among Japanese men. International
Urology and Nephrology 48 (9):1453–60. doi: 10.1007/s11255-016-
1335-7.
Nakamura, Y., M. Yashiro, R. Uehara, A. Sadakane, S. Tsuboi, Y.
Aoyama, K. Kotani, E.-O. Tsogzolbaatar, and H. Yanagawa. 2012.
Epidemiologic features of Kawasaki disease in Japan: Results of the
2009-2010 nationwide survey. Journal of Epidemiology 22 (3):
216–21. doi: 10.2188/jea.je20110126.
Nalaboff, K. M., J. S. Pellerito, and E. Ben-Levi. 2001. Imaging the
endometrium: Disease and normal variants. Radiographics: A Review
Publication of the Radiological Society of North America, Inc 21 (6):
1409–24. doi: 10.1148/radiographics.21.6.g01nv211409.
National Toxicology Program UDoHaHS, Center for the Evaluation of
Risks to Human Reproduction. 2006. NTP-CERHR Expert Panel
Report on the Reproductive and Developmental Toxicity of Soy
Formula. doi: 10.1002/bdrb.20087.
Nechuta, S. J., B. J. Caan, W. Y. Chen, W. Lu, Z. Chen, M. L. Kwan,
S. W. Flatt, Y. Zheng, W. Zheng, J. P. Pierce, et al. 2012. Soy food
intake after diagnosis of breast cancer and survival: An in-depth
analysis of combined evidence from cohort studies of US and
Chinese women. The American Journal of Clinical Nutrition 96 (1):
123–32. doi: 10.3945/ajcn.112.035972.
Nemeth, K., G. W. Plumb, J.-G. Berrin, N. Juge, R. Jacob, H. Y. Naim,
G. Williamson, D. M. Swallow, and P. A. Kroon. 2003.
Deglycosylation by small intestinal epithelial cell beta-glucosidases is
a critical step in the absorption and metabolism of dietary flavonoid
glycosides in humans. European Journal of Nutrition 42 (1):29–42.
doi: 10.1007/s00394-003-0397-3.
Newburger, J. W., M. Takahashi, M. A. Gerber, et al. 2004. Diagnosis,
treatment, and long-term management of Kawasaki disease: A state-
ment for health professionals from the Committee on Rheumatic
Fever, Endocarditis and Kawasaki Disease, Council on
Cardiovascular Disease in the Young. American Heart Association.
Circulation 110:2747–71. https://pubmed.ncbi.nlm.nih.gov/
15505111/.
Nikolaidis, A., M. Andreadis, and T. Moschakis. 2017. Effect of heat,
pH, ultrasonication and ethanol on the denaturation of whey protein
isolate using a newly developed approach in the analysis of differ-
ence-UV spectra. Food Chemistry 232:425–33. doi: 10.1016/j.food-
chem.2017.04.022.
Noel, J.-C., V. Anaf, I. Fayt, and E. Wespes. 2006. Ureteral mullerian
carcinosarcoma (mixed mullerian tumor) associated with endometri-
osis occurring in a patient with a concentrated soy isoflavones sup-
plementation. Archives of Gynecology and Obstetrics 274 (6):389–92.
doi: 10.1007/s00404-006-0188-1.
Nordenvall, A. S., L. Frisen, A. Nordenstr€om, P. Lichtenstein, and A.
Nordenskj€old. 2014. Population based nationwide study of hypospa-
dias in Sweden, 1973 to 2009: Incidence and risk factors. The
Journal of Urology 191 (3):783–9. doi: 10.1016/j.juro.2013.09.058.
Nordkap, L., U. N. Joensen, M. Blomberg Jensen, and N. Jørgensen.
2012. Regional differences and temporal trends in male reproductive
health disorders: Semen quality may be a sensitive marker of envir-
onmental exposures. Molecular and Cellular Endocrinology 355 (2):
221–30. doi: 10.1016/j.mce.2011.05.048.
North, K., and J. Golding. 2000. A maternal vegetarian diet in preg-
nancy is associated with hypospadias. The ALSPAC Study Team.
Avon Longitudinal Study of Pregnancy and Childhood. BJU
International 85 (1):107–13. doi: 10.1046/j.1464-410x.2000.00436.x.
North American Menopause Society. 2003. Role of progestogen in hor-
mone therapy for postmenopausal women: Position statement of
The North American Menopause Society. Menopause 10:113–32.
doi: 10.1097/00042192-200310020-00003.
CRITICAL REVIEWS IN FOOD SCIENCE AND NUTRITION 53
Novak, W. K., and A. G. Haslberger. 2000. Substantial equivalence of
antinutrients and inherent plant toxins in genetically modified novel
foods. Food and Chemical Toxicology: An International Journal
Published for the British Industrial Biological Research Association 38
(6):473–83. doi: 10.1016/s0278-6915(00)00040-5.
Ogawa, K., S.-C. Jwa, M. Kobayashi, N. Morisaki, H. Sago, and T.
Fujiwara. 2017. Validation of a food frequency questionnaire for
Japanese pregnant women with and without nausea and vomiting in
early pregnancy. Journal of Epidemiology 27 (5):201–8. doi: 10.1016/
j.je.2016.06.004.
Ohlsson, C., M. Bygdell, J. Celind, A. Sonden, A. Tidblad, L.
S€avendahl, and J. M. Kindblom. 2019. Secular trends in pubertal
growth acceleration in Swedish boys born from 1947 to 1996. JAMA
Pediatrics 173 (9):860–5. doi: 10.1001/jamapediatrics.2019.2315.
Ohno, S., S. Shinoda, S. Toyoshima, H. Nakazawa, T. Makino, and S.
Nakajin. 2002. Effects of flavonoid phytochemicals on cortisol pro-
duction and on activities of steroidogenic enzymes in human
adrenocortical H295R cells. The Journal of Steroid Biochemistry
and Molecular Biology 80 (3):355–63. doi: 10.1016/S0960-
0760(02)00021-3.
Onland-Moret, N. C., P. H. M. Peeters, C. H. van Gils, F. Clavel-
Chapelon, T. Key, A. Tjønneland, A. Trichopoulou, R. Kaaks, J.
Manjer, S. Panico, et al. 2005. Age at menarche in relation to adult
height: The EPIC study. American Journal of Epidemiology 162 (7):
623–32. doi: 10.1093/aje/kwi260.
Onoda, A., T. Ueno, S. Uchiyama, S.-I. Hayashi, K. Kato, and N.
Wake. 2011. Effects of S-equol and natural S-equol supplement
(SE5-OH) on the growth of MCF-7 in vitro and as tumors
implanted into ovariectomized athymic mice. Food and Chemical
Toxicology: An International Journal Published for the British
Industrial Biological Research Association 49 (9):2279–84. doi: 10.
1016/j.fct.2011.06.027.
Orlich, M. J., P. N. Singh, J. Sabate, K. Jaceldo-Siegl, J. Fan, S.
Knutsen, W. L. Beeson, and G. E. Fraser. 2013. Vegetarian dietary
patterns and mortality in Adventist Health Study 2. JAMA Internal
Medicine 173 (13):1230–8. doi: 10.1001/jamainternmed.2013.6473.
Ormond, G., M. J. Nieuwenhuijsen, P. Nelson, M. B. Toledano, N.
Iszatt, S. Geneletti, and P. Elliott. 2009. Endocrine disruptors in the
workplace, hair spray, folate supplementation, and risk of hypospa-
dias: Case-control study. Environmental Health Perspectives 117 (2):
303–7. doi: 10.1289/ehp.11933.
Oseni, T., R. Patel, J. Pyle, and V. C. Jordan. 2008. Selective estrogen
receptor modulators and phytoestrogens. Planta Medica 74 (13):
1656–65. doi: 10.1055/s-0028-1088304.
Otokozawa, S., R. Tanaka, H. Akasaka, E. Ito, S. Asakura, H. Ohnishi,
S. Saito, T. Miura, T. Saito, M. Mori, et al. 2015. Associations of
serum isoflavone, adiponectin and insulin levels with risk for epithe-
lial ovarian cancer: Results of a case-control study. Asian Pacific
Journal of Cancer Prevention 16 (12):4987–91. doi: 10.7314/APJCP.
2015.16.12.4987.
Otun, J., A. Sahebkar, L. €Ostlundh, S. L. Atkin, and T. Sathyapalan.
2019. Systematic review and meta-analysis on the effect of soy on
thyroid function. Scientific Reports 9 (1):3964. doi: 10.1038/s41598-
019-40647-x.
Ozasa, K., M. Nakao, Y. Watanabe, K. Hayashi, T. Miki, K. Mikami,
M. Mori, F. Sakauchi, M. Washio, Y. Ito, et al. 2004. Serum phytoes-
trogens and prostate cancer risk in a nested case-control study
among Japanese men. Cancer Science 95 (1):65–71. doi: 10.1111/j.
1349-7006.2004.tb03172.x.
Padgette, S. R., N. B. Taylor, D. L. Nida, M. R. Bailey, J. MacDonald,
L. R. Holden, and R. L. Fuchs. 1996. The composition of glypho-
sate-tolerant soybean seeds is equivalent to that of conventional soy-
beans. The Journal of Nutrition 126 (3):702–16. doi: 10.1093/jn/126.
3.702.
Padilla-Banks, E., W. N. Jefferson, P. H. Myers, D. R. Goulding, and
C. J. Williams. 2012. Neonatal phytoestrogen exposure causes hypo-
spadias in female mice. Molecular Reproduction and Development 79
(1):3 doi: 10.1002/mrd.21395.
Palomares, M. R., L. Hopper, L. Goldstein, et al. 2004. Effect of soy iso-
flavones on breast proliferation in postmenopausal breast cancer
survivors. Breast Cancer Res Treatment 88 (1):4002.
Pan, Y., M. Anthony, and T. B. Clarkson. 1999a. Effect of estradiol and
soy phytoestrogens on choline acetyltransferase and nerve growth
factor mRNAs in the frontal cortex and hippocampus of female rats.
Proceedings of the Society for Experimental Biology and Medicine.
Society for Experimental Biology and Medicine (New York, N.Y.) 221
(2):118–25. doi: 10.1046/j.1525-1373.1999.d01-64.x.
Pan, Y., M. Anthony, and T. B. Clarkson. 1999b. Evidence for up-regu-
lation of brain-derived neurotrophic factor mRNA by soy phytoes-
trogens in the frontal cortex of retired breeder female rats.
Neuroscience Letters 261 (1-2):17–20. doi: 10.1016/S0304-
3940(98)00994-X.
Parkin, D. M., P. Pisani, and J. Ferlay. 1999. Estimates of the world-
wide incidence of 25 major cancers in 1990. International Journal of
Cancer 80 (6):827–41. doi: 10.1002/ijc.1571.
Paruthiyil, S., H. Parmar, V. Kerekatte, G. R. Cunha, G. L. Firestone,
and D. C. Leitman. 2004. Estrogen receptor beta inhibits human
breast cancer cell proliferation and tumor formation by causing a
G2 cell cycle arrest. Cancer Research 64 (1):423–8. doi: 10.1158/
0008-5472.can-03-2446.
Patisaul, H. B. 2017. Endocrine disruption by dietary phyto-oestrogens:
Impact on dimorphic sexual systems and behaviours. The
Proceedings of the Nutrition Society 76 (2):130–44. doi: 10.1017/
S0029665116000677.
Patisaul, H. B., and W. Jefferson. 2010. The pros and cons of phytoes-
trogens. Frontiers in Neuroendocrinology 31 (4):400–19. doi: 10.1016/
j.yfrne.2010.03.003.
Patisaul, H. B., S. E. Fenton, and D. Aylor. 2018. Animal models of
endocrine disruption. Best Practice & Research. Clinical
Endocrinology & Metabolism 32 (3):283–97. doi: 10.1016/j.beem.
2018.03.011.
Paul, B., K. J. Royston, Y. Li, M. L. Stoll, C. F. Skibola, L. S. Wilson, S.
Barnes, C. D. Morrow, and T. O. Tollefsbol. 2017. Impact of genis-
tein on the gut microbiome of humanized mice and its role in
breast tumor inhibition. PloS One 12 (12):e0189756. doi: 10.1371/
journal.pone.0189756.
Paulozzi, L. J. 1999. International trends in rates of hypospadias and
cryptorchidism. Environmental Health Perspectives 107 (4):297–302.
doi: 10.1289/ehp.99107297.
Paulozzi, L. J., J. D. Erickson, and R. J. Jackson. 1997. Hypospadias
trends in two US surveillance systems. Pediatrics 100 (5):831–4. doi:
10.1542/peds.100.5.831.
Pavone, D., S. Clemenza, F. Sorbi, M. Fambrini, and F. Petraglia. 2018.
Epidemiology and risk factors of uterine fibroids. Best Practice &
Research. Clinical Obstetrics & Gynaecology 46:3–11. doi: 10.1016/j.
bpobgyn.2017.09.004.
Peeters, P. H. M., N. Slimani, Y. T. van der Schouw, P. B. Grace, C.
Navarro, A. Tjonneland, A. Olsen, F. Clavel-Chapelon, M.
Touillaud, M.-C. Boutron-Ruault, et al. 2007. Variations in plasma
phytoestrogen concentrations in European adults. The Journal of
Nutrition 137 (5):1294–300. doi: 10.1093/jn/137.5.1294.
Peng, J.-H., J.-D. Zhu, M.-T. Mi, F.-J. Li, L. Cai, J.-Z. Dong, H.-X.
Zhang, Y. Zhao, and R.-L. Xue. 2010. Prepubertal genistein exposure
affects erbB2/Akt signal and reduces rat mammary tumorigenesis.
European Journal of Cancer Prevention: The Official Journal of the
European Cancer Prevention Organisation (ECP) 19 (2):110–9. doi:
10.1097/CEJ.0b013e3283362a3e.
Petrakis, N. L., S. Barnes, E. B. King, J. Lowenstein, J. Wiencke, M. M.
Lee, R. Miike, M. Kirk, and L. Coward. 1996. Stimulatory influence
of soy protein isolate on breast secretion in pre- and postmeno-
pausal women. Cancer Epidemiology, Biomarkers & Prevention: A
Publication of the American Association for Cancer Research,
Cosponsored by the American Society of Preventive Oncology 5 (10):
785–94. https://pubmed.ncbi.nlm.nih.gov/8896889/.
Pierik, F. H., A. Burdorf, J. A. Deddens, R. E. Juttmann, and R. F. A.
Weber. 2004. Maternal and paternal risk factors for cryptorchidism
and hypospadias: A case-control study in newborn boys.
54 M. MESSINA ET AL.
Environmental Health Perspectives 112 (15):1570–6. doi: 10.1289/
ehp.7243.
Pi~na-Medina, A. G., V. Hansberg-Pastor, A. Gonzalez-Arenas, M.
Cerbon, and I. Camacho-Arroyo. 2016. Progesterone promotes cell
migration, invasion and cofilin activation in human astrocytoma
cells. Steroids 105:19–25. doi: 10.1016/j.steroids.2015.11.008.
Pinchera, A., M. H. Macgillivray, J. D. Crawford, and A. G. Freeman.
1965. Thyroid refractoriness in an athyreotic cretin fed soybean for-
mula. The New England Journal of Medicine 273:83–7. doi: 10.1056/
NEJM196507082730205.
Pisani, P., F. Bray, and D. M. Parkin. 2002. Estimates of the world-
wide prevalence of cancer for 25 sites in the adult population.
International Journal of Cancer 97 (1):72–81. doi: 10.1002/ijc.1571.
Portman, M. A. 2013. Kawasaki disease and soy: Potential role for iso-
flavone interaction with Fcc receptors. Pediatric Research 73 (2):
130–4. DOI: 10.1097/INF.0b013e3181cf8705
Portman, M. A., S. L. Navarro, M. E. Bruce, and J. W. Lampe. 2016.
Soy isoflavone intake is associated with risk of Kawasaki disease.
Nutrition Research (New York, N.Y.) 36 (8):827–34. doi: 10.1016/j.
nutres.2016.04.002.
Potter, S. M., J. A. Baum, H. Teng, R. J. Stillman, N. F. Shay, and J. W.
Erdman. 1998. Soy protein and isoflavones: Their effects on blood
lipids and bone density in postmenopausal women. The American
Journal of Clinical Nutrition 68 (6):1375S–9S. doi: 10.1093/ajcn/68.6.
1375S.
Povey, A. C., J. A. Clyma, R. McNamee, H. D. Moore, H. Baillie, A. A.
Pacey, J. E. Cade, and N. M. Cherry. 2020. Phytoestrogen intake and
other dietary risk factors for low motile sperm count and poor
sperm morphology. Andrology 8 (6):1805–14. Nov doi: 10.1111/
andr.12858.
Prasain, J. K., N. Peng, E. Acosta, R. Moore, A. Arabshahi, E. Meezan,
S. Barnes, and J. M. Wyss. 2007. Pharmacokinetic study of puerarin
in rat serum by liquid chromatography tandem mass spectrometry.
Biomedical Chromatography: BMC 21 (4):410–4. doi: 10.1002/bmc.
772.
Prossnitz, E. R., J. B. Arterburn, and L. A. Sklar. 2007. GPR30: A G
protein-coupled receptor for estrogen. Molecular and Cellular
Endocrinology 265-266:138–42. doi: 10.1016/j.mce.2006.12.010.
Pumford, S. L., M. M. Morton, A. Turkes, and K. Griffiths. 2002.
Determination of the isoflavonoids genistein and daidzein in bio-
logical samples by gas chromatography-mass spectrometry. Annals
of Clinical Biochemistry 39 (Pt 3):281–92. doi: 10.1258/
0004563021901982.
Qiao, L., E. Rodriguez, D. A. Weiss, M. Ferretti, G. Risbridger, G. R.
Cunha, and L. S. Baskin. 2012. Expression of estrogen receptor alpha
and beta is decreased in hypospadias. Journal of Urology 187 (4):
1427–33. doi: 10.1016/j.juro.2011.12.008.
Qin, H., Z. Lin, E. Vasquez, X. Luan, F. Guo, and L. Xu. 2019. High
soy isoflavone or soy-based food intake during infancy and in adult-
hood is associated with an increased risk of uterine fibroids in pre-
menopausal women: a meta-analysis. Nutrition Research (New York,
N.Y.) 71:30–42. doi: 10.1016/j.nutres.2019.06.002.
Qin, W., W. Zhu, H. Shi, J. E. Hewett, R. L. Ruhlen, R. S. MacDonald,
G. E. Rottinghaus, Y.-C. Chen, and E. R. Sauter. 2009. Soy isofla-
vones have an antiestrogenic effect and alter mammary promoter
hypermethylation in healthy premenopausal women. Nutrition and
Cancer 61 (2):238–44. doi: 10.1080/01635580802404196.
Qin, Y., G. Du, M. Chen, W. Hu, C. Lu, W. Wu, B. Hang, Z. Zhou, X.
Wang, and Y. Xia. 2014. Combined effects of urinary phytoestrogens
metabolites and polymorphisms in metabolic enzyme gene on idio-
pathic male infertility. Archives of Toxicology 88 (8):1527–36. doi:
10.1007/s00204-014-1205-y.
Qiu, S., and C. Jiang. 2019. Soy and isoflavones consumption and
breast cancer survival and recurrence: A systematic review and
meta-analysis. European Journal of Nutrition 58 (8):3079–90. doi: 10.
1007/s00394-018-1853-4.
Quaas, A. M., N. Kono, W. J. Mack, H. N. Hodis, J. C. Felix, R. J.
Paulson, and D. Shoupe. 2013. Effect of isoflavone soy protein sup-
plementation on endometrial thickness, hyperplasia, and endomet-
rial cancer risk in postmenopausal women: A randomized controlled
trial. Menopause (New York, N.Y.) 20 (8):840–4. doi: 10.1097/GME.
0b013e3182804353.
Radovic, B., B. Mentrup, and J. Kohrle. 2006. Genistein and other soya
isoflavones are potent ligands for transthyretin in serum and cere-
brospinal fluid. The British Journal of Nutrition 95 (6):1171–6. doi:
10.1079/bjn20061779.
Rahal, O. M., and R. C. Simmen. 2011. Paracrine-acting adiponectin
promotes mammary epithelial differentiation and synergizes with
genistein to enhance transcriptional response to estrogen receptor b
signaling. Endocrinology 152 (9):3409–21. doi: 10.1210/en.2011-1085.
Rahmanzadeh, R., G. H€uttmann, J. Gerdes, and T. Scholzen. 2007.
Chromophore-assisted light inactivation of pKi-67 leads to inhib-
ition of ribosomal RNA synthesis. Cell Proliferation 40 (3):422–30.
doi: 10.1111/j.1365-2184.2007.00433.x.
Rannikko, A., A. Petas, S. Rannikko, and H. Adlercreutz. 2006. Plasma
and prostate phytoestrogen concentrations in prostate cancer
patients after oral phytoestogen supplementation. The Prostate 66
(1):82–7. doi: 10.1002/pros.20315.
Reed, K. E., J. Camargo, J. Hamilton-Reeves, M. Kurzer, and M.
Messina. 2020. Neither soy nor isoflavone intake affects male repro-
ductive hormones: An expanded and updated meta-analysis of clin-
ical studies. Reproductive Toxicology (Elmsford, N.Y.) 100:60–7. doi:
10.1016/j.reprotox.2020.12.019.
Rice, M. S., K. A. Bertrand, T. J. VanderWeele, B. A. Rosner, X. Liao,
H.-O. Adami, and R. M. Tamimi. 2016. Mammographic density and
breast cancer risk: A mediation analysis. Breast Cancer Research 18
(1):94. doi: 10.1186/s13058-016-0750-0.
Rice, S., H. D. Mason, and S. A. Whitehead. 2006. Phytoestrogens and
their low dose combinations inhibit mRNA expression and activity
of aromatase in human granulosa-luteal cells. Journal of Steroid
Biochemistry and Molecular Biology 101 (4-5):216–25. doi: 10.1016/j.
jsbmb.2006.06.021.
Richelle, M., S. Pridmore-Merten, S. Bodenstab, M. Enslen, and E. A.
Offord. 2002. Hydrolysis of isoflavone glycosides to aglycones by
beta-glycosidase does not alter plasma and urine isoflavone pharma-
cokinetics in postmenopausal women. The Journal of Nutrition 132
(9):2587–92. doi: 10.1093/jn/132.9.2587.
Rietjens, I., J. Louisse, and K. Beekmann. 2017. The potential health
effects of dietary phytoestrogens. British Journal of Pharmacology
174 (11):1263–80. doi: 10.1111/bph.13622.
Rıpodas, C., V. D. Via, O. M. Aguilar, M. E. Zanetti, and F. A. Blanco.
2013. Knock-down of a member of the isoflavone reductase gene
family impairs plant growth and nodulation in Phaseolus vulgaris.
Plant Physiology and Biochemistry: PPB 68:81–9. doi: 10.1016/j.pla-
phy.2013.04.003.
Rivera-Sagredo, A., F. J. Ca~nada, O. Nieto, J. Jimenez-Barbero, and M.
Martın-Lomas. 1992. Substrate specificity of small-intestinal lactase.
Assessment of the role of the substrate hydroxyl groups. European
Journal of Biochemistry 209 (1):415–22. doi: 10.1111/j.1432-1033.
1992.tb17304.x.
Rizzo, N. S., K. Jaceldo-Siegl, J. Sabate, and G. E. Fraser. 2013.
Nutrient profiles of vegetarian and nonvegetarian dietary patterns.
Journal of the Academy of Nutrition and Dietetics 113 (12):1610–9.
doi: 10.1016/j.jand.2013.06.349.
Robinson, J. D., H. L. Judd, P. E. Young, O. W. Jones, and S. S. Yen.
1977. Amniotic fluid androgens and estrogens in midgestation. The
Journal of Clinical Endocrinology and Metabolism 45 (4):755–61. doi:
10.1210/jcem-45-4-755.
Rock, C. L., C. Doyle, W. Demark-Wahnefried, J. Meyerhardt, K. S.
Courneya, A. L. Schwartz, E. V. Bandera, K. K. Hamilton, B. Grant,
M. McCullough, et al. 2012. Nutrition and physical activity guide-
lines for cancer survivors. CA: A Cancer Journal for Clinicians 62
(4):242–74. doi: 10.3322/caac.21142.
Rodo, X., R. Curcoll, M. Robinson, J. Ballester, J. C. Burns, D. R.
Cayan, W. I. Lipkin, B. L. Williams, M. Couto-Rodriguez, Y.
Nakamura, et al. 2014. Tropospheric winds from northeastern China
carry the etiologic agent of Kawasaki disease from its source to
Japan. Proceedings of the National Academy of Sciences 111 (22):
7952–7. doi: 10.1073/pnas.1400380111.
CRITICAL REVIEWS IN FOOD SCIENCE AND NUTRITION 55
Rogers, I. S., K. Northstone, D. B. Dunger, A. R. Cooper, A. R. Ness,
and P. M. Emmett. 2010. Diet throughout childhood and age at
menarche in a contemporary cohort of British girls. Public Health
Nutrition 13 (12):2052–63. doi: 10.1017/S1368980010001461.
Romualdi, D., B. Costantini, G. Campagna, A. Lanzone, and M. Guido.
2008. Is there a role for soy isoflavones in the therapeutic approach
to polycystic ovary syndrome? Results from a pilot study. Fertility
and Sterility 90 (5):1826–33. doi: 10.1016/j.fertnstert.2007.09.020.
Ronis, M. J., J. M. Little, G. W. Barone, G. Chen, A. Radominska-
Pandya, and T. M. Badger. 2006. Sulfation of the isoflavones genis-
tein and daidzein in human and rat liver and gastrointestinal tract.
Journal of Medicinal Food 9 (3):348–55. doi: 10.1089/jmf.2006.9.348.
Rosenberg, R. 1994. Malabsorption of thyroid hormone with cholestyr-
amine administration. Conn Med 58 (109) https://pubmed.ncbi.nlm.
nih.gov/8004946/.
Ross, A. E., L. Marchionni, T. M. Phillips, R. M. Miller, P. J. Hurley,
B. W. Simons, A. H. Salmasi, A. J. Schaeffer, J. P. Gearhart, and
E. M. Schaeffer. 2011. Molecular effects of genistein on male ureth-
ral development. Journal of Urology 185 (5):1894–8. doi: 10.1016/j.
juro.2010.12.095.
Ross, J. A. 1998. Maternal diet and infant leukemia: A role for
DNA topoisomerase II inhibitors? International Journal of
Cancer. Supplement¼ Journal International du Cancer. Supplement
11:26–8. doi: 10.1002/(SICI)1097-0215(1998)78:11þ<26::AID-
IJC8>3.0.CO;2-M.
Rowland, I. R., H. Wiseman, T. A. B. Sanders, H. Adlercreutz, and
E. A. Bowey. 2000. Interindividual variation in metabolism of soy
isoflavones and lignans: Influence of habitual diet on equol produc-
tion by the gut microflora. Nutrition and Cancer 36 (1):27–32. doi:
10.1207/S15327914NC3601_5.
Ruder, E. H., J. F. Dorgan, S. Kranz, P. M. Kris-Etherton, and T. J.
Hartman. 2008. Examining breast cancer growth and lifestyle risk
factors: Early life, childhood, and adolescence. Clinical Breast Cancer
8 (4):334–42. doi: 10.3816/CBC.2008.n.038.
Russo, J., D. Mailo, Y. F. Hu, G. Balogh, F. Sheriff, and I. H. Russo.
2005. Breast differentiation and its implication in cancer prevention.
Clinical Cancer Research 11:931s–6s. https://pubmed.ncbi.nlm.nih.
gov/15701889/.
Sabry, M., and A. Al-Hendy. 2012. Medical treatment of uterine leio-
myoma. Reproductive Sciences (Thousand Oaks, Calif.) 19 (4):
339–53. doi: 10.1177/1933719111432867.
Salsano, S., S. Perez-Deben, A. Qui~nonero, R. Gonzalez-Martın, and F.
Domınguez. 2019. Phytoestrogen exposure alters endometrial stro-
mal cells and interferes with decidualization signaling. Fertility and
Sterility 112 (5):947–58 e3. doi: 10.1016/j.fertnstert.2019.06.014.
Samtani, R., M. Bajpai, P. K. Ghosh, and K. N. Saraswathy. 2014.
Hypospadias risk among North-Indian children. Annals of Health
and Health Sciences 1 (1):61–4. doi: 10.5958/j.2322-0422.1.1.012.
Sangi-Haghpeykar, H., and A. N. Poindexter. 1995. 3rd. Epidemiology
of endometriosis among parous women. Obstetrics & Gynaecology
85:983–92. doi: 10.1016/0029-7844(95)00074-2.
Sansai, K., M. Na Takuathung, R. Khatsri, S. Teekachunhatean, N.
Hanprasertpong, and N. Koonrungsesomboon. 2020. Effects of iso-
flavone interventions on bone mineral density in postmenopausal
women: A systematic review and meta-analysis of randomized con-
trolled trials. Osteoporosis International 31 (10):1853–64. oi: 10.1007/
s00198-020-05476-z. doi: 10.1007/s00198-020-05476-z.
Santell, R. C., N. Kieu, and W. G. Helferich. 2000. Genistein inhibits
growth of estrogen-independent human breast cancer cells in culture
but not in athymic mice. The Journal of Nutrition 130 (7):1665–9.
doi: 10.1093/jn/130.7.1665.
Sarathi, V., A. Kolly, H. B. Chaithanya, and C. S. Dwarakanath. 2016.
Effect of soya based protein rich diet on glycaemic parameters and
thyroid function tests in women with gestational diabetes mellitus.
Romanian Journal of Diabetes Nutrition and Metabolic Diseases 23
(2):201–8. doi: 10.1515/rjdnmd-2016-0024.
Sartippour, M. R., J. Y. Rao, S. Apple, D. Wu, S. Henning, H. Wang,
R. Elashoff, R. Rubio, D. Heber, and M. N. Brooks. 2004. A pilot
clinical study of short-term isoflavone supplements in breast cancer
patients. Nutrition and Cancer 49 (1):59–65. doi: 10.1207/
s15327914nc4901_8.
Sathyapalan, T., A. J. Dawson, A. S. Rigby, N. J. Thatcher, E. S.
Kilpatrick, and S. L. Atkin. 2018. The effect of phytoestrogen on
thyroid in subclinical hypothyroidism: Randomized, double blind,
crossover study. Frontiers of Endocrinology (Lausanne) 9:531. doi:
10.3389/fendo.2018.00531.
Sathyapalan, T., A. M. Manuchehri, N. J. Thatcher, A. S. Rigby, T.
Chapman, E. S. Kilpatrick, and S. L. Atkin. 2011. The effect of soy
phytoestrogen supplementation on thyroid status and cardiovascular
risk markers in patients with subclinical hypothyroidism: A random-
ized, double-blind, crossover study. Journal of Clinical Endocrinology
and Metabolism 96 (5):1442–9. doi: 10.1210/jc.2010-2255.
Sathyapalan, T., A. S. Rigby, S. Bhasin, N. J. Thatcher, E. S. Kilpatrick,
and S. L. Atkin. 2016. Effect of soy in men with type 2 diabetes mel-
litus and subclinical hypogonadism: A randomized controlled study.
Journal of Clinical Endocrinology and Metabolism 102:425–33. doi:
10.1210/jc.2016-2875.
Sathyapalan, T., J. K€ohrle, E. Rijntjes, A. S. Rigby, S. R. Dargham, E. S.
Kilpatrick, and S. L. Atkin. 2018. The effect of high dose isoflavone
supplementation on serum reverse T3 in euthyroid men with type 2
diabetes and post-menopausal women. Frontiers in Endocrinology 9:
698. doi: 10.3389/fendo.2018.00698.
Sathyapalan, T., M. Aye, A. S. Rigby, W. D. Fraser, N. J. Thatcher,
E. S. Kilpatrick, and S. L. Atkin. 2017. Soy reduces bone turnover
markers in women during early menopause: A randomized con-
trolled trial. Journal of Bone and Mineral Research 32 (1):157–64.
doi: 10.1002/jbmr.2927.
Savarese, T. M., W. C. Strohsnitter, H. P. Low, Q. Liu, I. Baik, W.
Okulicz, D. P. Chelmow, P. Lagiou, P. J. Quesenberry, K. L. Noller,
et al. 2007. Correlation of umbilical cord blood hormones and
growth factors with stem cell potential: Implications for the prenatal
origin of breast cancer hypothesis. Breast Cancer Research 9 (3):R29.
doi: 10.1186/bcr1674.
Schmidt, R. L., J. S. LoPresti, M. T. McDermott, S. M. Zick, and J. A.
Straseski. 2018. Does reverse triiodothyronine testing have clinical
utility? An analysis of practice variation Based on order data from a
national reference laboratory. Thyroid: Official Journal of the
American Thyroid Association 28 (7):842–8. doi: 10.1089/thy.2017.
0645.
Schmitt, E., W. Dekant, and H. Stopper. 2001. Assaying the estrogenic-
ity of phytoestrogens in cells of different estrogen sensitive tissues.
Toxicology in Vitro 15 (4-5):433–9. doi: 10.1016/S0887-
2333(01)00048-0.
Schneider, L. S., G. Hernandez, L. Zhao, A. A. Franke, Y.-L. Chen, S.
Pawluczyk, W. J. Mack, and R. D. Brinton. 2019. Safety and feasibil-
ity of estrogen receptor-b targeted phytoSERM formulation for
menopausal symptoms: phase 1b/2a randomized clinical trial .
Menopause (New York, N.Y.) 26 (8):874–84. doi: 10.1097/GME.
0000000000001325.
Schoemaker, M. J., M. E. Jones, S. Allen, J. Hoare, A. Ashworth, M.
Dowsett, and A. J. Swerdlow. 2017. Childhood body size and puber-
tal timing in relation to adult mammographic density phenotype.
Breast Cancer Research 19 (1):13. doi: 10.1186/s13058-017-0804-y.
Scholzen, T., and J. Gerdes. 2000. The Ki-67 protein: From the
known and the unknown. Journal of Cellular Physiology 182 (3):
311–22. doi: 10.1002/(SICI)1097-4652(200003)182:3< 311::AID-
JCP1> 3.0.CO;2-9.
Schulster, M., A. M. Bernie, and R. Ramasamy. 2016. The role of estra-
diol in male reproductive function. Asian Journal of Andrology 18
(3):435–40. doi: 10.4103/1008-682X.173932.
Scilewski da Costa Zanatta, T., R. Manica-Berto, C. D. Ferreira,
M. M. C. Cardozo, C. V. Rombaldi, R. C. Zambiazi, and A. R. G.
Dias. 2017. Phosphate fertilizer and growing environment change
the phytochemicals, oil quality, and nutritional composition of
Roundup Ready genetically modified and conventional soybean.
Journal of Agricultural and Food Chemistry 65 (13):2661–9. doi: 10.
1021/acs.jafc.6b05499.
Sebastian, R. S., C. Wilkinson Enns, J. D. Goldman, C. L. Martin, L. C.
Steinfeldt, T. Murayi, and A. J. Moshfegh. 2015. A new database
56 M. MESSINA ET AL.
facilitates characterization of flavonoid intake, sources, and positive
associations with diet among US adults. The Journal of Nutrition
145 (6):1239–48. doi: 10.3945/jn.115.213025.
Segars, J. H., E. C. Parrott, J. D. Nagel, X. C. Guo, X. Gao, L. S.
Birnbaum, V. W. Pinn, and D. Dixon. 2014. Proceedings from the
Third National Institutes of Health International Congress on
Advances in Uterine Leiomyoma Research: Comprehensive review,
conference summary and future recommendations. Human
Reproduction Update 20 (3):309–33. doi: 10.1093/humupd/dmt058.
Segovia-Siapco, G., G. Khayef, P. Pribis, K. Oda, E. Haddad, and J.
Sabate. 2019. Animal protein intake is associated with general adi-
posity in adolescents: The Teen Food and Development Study.
Nutrients 12 (1):110. doi: 10.3390/nu12010.
Segovia-Siapco, G., P. Pribis, K. Oda, and J. Sabate. 2018. Soy isofla-
vone consumption and age at pubarche in adolescent males.
European Journal of Nutrition 57 (6):2287–94. DOI: 10.3945/jn.108.
090928
Segovia-Siapco, G., P. Pribis, M. Messina, K. Oda, and J. Sabate. 2014.
Is soy intake related to age at onset of menarche? A cross-sectional
study among adolescents with a wide range of soy food consump-
tion. Nutrition Journal 13:54 doi: 10.1186/1475-2891-13-54.
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